>>GOOD MORNING, EVERYONE.
THIS IS SAMIA NOURSI AND THE
EXECUTIVE SECRETARY OF THIS
COMMITTEE.
WE ARE WAITING FOR A FEW MORE
MEMBERS SO WE CAN HAVE A FORUM
TO START THIS MEETING.
WE WILL START SHORTLY.
>>GOOD MORNING, SARAH AND
SAMIA.
IT'S JUDY.
>>Samia Noursi: GOOD MORNING,
JUDY.
>>Samia Noursi: WE'RE STARTING
THE MEETING.
AS I MENTIONED, I WOULD LIKE TO
CALL TO ORDER THE 58th MEETING
OF THE NIH ADVISORY COMMITTEE ON
RESEARCH AND WOMAN'S HEALTH.
I'M SAMIA NOURSI FOR SCIENCE
POLICY AND PLANNING AND ANNAL IS
SIS AND THE EXECUTIVE SECRETARY
OF THIS COMMITTEE.
THIS MEETING IS OPEN TO THE
PUBLIC VIA LIVE BROADCAST ON THE
NIH VIDEO CAST NETWORK AND IT'S
BEING RECORD FORWARD OUR OR
KIVES AND FUTURE DEMAND BY THE
PUBLIC.
IF YOU WILL REMEMBER OF THE
PUBLIC, FOR THE FEDERAL REGISTER
NOTICE, YOU MAY SUBMIT YOUR
QUESTIONS IN WRITING TO ME YOU
WILL RECEIVE A RESPONSE FROM ME
CORRECTLY.
WE ARE PARTICIPATING REMOTELY.
THEY ARE PARTICIPATING THROUGH
ZOOM.
NOW I'M TURNING TO OUR MEMBERS.
AS MEMBERS OF THIS FEDERAL
ADVISORY COMMITTEE, YOU ARE
SPECIAL GOVERNMENT EMPLOYEES.
SEGs WHICH MEANS YOU ARE
SUBJECT TO THE SAME ETHIC RULES
THAT APPLY TO GOVERNMENT
EMPLOYEES.
THESE RULES ARE DESCRIBED IN THE
PAMPHLET EP TITLED "STANDARDS OF
ETHICAL CONDUCT FOR EMPLOYEES OF
THE EXECUTIVE BRANCH."
YOU RECEIVE THE COPY OF THIS
DOCUMENT WHEN YOU WERE APPOIN
APPOINTED.
YOU RECEIVED A COPY OF THIS
DOCUMENT WHEN YOU WERE
APPOINTED.
AT EVERY MEETING, WE LIKE TO
REVIEW THE STEPS WE TAKE AND THE
PROCESS WE FOLLOW TO IDENTIFY
AND ADDRESS ANY CONFLICTS
BETWEEN THE PUBLIC
RESPONSIBILITIES AND YOUR
PRIVATE INTERESTS.
AS YOU KNOW, BEFORE EVERY
MEETING, YOU PROVIDE US WITH A
GREAT DEAL OF INFORMATION ABOUT
YOUR PROFESSIONAL, PERSONAL AND
FINANCIAL INTERESTS.
WE USE THIS INFORMATION AS THE
FOUNDATION FOR ASSESSING WHETHER
YOU HAVE ANY REAL, POTENTIAL, OR
APPARENT CONFLICTS OF INTEREST
THAT COULD COMPROMISE YOUR
ABILITY TO BE OBJECTIVE IN
GIVING AT VICE DURING EXIT'
MEETINGS.
WE HAVE IDENTIFIED WE WOULD
ISSUE YOU A WAIVER OR RECUSE YOU
FROM A PARTICULAR PORTION OF THE
MEETING.
WE USUALLY WAVE CONFLICTS OF
INTEREST FOR GENERAL MATTERS
BECAUSE WE BELIEVE YOUR ABILITY
TO BE OBJECTIVE WILL NOT BE
EFFECTED BY YOUR FINANCIAL
INTERESTS.
WE ALSO RELY A GREAT DEAL ON
YOU.
YOU NEED TO BE ATTENTIVE DURING
MEETINGS TO THE POSSIBILITY THAT
AN ISSUE COULD ARISE THAT COULD
EFFECT OUR APPEAR TO EFFECT YOUR
FINANCIAL INTERESTS WITH RESPECT
TO A SPECIFIC PARTY OR MATTER.
YOU WILL BE ASKED TO RECUSE
YOURSELF FROM THAT PORTION OF
THE MEETING.
BEFORE INTRODUCTION, I WILL
BRIEFLY REVIEW BEST PRACTICES
FOR OUR ZOOM PARTICIPANTS.
PLEASE MUTE YOUR MIC IF YOU ARE
NOT SPEAKING.
YOU CAN LEAVE YOUR CAMERA ON, WE
HAVE BANDWIDTH.
STATE YOUR NAME BEFORE MAKING
COMMENTS AND MOTIONS OR
RECOMMENDATIONS INTRODUCE TO USE
A HEAD SEAT AND IT WILL RESULT
IN THE CLEARER SOUND AND PROVIDE
THE LEAST AMOUNT OF AUDIO
FEEDBACK.
IF APPROXIMATE YOU HAVE A
QUESTION, OR WOULD LIKE TO MAKE
A COMMENT, PLEASE UTILIZE THE
CHAT FEATURE.
THE ZOOM CHAT WILL BE KEPT AS
PART OF THE OFFICIAL MEETING
RECORD.
REMINDER THAT YOU WILL BE
PRESENTING TWO CONCEPT
CLEARANCES IN THE AFTER SO YOU
HOPE THAT YOU WILL BE IN
ATTENDANCE FOR THE VOTES.
WE'LL UTILIZE THE SAMPLE
FUNCTION FOR THAT PURPOSE AND
DURING THE VOTE, MULTIPLE CHOICE
PORTION WILL DISPLAY ON YOUR
SCREEN.
AND WE WOULD LIKE YOU TO SELECT
THE NEW RESPONSE AND CLICK
SUBMIT BUT WE'LL GET TO THAT
LATER.
AS I GO THROUGH THE ROSTER, WHEN
YOU HEAR YOUR NAME, UNMUTE YOUR
MIC AND INTRODUCE YOURSELVES.
BY NAME AND WHAT INSTITUTION YOU
PRESENT.
Dr. ANDERSON.
GOOD MORNING, EVERYONE, GARNET
ANDERSON FROM HUTCHINSON CANCER
CENTER.
>>Samia Noursi: Dr. ANINA.
>>GOOD MORNING.
IRENE FROM SOCIETY FOR WOMEN'S
HEALTH RESEARCH.
>>Samia Noursi: THANK YOU, VERY
MUCH.
Dr. BRIEGAL.
>>Dr. HIGGINS.
>>STEVE HIGGINS FROM THE
UNIVERSITY OF VERMONT.
>>Samia Noursi: THANK YOU.
Dr. JAGSI.
>>HELLO, RASH MA JAGSI FROM
EMERY UNIVERSITY IN ATLANTA.
>>Samia Noursi: Dr.
McGREGOR.
>>HI, ALISON McGREGOR FROM
UNIVERSITY OF SOUTH CAROLINA
GREENVILLE.
>>Samia Noursi: THANK YOU.
Dr. MILLANCE.
>>GOOD MORNING, THELMA MILLANCE
FROM COLOMBIA UNIVERSITY.
>>Samia Noursi: THANK YOU.
Dr. NOEL.
>>GOOD MORNING, EVERYONE.
Dr. NOEL LOUISIANA STATE
UNIVERSITY.
>>Samia Noursi: Dr. JONES.
>>GOOD MORNING, EVERYONE.
ANDRE JONES FROM UNIVERSITY OF
NORTH CAROLINE CHAPEL HILL.
>>Samia Noursi: THANK YOU.
Dr. ROBINSON.
>>GOOD MORNING, EVERYBODY,
MICHELLE ROB I AM SON UNIVERSITY
OF ALABAMA AT BIRMINGHAM.
>>Samia Noursi: THANK YOU.
Dr>>JUDY FROM THE UNIVERSITY OF
COLORADO MEDICAL CAMPUS.
>>Samia Noursi: THANK YOU.
Dr. SADOFSKY.
>>FROM WOMEN'S RESEARCH
INSTITUTE AT UNIVERSITY EVER
PITTSBURGH.
>>Samia Noursi: Dr. SHARP.
>>WILL NOT BE JOINING TODAY.
>>Dr. SIMON.
>>Dr. SIMON HAS NOT JOINED US
YET.
>>Samia Noursi: THANK YOU.
AND Dr. TEMPLETON.
>>GOOD MORNING, KIM TEMPLETON
AMERICAN MEDICAL WOMEN'S
ASSOCIATION AND THE UNIVERSITY
OF KANSAS AND KANSAS CITY.
>>Samia Noursi: THANK YOU,
EVERYONE.
WE WERE ONE MORE HOUSEKEEPING
ITEM TO TAKE CARE OF YOU HAVE
THE MINUTES FROM OCTOBER 18th,
2022 FOR YOUR REVIEW.
IS THERE A MOTION ON THE TABLE
TO ACCEPT THE OCTOBER 18th,
2022 MINUTES AS WRITTEN.
>>I MOVE TO ACCEPT THOSE
MINUTES AS WRITTEN.
>>Samia Noursi: THANK YOU.
Dr. RAGGENSTEINER HAS THE
MOTION DO I HEAR A SECOND.
>>SECOND.
>>Samia Noursi: WHO IS THAT?
>>Dr. JAGSI.
>>Samia Noursi: THANK YOU,
Dr. JAGSI.
Dr. JAGSI HAS SECONDED THE
MOTION.
THE POLL HAS BEEN OPEN TO
RESPOND IF YOU ARE IN FAVOR,
OPPOSED OR ABSTAIN.
YOU HAVE 30 SECONDS.
>>Samia Noursi: HAVE THE VOTES
BEEN RECORDED.
>>YES WITH 12 IN FAVOR.
>>Samia Noursi: GREAT.
THANK YOU.
THE OCTOBER 18th, 2022 MEETING
MINUTES HAVE BEEN ACCEPTED WITH
12 IN FAVOR.
NOW I WOULD LIKE TO INTRODUCE
THE CHAIR Dr. JANINE CLAYTON.
Dr. CLAYTON --
>>Janine A. Clayton: THANK YOU,
Dr. NOURSI AND I'M EXCITED TO
BE HERE WITH YOU ALL TODAY.
I WILL BE RIGHT WITH YOU.
GOOD MORNING, EVERYONE.
IT'S MY PLEASURE TO BRING THE
ORWH DIRECTOR'S REPORT TO YOU
AND I'M GOING TO COVER THE SIX
YEARS JUST BRIEFLY OPENING
UPDATES ON NIH, FUNDING BUDGET
AND LEGISLATIVE INFORMATION,
POLICY AND SCIENTIFIC
INFORMATION.
I'LL DESCRIBE SOME OF OUR
COLLABORATIONS WITH THE NIH
INSTITUTE CENTERS AND OFFICES OR
ICOs AND GIVE YOU A BRIEF
UPDATE ON CAREERS AND THEN I
WILL CLOSE.
BEFORE WE BEGIN, OUR FORMAL
REMARKS, I DID WANT TO PROVIDE
REMARKS REGARDING THE RECENT
PASSING OF CONGRESSWOMAN
PATRICIA SCHROEDER.
PAT SCHROEDER WAS A LONG-TIME
CONGRESSWOMAN OVER TWO DECADES
AND A PIONEER FOR WOMEN AND
POLITICS.
CONGRESSWOMAN SCHROEDER WAS A CO
RESPONSE OVERTIME WOMEN'S HEALTH
EQUITY ACT OF 1990 THAT CREATED
THE NIH WOMEN OF RESEARCH.
SHE'S NEAR AND DEAR TO OUR
HEARTS.
ORWH WAS ESTABLISHED TO EXPAND
WOMEN'S HEALTH RESEARCH AT NIH
AND INCORPORATE IT IN OUR
MISSION FROM THE OUTSET WAS
EFFORTS RELATED TO RECRUITMENT,
RETENTION AND ADVANCEMENT OF
WOMEN AND SCIENCE CAREERS.
SHE WAS THE FIRST WOMAN ELECTED
IN THE COLORADO STATE
LEGISLATURE TO SERVE ON THE
HOUSE ARMED SERVICES COMMITTEE
AND THE FIRST WOMAN TO BE
INDUCTED INTO THE NATIONAL
WOMEN'S HEALTH.
I'M GOING TO PULL ONE OF HER
QUOTES HERE BECAUSE I THINK IT
IS CERTAI APP RA PO.
WE NEED TO MAKE SURE THAT WOMEN
HAVE ACCESS TO QUALITY
HEALTHCARE.
WOMEN'S HEALTH IS IMPORTANT AND
WE NEED TO MAKE SURE THAT WOMEN
HAVE THE CARE THAT THEY NEED.
IMPACT IS OFTEN SOMETHING THAT
WE THINK ABOUT MAYBE NOT A DAILY
BASIS BUT SHE HAD AN IMPACT.
RIPPLE IN THE POND.
THE STONE THAT'S THROWN INTO THE
LAKE.
AND THE WAVE THAT CRASHES
THROUGH THE SHORE.
I AM THE CHANGE THAT YOU CAN'T
SEE.
THE FORCE THAT PICKS THINGS
MAKES THINGS HAPPEN.KONG RUSS WA
SCHROEDER HAD A PRO FOUND IMPACT
ON WOMEN'S HEALTH.
AND AS I MOVE ON, I LIKE TO
INCLUDE DATA IN ALL OF MY
PRESENTATIONS AND I PROMISED
THERE WON'T BE TOO MUCH DATA BUT
I WANT TO HAVE THIS RIGHT UP
FRONT AND THIS INFORMATION IS
FROM THE WOMEN'S W.H.O. 2023
REPORT AND THIS LOOKED AT
COUNTRIES AND TERRITORIES AROUND
THE WORLD FROM 2000 TO 2020.
THIS DATA IS ON MATERNAL
MORTALITY.
2000 IS THE DARK BLUE AND 2020
IS THE KEEL COLOR AND YOU CAN
SEE IN THESE REGIONS WITH A
REDUCTION OF MATERNAL MORTALITY
NORTHERN, SOUTHERN AND WESTERN
EUROPE WITH MORE MODEST
REDUCTIONS AND NORTH AMERICA AND
THIS IN CONTRAST TO OUR
COMPARABLE REGIONS.
HERE IS ANOTHER SET OF DATA THAT
I DO WANT TO SHARE WITH YOU AND
THIS IS THE COMMODITIES FUNDS
AND IT LOOKS AT HIGH INCOME
COUNTRIES AND DESCRIBES A
VARIETY OF IMPORTANT PARAMETERS.
THE U.S. HAS THE LOWEST LIFE
EXPECTANT' AND THE HIGHEST
MATERNAL INFANT MORTALITY RATES
AMONG HIGH INCOME COUNTRIES IN
THE WORLD.
ALSO THE HIGHEST RATE OF
INDIVIDUALS WITH MULTIPLE
CHRONIC CONDITIONS AND IS ONE OF
THE GOOD POINTS IS THE U.S. HAD
HIGH SCREENING RATES FOR BREAST
AND COLORECTAL CANCER AND HIGH
VACCINATION RATES FOR THE FLU.
THE RATES ARE VERY, VERY
DISTURBING.
THE ADVISORY COMMITTEE FOR
RESEARCH ON WOMEN'S HEALTH
PLAYED A CRITICAL ROLE IN
ORGANIZING, CONDUCTING, AND
SUMMARIZING THE WOMEN'S HEALTH
CONFERENCE OF 2021, ADVANCING
NIH RESEARCH ON WOMEN'S HEALTH
CONGRESSIONAL REQUEST.
AND BUILDING UPON THE
OPPORTUNITIES THAT WERE
IDENTIFIED IN THE REPORT, FROM
THAT CONFERENCE, WE WANT TO
THANK A CHWH MEMBERS FOR
ORGANIZING THE CONFERENCE AND
YOU RECALL PULLING FORWARD ALONG
WITH THE LEAD FOR THIS ACTIVITY,
Dr. SARAH TEMKIN AND ALONG
WITH Dr. SAMIA NOURSI A
FRAMEWORK FOR CHRONIC DISEASE.
MULTI MORBIDITY WAS HIGHLIGHTED
IN THAT WOMEN'S HEALTH
CONFERENCE REPORT AND ALIGNED
WITH GOAL ONE OF THE NIH WIDE
STRATEGIC PLAN FOR WOMEN'S
HEALTH RESEARCH, IS ADVANCING
RIGOROUS RESEARCH RELEVANT TO
THE HEALTH OF WOMEN AND ARE NEW
FUNDING HIGHLIGHTS.
UNDERSTANDING CHRONIC
CONDITIONS, UNDER STUDIED AMONG
WOMEN.
THE FRAMEWORK USED FOR THAT,
THESE TWO ARE NOTICES OF FUNDING
OPPORTUNITIES INCLUDE THE
FRAMEWORK THAT WAS PRESENTED AT
WOMEN'S HEALTH CONFERENCE
LOOKING AT FEMALE-SPECIFIC
CONDITIONS LIKE MENOPAUSE OR
CANCER.
CONDITIONS THAT ARE MORE COMMON
IN WOMEN OR MORBIDITY IS GREATER
FOR WOMEN LIKE IN MENTAL HEALTH
CONDITIONS.
POTENTIALLY UNDER STUDIED IN
WOMEN SUCH AS INTIMATE PARTNER
VIOLENCE AND THOSE CONDITIONS
THAT ARE CRON PICK AND HAVE HIGH
MORBIDITY FOR WOMEN LIKE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
HAS.
THE FIRST RECEIPT DATE FOR THESE
TWO NEW FUNDING OPPORTUNITIES IS
MAY 19th AND WE ARE PARTNERING
WITH A VARIETY OF ICOs
DEPICTED HERE ON THE BOTTOM OF
THE SLIDE SO VERY EXCITED TO BE
HAVING THIS NEW FUNDING
OPPORTUNITIES AVAILABLE TO
RESEARCHERS TO ADDRESS CHRONIC
DISEASES IN FEDERAL UNDER
STUDIED AND EFFECT WOMEN.
AS I MOVE ONTO THE NEXT SECTION
OVER NIH UPDATES, I WANT TO
HIGHLIGHT Dr. JOANN JONI RUTTERS
THE DIRECTOR OF NCATS FOR
ADVANCING TRANSLATIONAL SCIENCES
AND YOU WILL HEAR FROM HER
TODAY.
Dr. RUTTER WILL OVERSEE THE
DIVERSE -- SHE'S OVERSEEING THE
DIVERSE PORTFOLIO RESEARCH
ACTIVITIES IN NCATS AND PROVING
THE TRANSLATIONAL PROCESSES OF
TURNING SCIENTIFIC DISCOVERIES
INTO HEALTH INTERVENTIONS AND
THE PORTFOLIO FOR NCATS IS THE
TRANSLATIONAL SCIENCE AWARDS OR
CTSA PROGRAM THAT PLAYED A ROLE
IN THE AGENCY'S COVID-19
RESPONSE.
Dr. RUTTER JOINED NCATS IN
2019 AND SERVED AS ACTING
DIRECTOR IN APRIL OF 2021 AND
HER EARLIER WORK AT NIH INVOLVED
THE ALL OF US PROGRAM AND THE
NATIONAL INSTITUTE ON DRUG
ABUSE.
SHE BRINGS TO 11 THE NUMBER OF
IC DIRECTORS INSTITUTE AND
CENTER DIRECTORS THAT ARE WOMEN
CURRENTLY AND I WANT TO
HIGHLIGHT CHANGES IN IC
LEADERSHIP, Dr. PETER
KILLMARKS ARE ACTING DIRECTORS
OF NIAID.
ON THE RIGHT, I ALSO WANT TO
HIGHLIGHT ON BEHALF OF NIH
LEADERSHIP THE VERY FIRST NIH
WIDE STRATEGIC PLAN FOR
DIVERSITY, EQUITY, INCLUSION AND
ACCESSIBILITY.
AND I REFER YOU TO THE NIH
LEADERSHIP WEBSITE FOR MORE
INFORMATION ABOUT THAT IMPORTANT
NEW STRATEGIC PLAN.
WE ALSO WANT TO ACKNOWLEDGE
Dr. RENEE WAGERSAN AND ARPA-H
WHO CELEBRATED THEIR FIRST
BIRTHDAY ON MARCH 15th.
AS YOU KNOW, ARPA-H STANDS FOR
ADVANCED RESEARCH AGENCY FOR
HEALTH AND IT SUPPORTS
TRANSFORMATIVE RESEARCH TO DRIVE
BIOMEDICAL AND HEALTH
BREAKTHROUGHS TO TRANSFORM
HEALTH SOLUTIONS FOR ALL SO
HAPPY BIRTHDAY ARPA-H.
WE CONTINUE TO LOOK FORWARD TO
ADVANCES THROUGH ARPA-H AND THAT
INCLUDING WOMEN'S HEALTH,
HOPEFULLY IN THE FUTURE.
AND IMPORTANT PART OF THIS
MEETING IS TO PROVIDE YOU WITH
AN UPDATE ON ORWH RESEARCH
PROGRAMS AND FUNDING.
EACH YEAR I HIGHLIGHT THE BUDGET
HISTORY FOR YOU AND YOU CAN SEE
IN THE SLIDE ON THE LEFT THE
BUDGET HISTORY FOR ORWH.
FOR THE FIRST 10 YEARS OF THE
OFFICE'S EXISTENCE, YOU CAN SEE
A STEADY INCREASE IN OUR BUDGET
AND THEN IN 2002, A SIGNIFICANT
INCREASE OF OVER 10 MILLION TO
CREATE THE BIRCH PROGRAM.
SUBSEQUENTLY A FLAT BUDGET AND
RECENTLY IN 2021 A BUDGET OF
$51.5 MILLION, 2022,
60.6 MILLION AND ON THE RIGHT
YOU CAN SEE THE BREAKDOWN IF
TERMS OF OUR EXTRAMURAL GRANT
AWARDS AND THE PROFILE HERE.
LET ME HIGHLIGHT FOR YOU.
OUR BIRCH PROGRAM AT ABOUT A
QUARTER OF OUR FUNDING AND THE
SCORE PROGRAM AND A LITTLE MORE
THAN A QUARTER OF VARIETY OF
OTHER ORWH SIGNATURE PROGRAMS
AND OUR SIX AND GENDER RO1
APPROXIMATE U3 PROGRAM AND
ADMINISTRATIVE SUPPLEMENTS.
THIS 20.4% REPRESENTS OTHER IC
CO FUNDING AND HERE IS ANOTHER
NEW SECTION ON OTHER CAREER
PROGRAMS.
THE BIRCH PROGRAM REPRESENTING
THREE QUARTERS OF THAT FUNDING
BUT ALSO OUR CAREER CONTINUITY
SUPPLEMENTS FOR WHICH ORWH TOOK
A LEADERSHIP ROLE IN DEVELOPING
THROUGH THE WORKING GROUP AND
BIOMEDICAL CAREERS, DIVERSITY
SUPPLEMENT OF KINDS, EFFORTS
FOCUSED ON ADDRESSING SEXUAL
HARASSMENT, LOAN REPAYMENT AND
RECRUITMENT AND REENTRY AND
REINTEGRATION SUPPLEMENTS AND
YOU WILL HEAR A LITTLE BIT MORE
FROM OUR ASSOCIATE DIRECTOR OF
CAREERS ABOUT PROPOSED CONCEPTS
FOR EXPANDING THE REENTRY
PROGRAM LATER TODAY.
UNTIL TERMS OF THE IPSOS-REID TO
USE THE AND CENTERS TO WHOM THE
ORWT FUNDS FLOW, YOU CAN SEE
HERE NICHD, IN THE LEAD WITH
SUBSTANTIAL PREPORTION RELATED
TO THE BIRCH PROGRAM AND NIA AND
NHLBA IN THE TOP FIVE HERE AND
IF WE REMOVE THE BIRCH YOU CAN
SEE A LITTLE BIT MORE EASILY
THESE INSTITUTES WITH WHOM WE
HAVE PROVIDED THE MAJORITY OF
FUNDING AS WELL AS OTHER
INSTITUTES AND CENTERS THAT HAVE
RECEIVED WOMEN'S HEALTH SUPPORT
FROM ORWH OVER FOR FY22.
HERE IS A LITTLE BIT MORE DETAIL
FOR YOU WITH THE ORWH SIGNATURE
PROGRAMS DELINEATED.
YOU CAN SEE THE BIRCH PROGRAM
OUR ORWH INVESTMENTS AS WELL AS
THE CO-FUNDING ICs FOR BIRCH.
WE SEE DID RECEIVE ADDITIONAL
FUNDING FROM NCI AND NIAAA AND
NNIAD IN 2022 IN TERMS IT OF THE
CAREER PROGRAMS AND HERE ARE THE
INSTITUTES AND CENTERS WITH WHOM
WE COLLABORATE FORWARD OUR SCORE
PROGRAM, THERE ARE FIVE
INSTITUTES THAT ARE
ADMINISTERING AND SUPPORTING THE
SCORE PROGRAM.
SEX AND GENDER RO1.
EIGHT INSTITUTES THAT ARE
WORKING WITH US ON THE SEX AND
GENDER RO1 AND SUPPORTING THOSE
EFFORTS.
IN TERMS OF THE SEX AND GENDER
ADMINISTRATIVE SUPPLEMENTS EIGHT
INSTITUTES ARE RECEIVING
GRANTEES FROM THOSE -- THEY ARE
RECEIVING FUNDING AND OUR U3
UNDER STUDIED, UNDER REPORTED
AND UNDER STUDIED POPULATIONS OF
WOMEN AND PROGRAM AT $3 MILLION
WITH 11 INSTITUTES AND FOR OTHER
INSTITUTES, CO FUNDING A WIDER
VARIETY OF INSTITUTES AND
CENTERS AT ALMOST $9 MILLION FOR
ORWH CO FUNDING AND SUPPORT FOR
FY22.
AND WE DECIDE TODAY SHARE WITH
YOU AN FY23 ORWH RECEIVED A
BUDGET OF $76.48 MILLION WITH AN
ADDITIONAL $17 MILLION WITH
THESE REQUIREMENTS FROM THE U.S.
CONGRESS AND FIVE MILLION
DOLLARS TO SUPPORT THE BIRCH
PROGRAM AND IN ADDITION AND
$10 MILLION ESTABLISH AN OFFICE
OF AUTOIMMUNE DISEASE RESEARCH
AND TWO MILLION DOLLARS TO
CONTRACT WITH THE NATIONAL A CAT
PIECE OF SCIENCE AND ENGINEERING
AND MEDICINE TO CONDUCT A STUDY
ON GAPS IN NIH WOMEN'S HEALTH
RESEARCH.
THE CONGRESSIONAL LANGUAGE
REQUIRED EVALUATE SEX
DIFFERENCES AND RACIAL AND
HEALTH DISPARITIES AND DETERMINE
THE LEVEL IN WOMEN'S HEALTH
RESEARCH AT NIH AND ALONG WITH
THE REQUIREMENT FOR THE NATIONAL
ACADEMIES TO REPORT TO CONGRESS
IN 18 MONTHS ON RECOMMENDATIONS
TO ADDRESS RESEARCH GAPS AND
WOMEN'S HEALTH RESEARCH.
HERE IS A LITTLE BIT MORE DETAIL
ON THE OMNIBUS LANGUAGE RELATED
TO THE NEW OFFICE AUTOIMMUNE
DISEASE RESEARCH.
AS MANY AUTOIMMUNE DISS EFFECT
WOMEN AS STATED IN HAD
CONGRESSIONAL LANGUAGE.
AND NATIONAL ACADEMY OF SCIENCE
ENGINEERING AND MEDICINE 2022
REPORT RECOMMENDED THE
ESTABLISHMENT OF AN NIH OFFICE
OF AUTOIMMUNE DISEASE RESEARCH
AND THE APPROPRIATIONS AND
DISTRICTS THE OADR FOR THE
DEVELOPMENT OF A MULTI INSTITUTE
AND CENTER STRATEGIC RESEARCH
PLAN TO IDENTIFY OF AREAS OF
INNOVATION EMERGING AREAS OF
INNOVATION AND RESEARCH
OPPORTUNITIES TO COORDINATE AND
FOSTER COLLABORATIVE RESEARCH
ACROSS THE INSTITUTES AND
CENTERS AND ANNUALLY EVALUATE
THE PORTFOLIO AND TO PROVIDE
RESOURCES TO SUPPORT PLANNING,
COLLABORATION AND INNOVATION AND
TO DEVELOP AND OVERSEE A
PUBLICLY ACCESSIBLE CENTRAL
REPOSITORY FOR AUTOIMMUNE
DISEASE RESEARCH AS WELL AS TO
REPORT BACK TO THE COMMITTEES
WITHIN 150 DAYS OF THE
CONSOLIDATED APPROPRIATIONS ACT
ON EFFORTS THAT NIH HAS TAKEN TO
STAND UP OADR AND THE STATUS OF
THESE DIRECTIVES.
I'M GRATEFUL FOR THE FOCUS
ATTENTION AUTOIMMUNE DISEASES
AND THE OPPORTUNITIES TO ADVANCE
AN IMPORTANT RESEARCH FOR WOMEN
THAT TOUCHES ALMOST EVERY ORGAN
IN THE BODY ACROSS THE LIFESPAN,
AUTOIMMUNE DISEASES HAVE BEEN ON
ORWH'S RADAR GIVEN THE HIGH
RATES OF DISEASE AND FEMALE
HIGHER RATES OF DISEASE IN WOMEN
FOR MOST AUTO AWSO PESHDARY.
THE CHARGE IS CROSS CUTTING.
WE WILL HELP LEAD THIS NEXT
CHAPTER OF AUTOIMMUNE DISEASE
RESEARCH AT NIH LEVERAGING OUR
ORWH TO COMPLIMENT, SIN I
REMEMBERSYNERGIESTHROUGH RESEARO
ACCELERATE PROGRESS.
THIS GRAPHIC DEPICTS INFORMATION
RELATED TO NIH INVESTMENTS AND
AUTOIMMUNE DISEASE RESEARCH AND
OVER THE PAST FIVE YEARS, THOSE
INVESTMENTS HAVE INCREASED AND
IN FY21 WE'RE A BILLION DOLLARS
AT $946 MILLION AND FY21 AND 22
OVER NEW RESEARCH AND STRAT TIVE
SUPPLEMENT GRANTS WERE LISTED IN
THE CATEGORY AS A SPENDING
CATEGORY IN R CDC FOR EXAMPLE.
THE GRAPHIC ON THE LEFT
HIGHLIGHTS LIST THE AREAS WHERE
THEY OVERLAP.
JUST AS THERE ARE CROSS CUTTING
ISSUES ACROSS ALL THE OWE 'EM AS
SEE, THEY CAN BE CATEGORIZED
UNDER VARIOUS MULTIPLE SPENDING
CATEGORIES DEPICTED IN THE
GRAPHIC HERE AND FY21 AND 22 THE
NUMBER OF NEW INVESTMENTS AND
THIS FIGURE SHOWS THE OTHER
SPENDING CATEGORIES THAT WERE
LISTED, ALONG WITH AUTOIMMUNE
DISEASE, AND THEY DEMONSTRATE
THE COMMON INTERSECTION OF THOSE
INVESTMENTS AND AUTOIMMUNE
DISEASES RESEARCH WITH OTHER
TOPICS LIKE WOMEN'S HEALTH, LIKE
TRANSLATIONAL RESEARCH, AND LIKE
MINORITY HEALTH.
SO AT NIH, DISEASE FOCUSED
RESEARCH OFTEN ALIGNS WITH
MULTIPLE INSTITUTES AND CENTER
MISSIONS AND WE CHAMPION A WHOLE
PERSON PERSPECTIVE RECOGNIZING
THE DISEASES DO NOT HAPPEN IN A
VACUUM AND WE LOOK FORWARD TO
PROVIDING PATHWAYS AND
OPPORTUNITIES FOR INTER
DISCIPLINARY COLLABORATION
ACROSS THE DIFFERENT ICOs AND
CREATIVE WAYS TO INCORPORATE A
LIFE COURSE PERSPECTIVE WITH AN
INTEGRATED APPROACH TO HEALTH IN
AUTOIMMUNE DISEASE RESEARCH.
WE HAVE CURRENT AND FUTURE
ACTIVITIES AND I'M DIVIDING THEM
INTO INFRASTRUCTURE, SCIENTIFIC
DIRECTION, PUBLIC ENGAGEMENT AND
FUNDING OPPORTUNITIES.
WITH RESPECT TO INFRASTRUCTURE
WE HAVE A ORWH CORE WHO FOCUS IS
TO STAND UP THE OFFICE AND WE
HAVE EXISTING SCIENTIFIC STAFF
WHO HAVE AGREED TO TAKE TIME
BEYOND THEIR PRIMARY
RESPONSIBILITIES AND SELECT AID
SCIENTIFIC COORDINATOR TO SET UP
THE STEPS TO LAUNCH AND WE'RE
ABLE TO SECURE TWO FULL TIME
STAFF POSITIONS DEDICATED TO
OADR AND ONE OF THESE WILL BE
THE OADR DIRECTOR AND GOING
FORWARD TO SUSTAIN AND GROW THE
OFFICE, WE LOOK FORWARD TO
ASSESSING NEEDS FOR FURTHER
RESOURCES AND EFFORTS.
WE'RE TAPPING INTO NIH PLATFORM
SUCH AS THE OFFICE OF INTRAMURAL
TRAINING AND EDUCATION AND
ACCELERATING MEDICINE
PARTNERSHIPS FOR AUTOIMMUNE AND
IMMUNE DISEASES OR AMP AIM AND
WE PLAN ON IDENTIFYING EXISTING
DATASDATASETS TO DETERMINE HOW O
BUILD UPON THEM.
WE CERTAINLY COORDINATE WITH NIH
TO AND OTHER COMPONENTS TO
DEVELOP A CORSET OF AUTOIMMUNE
DISEASE RESEARCH COMMON DATA
ELEMENTS THAT WILL BE RECOGNIZED
BROADLY AND HELPED TO IDENTIFY
AND TRACK RESEARCH EFFORTS AND
INVESTMENTS AND COMMUNICATIONS
AND SEE THAT AS A CRUCIAL
BUILDING BLOCK OF THE NIH
LANGUAGE TO EXPAND THE
RECOGNITION OF AUTOIMMUNE
DISEASES.
PREVIOUSLY MENTIONED WHICH
CLEARLY IDENTIFIED AREAS FOR
IMPROVEMENT AND TO TO HAVE OUR
STEPS MOVING FORWARD AND WE HAVE
A COMMITTEE FOR AUTO I AM SEWN
DISEASE RESEARCH PROVIDING A
STRUCTURE FORUM TO LEVERAGE THE
AUTOIMMUNE DISEASE RESEARCH
EXPERTISE, ACROSS THE VARIOUS
INSTITUTES CENTERS AND OFFICES
AT NIH AND OFFER STREAMLINE
PROCESSES FOR EXPANDING
COLLABORATIONS ACROSS NIH AND
ALL NIH INSTITUTES AND CENTERS
DIRECTORS HAVE RECEIVE
COMMUNICATION ANNOUNCING NEW
CCADR AND RESPONDED TO ITS
REQUEST TO IDENTIFY THE
APPROPRIATE SCIENTIFIC EXPERTS
TO SERVE AS THEIR IC
REPRESENTATIVES AND ADDITIONALLY
OEDR EFFORTS WE HAVE EXPLORED
SEVERAL METHODS TO PARTNER WITH
INSTITUTES CENTERS AND OFFICE
THAT'S HAVE EXISTING ROBUST
AUTOIMMUNE DIS SEE RESEARCH
PORTFOLIOS AS WELL AS TO EXPAND
UPON EXISTING OPPORTUNITIES AND
MAP TO PERFORM PORTFOLIO
ANALYSIS AS PART OF THAT HAVE
SCIENTIFIC SETTING AND AND
REDEVELOPING A STRATEGIC PLAN.
WITH REGARDING TO PUBLIC
ENGAGEMENT, WE RECENTLY MET WITH
SEVERAL PATIENT ADVOCACY GROUPS
AT THEIR REQUEST AND SHARED OUR
EFFORTS TO STAND UP OADR AND
HEARD THEIR PERSPECTIVES AND
RECEIVED QUESTIONS.
WE EXPECT TO HAVE ON GOING
CONVERSATIONS WITH PATIENT
ADVOCACY GROUPS AND PROFESSIONAL
ASSOCIATIONS IN SOCIETY AND WE
WILL SOLICIT I AM INPUT FOR ANF
SAY ON PATIENT CENTRIC
PERSPECTIVES AS WE GO FORWARD
AND PROCESS OF MESSAGING
COMMUNICATIONS AND PLANS AND
STAKEHOLDER ENGAGEMENT EFFORTS.
AND OFFICES OF SUPPORTING
AUTOIMMUNE DISEASE RESEARCH AND
INTEND TO SUPPORT HIGHLY
MERITORIOUS APPLICATIONS.
WE HAVE IDENTIFIED SEVERAL
PATHWAYS FOR FY23 FOR FUNDING IN
EXTRAMURAL AND INTRAMURAL
PROJECTS AND WE'RE TAKING A
PROACTIVE APPROACH FOR FY24 AND
WE'LL PLAN TO SHARE MORE
INFORMATION ABOUT THOSE EFFORTS
SOON AS NEW OADR PROGRAMS ARE
STOOD UP AND DEVELOPED.
I MENTIONED A FEW MINUTES AGO
THE WOMWOMEN'S HEALTH CONFERENCD
THE FOCUSED EFFORT ON CHRONIC
DISEASES TA CAME OUT OF THAT
CONFERENCE AS WELL AS THIS
FUNDING OPPORTUNITY.
I WANT TO HIGHLIGHT THESE
NOFOs ARE NOTICES OF FUNDING
AT THE PRESENT TIME TO SUPPORT
CHRONIC DISEASES THAT EFFECT
WOMEN AND INDIVIDUALS A SIGNED
FEMALE AT BIRTH TA ARE UNDER
STUDIED AND BUILT ON THOSE
OPPORTUNITIES IN THE WOMEN'S
HEALTH REPORT AND THEY HIGHLIGHT
SPECIFICALLY AUTOIMMUNE DISEASE.
AS WELL AS DISEASES THAT ARE
RELATE TO DIFFERENT CHRONIC
CONDITIONS, MULTI MORBIDITY AND
A LIFE COURSE PERSPECTIVE.
SO THIS EXCITING -- TWO FUNDING
OPPORTUNITIES ARE AVAILABLE NOW
WITH A FIRST RECEIPT DATE OF MAY
19th OF THIS YEAR TO HELP US
GET THE WORD OUT TO ADVANCE
RESEARCH IN THESE IMPORTANT
AREAS.
NEXT I'M GOING TO MOVE ON TO
POLICY AND SCIENTIFIC UPDATES.
NIH INCLUSION POLICIES HAVE
EVOLVED OVER TIME.
IT WAS MY PLEASURE TO SHARE
INFORMATION ABOUT INCLUSION
POLICIES ALONG WITH Dr. MONICA
WEB HOOPER FROM THE NATIONAL
INSTITUTE FOR MINORITY HEALTH
AND HEALTH DISPARITIES WITH WHOM
I CO-CHAIR THE NIH INCLUSION
GOVERNANCE COMMITTEE RECENTLY AT
A WORKSHOP ON I AM CONCLUSIVE
PARTICIPATION AND CLINICAL
RESEARCH AND LED BIT NATIONAL
INSTITUTE OF MINORITY HEALTH.
SOMEONE NEEDS TO MUTE.
THANK YOU.
YOU WILL HEAR A FULL INCLUSION
UPDATE LATER THIS MORNING FROM
DAWN CORBETT.
I WANT TO HIGHLIGHT FOR YOU SOME
INFORMATION THAT IS PARTICULARLY
IMPORTANT TO HELP GET OUT AS
BROADLY AS POSSIBLE.
AS YOU KNOW, NIH HAS
REQUIREMENTS RELATED TO NIH
BASED CLINICAL TRIALS THAT MUST
BE DESIGNED SUCH THAT THE VALID
ANALYSIS FOR OUTCOMES BY SEX OR
GENDER, RACE AND ETHNICITY CAN
BE PERFORMED AND THOSE CLINICAL
TRIALS MUST BE REGISTERED IN A
CLINICAL TRIALS.GOV.
THE REPORTS FROM THAT VALID
ANALYSIS MUST NOW BE REPORTED IN
CLINICAL TRIALS.GOV AS A RESULT
OF THE 21st CENTURY CURES ACT.
I WANT TO REMIND YOU THAT VALID
ANALYSIS IS DIFFERENT FROM A
STATISTICAL ANALYSIS AND THE
PRINCIPLE REQUIREMENTS FOR
INSURING A VALID ANALYSIS OF THE
REQUEST OF INTEREST OR
ALLOCATION OF STUDY PARTICIPANTS
FROM DIFFERENT GROUPS AND AN
UNBIASED PROCESS SUCH AS
RANDOMIZATION AND BIASED
EVALUATION OF THE OUT COMES OF
THE STUDY PARTICIPANTS, FOR
EXAMPLE, BY SEX OR GENDER AND
USE OF UNBIASED STATISTICAL
ANALYSIS AND PROPER METHODS OF
INFERENCE TO ESTIMATE ASK
COMPARE THE INTERCEPTIONS INTERX
RACE OR ETHNICITY.
I ALSO WANT TO HIGHLIGHT FOR YOU
THAT NIH RECENTLY UPDATED OUR
INSTRUCTIONS FOR RESEARCH
PERFORMANCE AND PROGRESS REPORTS
AND DRAW YOUR ATTENTION TO THE
SECTION ON NIH DEFINED PHASE 3
CL3CLINICAL TRIALS.
THEY SHOULD HAVE A STATEMENT
INDICATING THE STATUS OF
ANALYSIS OF THE PRIMARY OUTCOME
BY SEX OR GENDER, RACE AND
ETHNICITY.
IN ADDITION THE RESULTS OF THESE
ANALYSIS SHOULD BE INCLUDED IN
THE PROJECT OUTCOMES SECTION OF
THE RPPR.
IF APPROXIMATIF YOU NEED MORE I,
HERE IS THE WEBSITE UNDER GRANTS
AND FUNDING.
I ALSO WANT TO GIVE YOU AN
UPDATE ON SEVERAL OTHER POLICIES
AND EFFORTS THAT ARE NIH WIDE IN
PARTICULAR NIH UNITE.
AND NIH UNITE LED BY NIH
LEADERSHIP AND THE CHIEF OFFICER
FOR SCIENTIFIC WORKFORCE
DIVERSITY Dr. MARIE BERNARD
PUBLISHED A PROGRESS REPORT AND
HERE ARE SOME OF THE EFFORTS
THAT THEY HIGHLIGHTED.
IN THAT PROGRESS REPORT, THE RFA
LED BY NATIONAL INSTITUTE OF
MINORITY HEALTH AND HEALTH
DISPARITIES ON UNDERSTANDING AND
ADDRESSING THE IMPACT OF
STRUCTURAL RACISM AND
DISCRIMINATION ON MINORITY
HEALTH AND HEALTH DISPARITIES
WAS HIGHLIGHTED AND THE PLAN FOR
ANYTHING DIVERSE PERSPECTIVES OR
PDEP PILOT THAT NINDS IS LEADING
IN THE BRAIN INITIATIVE WAS
MENTION OF THE.
TWO COMMON FUND PROGRAMS, THE
TRANSFORMATIVE RESEARCH TO
ADDRESS HEALTH DISPARITIES AND
ADVANCE HEALTH ECONOMIC
INITIATIVE AND ADVANCE SCIENCE
FOR SOCIETY OR COMPASS EFFORTS
WERE HIGHLIGHTED AS WELL AND I
CONTINUE TO BE HOP RESIDENT TO
CO-CHAIR THE WORKING GROUP FOR
COMPASS.
A VARIETY OF OTHER EFFORTS
INCLUDING MORE TRANSPARENT DATA
REPORTING AND THE DATA
DASHBOARD, THE POWER OF AN
INCLUSIVE WORK SPACE RECOGNITION
PROJECTS AND OPPORTUNITIES FOR
GRANTEES TO NOTIFY NIH ABOUT A
CONCERN RELATED TO HARASSMENT,
DISCRIMINATION OR OTHER
INAPPROPRIATE CONDUCT INCLUDED
BUT NOT LIMITED TO SEXUAL
HARASSMENT, RACIAL
DISCRIMINATION AND FULLYING AND
WHAT CONTRIBUTING TO AN UNSAFE
OR HOSTILE WORK ENVIRONMENT
EFFECTING AN NIH FUNDED PROJECT
AND A RECIPIENT INSTITUTION AND
THERE'S A FORM AVAILABLE ON ERA
COMMONS TO REPORT SUCH CONCERNS.
AND I WANT TO THANK THE OFFICE
OF SCIENTIFIC WORKFORCE
DIVERSITY FOR LEADING THE
PREPARATION OF THE UNITE
PROGRESS REPORT.
OTHER UPDATES.
WE'RE EXCITED O SHAR EXCITE TO A
POLICYERS AND WERE HIGHLIGHTED
IN THE NIH IMPACT PAGES UNDER
THE REVOLUTIONIZING SCIENCE
SECTION.
THE IMPACT PAGES DEMONSTRATE THE
WAYS THAT NIH RESEARCH HAS HAD
IN INFLUENCE AND IMPACT ON THE
WORLD AROUND US.
SO TAKE A LOOK AT THE IMPACT
PAGES AND YOU CAN LEARN MORE
ABOUT THE SABB IMPACT PAGE.
ORWH UPDATED AND EXPANDED OUR
SEX AND GENDER WEB PAGE ON OUR
ORWH WEBSITE OUTLINING SEX AS A
BIOLOGICAL VARIABLE AND GENDER
AS A SOCIAL AND CULTURAL
VARIABLE AND PROVIDED AN UPDATE
TO OUR SEX AND GENDER INFORM
GRAPHIC OUTLINE ARE VARIOUS WAYS
THAT SEX AND GENDER CAN EFFECT
HEALTH AND DISEASE HERE I'M JUST
HIGHLIGHTING WITHIN OF THE MANY
ON MENTAL HEALTH.
TAKE A LOOK AT OUR WEBSITE AND
YOU CAN ALSO PULL OR SEX AND
GENDER AND HEALTH AND DISEASE
FACT SHARE TO SHARE MORE
INFORMATION AND I WANT TO
ACKNOWLEDGE OUR ORWH TEAM FOR
LEADING THOSE EFFORTS.
I'M GOING TO MOVE INTO THIS
SECTION ON ICO COLLABORATION AND
I'M GOING TO SHARE A NEW
COLLABORATION THAT ORWH HAS
EMBARKED UPON WITH THE NIH
OFFICE OF AIDS RESEARCH.
DESPITE IMMENSE SCIENTIFIC
ADVANCES, WOMEN AND GIRLS
INCLUDING TRANSGENDER AND GENDER
CONNECTICUT FIRMING PEOPLE ARE
AFFECTED BY HIV.
HALF OF ALL NEW INFECTIONS
WORLDWIDE ARE AMONG WOMEN AND
THIS IS HEAVILY WEIGHTED AMONG
ADOLESCENT GIRLS AND YOUNG WOMEN
IN EAST AND SOUTHERN AFRICA.
IN 2021, 20 MILLION AND GIRLS
WERE LIVING WELL HIV.
54% OF ALL PEOPLE.
AND THE PREVALENCE AMONG
TRANSGENDER WOMEN IS HIGH
ESTIMATED AT 20% AND THEY
EXPERIENCE 14-FOLD GREATER RISK
OF ACQUIRING LIVED THAN ADULT
CISGENDER WOMEN.
IN 2022, THE WOMEN'S HIV
RESEARCH FUNDING AT NIH WAS
ESTIMATED AT JUST UNDER
$500 MILLION DELINEATED HERE ON
THE SLIDE ON THE LEFT.
ALL WOMEN'S HEALTH PROJECTS HERE
AND THEN ALL HIV PROJECTS HERE.
TOPICS FUNDED INCLUDE ALL THE
NIH HIV RESEARCH PRIORITIES WITH
INVESTMENTS IN CROSS CUTTING
RESEARCH AND IMPROVING THERAPIES
FOR HIV ASSOCIATED CO-MORBIDITY
AND CO INFECTIONS AND DESPITE
THIS INVESTMENT RESEARCH ON
WOMEN AND HIV UNDER REPRESENTED
WITHIN THE HIV PORTFOLIO AND
RESEARCH TO IMPROVE WOMEN'S
HEALTH WE KNOWS REQUIRES A
MULTI-DISCIPLINARY APPROACH TO
ENSURE COMPREHENSIVE
CONSIDERATION OF MANY INTERNAL
AND EXTERNAL FACTORS ACROSS THE
LIFE COURSE.
THIS IS REFLECTED IN THE NIH-HIV
RESEARCH PORTFOLIO WITH 19 OF
THE 27 INSTITUTES AND CENTERS
SHOWN HERE INVESTING IN A WIDE
RANGE OF RESEARCH TOPICS ON HIV
AND WOMEN.
I LOOK FORWARD CONTINUING TO
WORK WITH OAR ON THIS NEW
COLLABORATION.
THE OBJE OBJECT OBJECTIVES OF TS
ORWH SIGNATURE PROGRAM ON HIV
AND WOMEN IN PARTNERSHIP WITH
ORWH ARE TO PRE MET HEALTH FOR
ALL WOMEN LIVING WITH OUR AT
RISK WITH HIV AND SUPPORT CAREER
DEVELOPMENT FOR WOMEN IN HIV
RESEARCH.
THE PROGRAM WILL SUPPORT
EFFORTS.
ONE OF THE STRATEGIES THAT WE'VE
EMPLOYED FIRST WAS TO FORM A
WORKING GROUP ON HIV IN WOMEN
AND THAT IS LINKING THE NATIONAL
ADVISE AIDS ADVISORY COMMITTEE
AS WELL AS THE CCRWH OUR NIH
COORDINATING COMMITTEE FOR
RESEARCH ON WOMEN'S HEALTH.
WE HAD A JOINT SYMPOSIUM AT THE
13th INTERNATIONAL WORKSHOP ON
WOMEN AND HIV CALLED
CONSIDERATIONS FROM ACROSS THE
LIFESPAN.
THAT SYMPOSIUM FOCUSED ON
ADOLESCENT GIRLS AND YOUNG
WOMEN.
MULTI MORBIDITY AND AGING AND
SOCIAL AND STRUCTURAL
CONSIDERATIONS IN HIV RESEARCH.
YOU CAN LEARN MORE ABOUT THIS
SYMPOSIUM AND THE NEW SIGNATURE
PROGRAM AT OUR WEBSITE AS WELL
AS OAR'S WEBSITE AND I WAS
PLEASED TO JOIN Dr. MARINE
GOODNOW WITH A JOINT BLOG ABOUT
THESE EFFORTS AND I WANT TO
THANK HER FOR HER COLLABORATION
AND SCIENTIFIC LEADERSHIP IN
THIS SPACE.
ANOTHER CRITICAL AREA FOR
WOMEN'S HEALTH IS THE RATES OF
MATERNAL MORTALITY.
I SHOWED YOU WORLDWIDE RATES AT
THE BEGINNING OF THIS
PRESENTATION AND NOW I WANT TO
SHARE WITH YOU RECENT DATA FROM
THE NATIONAL CENTER FOR HEALTH
STATISTICS ON U.S. RATES OF 2018
TO 2021.
TOTAL, YOU CAN SEE HERE WAS
SIGNIFICANT INCREASES IN THE
LAST THREE YEARS INDICATED BY
THE RED ASTERISKS THE RATES HERE
ARE WITH SIGNIFICANT INCREASES
AND THE LAST TWO YEARS AND THE
YEAR OVER YEAR INCREASES FOR
NON-HISPANIC WHITE.
YOU CAN SEE INCREASES FOR
PREGNANT WOMEN AS WELL AS FOR
NEW TRENDS IN INCREASES IN
HISPANIC MATERNAL MORTALITY
RATES THAT ARE OF SIGNIFICANT
CONCERN TO US ALL.
WHEN YOU BREAK THIS DOWN BY AGE,
YOU CAN SEE INCREASES ACROSS THE
BOARD, EVEN IN UNDER 25 AND 25
TO 39 AGE GROUPS AND OF COURSE
OLDER AGE GROUPS OVER 40 HAVE
HIGHER RATES OF MATERNAL
MORTALITY AND WE SEE THAT
INCREASING EVEN FURTHERMORE FURE
RECENTLY.
IN TERMS OF PREGNANCY MORTALITY
RATIOS THEY'VE INCREASED, MORE
IN 2021 NAN 2020.
THIS DATA DA LYNN IT'S A THE
PREGNANCY RELATED WITHOUT A
COVID-19 CODE IN TERMS OF
IDENTIFYING THIS DARKER BLUE
AREA AND A
CONCERNING MATERNITY MORTALITY
RATE IN THIS COUNTRY.
AND IF YOU LOOK AT RURAL OR
URBAN RESIDENTS IN A SIMILAR
TIME PERIOD, YOU CAN SEE LARGE
METROPOLITAN AREAS HAVE ALSO
SHOWN AN INCREASE, MEDIUM AND
SMALL METROPOLITAN AREAS WITH
RURAL AND URBAN RESIDENTS
CATEGORIES AND JUST RURAL AREAS
AS WELL OVER LYING THIS
COMPLICATED PICTURE IS THE
INCREASE WHERE THEY HAVE CARE
FOR WOMEN TO DELIVER.
IN TERMS IT OF THE COVID-19
ISSUES, I WANT TO HIGHLIGHT THAT
SOME NEW RESOURCE HAVE BECOME
AVAILABLE AND THERE ARE SOME NEW
PUBLICATIONS, SCIENCE RECENTLY
HIGHLIGHT THERE'S A HIGHLIGHT
OPT NIH LED RESEARCH RESPONSE TO
COVID-19 AND THAT IS A EXCELLENT
SUMMARY OF OVER ALL EFFORTS.
YOU'VE HEARD HERE BEFORE WILL
RECOVERY SEARCH AND DROVE
ENHANCE RECOVER ARE IN THE LEAD
FOR THESE EFFORTS ON NIH
RESEARCH ON COVID AND INCLUDING
LONG COVID AND BOTH PREGNANT AND
LACTATING PEOPLE ARE INCLUDED IN
THOSE RESEARCH EFFORTS AND THE
NIH COMMUNITY ENGAGEMENT
ALLIANCE OR SEAL HAS LONG COVID
RESOURCES I'M HIGHLIGHTING HERE
AS WELL AS A VARIETY OF OTHERS.
IN THE INTEREST OF TIME I WANT
TO HIGHLIGHT THESE IN SINGLE
SLIDE AND REFER YOU TO THOSE WEB
SITES FOR MORE DETAILED
INFORMATION.
I WANT TO UPDATE YOU ON THE
STEPS THAT NIH HAS TAKEN JOINING
FORCES TO TACKLE THE CRITICAL
PUBLIC-HEALTH CRISIS OF MATERNAL
MORTALITY IN THE UNITED STATES
THROUGH THE IMPROVE INITIATIVE.
IMPROVE STANDS FOR IMPLEMENTING
A MATERNAL HEALTH AND PREGNANCY
OUTCOMES VISION FOR EVERYONE AND
I CONTINUE TO BE PRIVILEGED TO
CO-CHAIR ALONG WITH THE DIRECTOR
OF THE EUNICE KENNEDY SHRIVER
NATIONAL INSTITUTE OF CHILD
DEVELOPMENT AND THE CO-CHAIR
NATIONAL INSTITUTE OF NURSING
RESEARCH Dr. SHANNON ZENK.
THE MATERNAL RESEARCH CENTERS
HEALTH OF EXCELLENCE AND OTHER
EFFORTS THAT SURROUND THAT
CENTER PIECE.
IT WAS LAUNCHED IN FY20 AND IN
21 AND 22 AND NIH WORKED ACROSS
THE INSTITUTES AND CENTERS TO
FUND THESE EFFORTS ON THE
PERIPHERY AND WE ARE LOOKING
FORWARD TO FUNDING THE MATERNAL
HEALTH RESEARCH CENTERS OF EX
TENSE AND FY23 FOLLOWING A
CONGRESSIONAL APPROPRIATION IN
FY22 AND FORWARD FOR $30 MILLION
TO THE IMPROVE INITIATIVE.
WE RECENTLY HOSTED AN AWARDEE
WORKSHOP WHERE GRANTEES
HIGHLIGHTED LESSONS LEARNED FROM
IMPROVED PROJECTS IDENTIFIED
COMMON THEMES AND SHARED
RESEARCH GAPS AND OPPORTUNITIES
FOR ON GOING COLLABORATION AND
FURTHER DEFINED THE NEEDS OF
PREGNANT AND POSTPARTUM
INDIVIDUALS TO REDUCE
PREVENTABLE DEATHS.
IMPROVE LEADERSHIP -- DELIVERED
A CONGRESSIONAL BRIEFING AND
UPDATED NIH LEADERSHIP ON THESE
ACTIVITIES AND I WOULD LIKE FOR
YOU TO PUT ON YOUR CALENDARS AN
UPCOMING HYBRID WORKSHOP ON
INNOVATIVE APPROACHES TO
IMPROVED MATERNAL HEALTH THAT
WE'LL HOLD ON MAY EIGHTH AND
NINTH.
I'M EXCITE TODAY SHARE THE
DIAGNOSTIC CHALLENGE.
FIRST PLACE WENT TO Dr.
BETHANY FOR HER HOME BASED
DIAGNOSIS OF SURGICAL SITE
INFECTION AND ANEMIA AND SECOND
PLACE WENT TO THE UNIVERSITY OF
CALIFORNIA IRVINE FOR THEIR
MATERNAL OBSTETRICAL MONITORING
SOCKS.
THESE ARE POINT OF CARE SOCKS
THAT TRACK BLOOD PRESSURE AND
HEART RATE AND MONITOR BLOOD
FLOW AND CAN BE USED DURING AND
AFTER DELIVERY IN LOW RESOURCE
SETTINGS.
THE FIRST WAS A TIE AND IT WENT
TO RADIANT OX SYMMETRY FOR A
VARIETY OF WEARABLE DEVICES ONE
RELATED TO ULTRASOUND AND
ELECTRIC CHEMICAL CENTER AND ONE
MONITORS HEMORRHAGE AND FETAL
DISTRESS.
SO I WANT TO CONGRATULATE ALL
THE WINNERS OF THE MATERNAL
HEALTH DIAGNOSTIC CHALLENGE AND
HIGHLIGHT THAT THIS IS ONE
IMPORTANT MECHANISM THAT WE CAN
SPUR INNOVATION IN THIS
CRITICALLY IMPORTANT AREA.
YOU'VE HEARD BEFORE ABOUT ORWH
AND NLHBI AND NI HMD AND OTHERS
AT NIH AND THE OFFICE OF DISEASE
PREVENTION LED PATHWAYS TO
PREVENTION PROGRAMS OR P2P.
WE'VE BEEN UNDERWAY WITH THE
PORTFOLIO ANALYSIS AND THE
EVIDENCE REPORT VARIOUS
PRESENTATIONS AND AUDIENCE
PARTICIPATION AND WORKSHOPS
BEING CONDUCTED AND I'M EXCITED
TO SHARE WITH YOU THAT THE
RECENT WORKSHOP SOME OF THE
TAKEAWAYS WERE THAT THE STRESS
TEST OF PREGNANCY CONTINUES
POSTPARTUM AND WE NEED TO BRIDGE
BETWEEN CARE OF THE PREGNANT
INDIVIDUAL AND THE POSTPARTUM
PERSON AND TAKE A LIVE COURSE
PERSPECTIVE ON WOMEN'S HEALTH
AND LISTEN TO THE PATIENT AND
THEIR FAMILIES AND THE PANEL
REPORT FROM THE RESENT WORKSHOP
IS NOW AVAILABLE FOR PUBLIC
COMMENT AND SO PLEASE TAKE A
LOOK AT THIS WEBSITE AND PROVIDE
YOUR THOUGHTS AND PERSPECTIVES.
AS WE MOVE FORWARD THROUGH THE
PATHWAYS TO PREVENTION PROJECTS.
IF YOU MISSED THE WORKSHOP, IT'S
AVAILABLE ON THE OFFICE OF
DISEASE PREVENTION WEBSITE.
THERE WERE TWO AMAZING DYNAMIC
KEYNOTE SPEAKERS AMONG MANY
OTHER PRESENTATIONS AND CARE
BRIDGES AND ALAN TIDA PRESENTED
ON MATERNAL HEALTH AND THE
NATION'S FAILURE TO COMMIT
ITSELF TO REPRODUCTIVE JUSTICE
FORMALLY AND ALAN TIDA ON
POSTPARTUM HEALTH AND EQUITY.
I WANT TO HIGHLIGHT JUST ONE OF
THE MULTIPLE SKETCHES THAT WERE
CREATED DURING THE WORKSHOP AND
THIS ONE IS THE ROUNDTABLE ON
ELEVATING PATIENT CENTERS
STRATEGIES AND CARE AND
IDENTIFYING RISKS AND
INTERVENTION TO OPTIMIZE
POSTPARTUM HEALTH WAS THE TITLE
OF THAT WORKSHOP AND YOU CAN SEE
THAT IT DELINEATES THE
IMPORTANCE OF A VARIETY OF
EFFORTS AND ELEVATING, SHARING
THE VOICE OF THE PATIENT, FOR
EXAMPLE AND SUPPORTING AND
EDUCATING THE INDIVIDUAL
MATERNAL MORBIDITY AND IN
INDIGENOUS POPULATIONS AND THE
PATIENT PERSPECTIVE.
THERE ARE SO MANY RICH CONCEPTS
DISCUSSED THERE, EQUITABLE BIRTH
CARE AND I HIGHLIGHT THE SKETCH
EFFECT HERE THAT YOU CAN REVIEW
WE HAVE SKETCHES FROM EACH OF
THE SECTIONS VEIL ONLY ON THE
WORKSHOP.
ANOTHER IMPORTANT AREA IS
INTIMATE PARTNER VIOLENCE.
AND FIRST MENTAL HEALTH OUTCOMES
AMONG WOMEN AND DURING THE
PANDEMIC, THIS PAPER LOOKED AT
THREE PERSPECTIVE POPULATION
BASED LONGITUDINAL U.S. COHORT
STUDIES WELL-KNOWN TO YOU AND
INCLUDING THE NURSES HEALTH
STUDY AND EXAMINED INTIMATE
PARTNER VIOLENCE AND EXPERIENCES
AT THE START OF THE PANDEMIC AND
THEY WERE ASSOCIATED WITH HIGHER
REPORTS OF DEPRESSION AND
ANXIETY AND POST TRAUMATIC
STRESS SYMPTOMS AS WELL AS POOR
SLEEP QUALITY, SHORT SLEEP
DURATION AND INCREASE USE OF
ALCOHOL AND OTHER SUBSTANCES TO
COPE WITH STRESS.
WITH PARTNERS WITH THE NATIONAL
INSTITUTE OF NURSING AND OFFICE
OF BEHAVIORAL AND ODP ON A
RECENT REQUEST FOR INFORMATION
ON FUTURE DIRECTIONS OF VIOLENCE
AGAINST WOMEN RESEARCH AND WE
ARE IN THE PROCESS OF ANALYZING
THE DATA IN COLLABORATION WITH
NINR AND PARTNERS SO STAY TUNED
FOR MORE THERE.
AS I MOVE INTO THIS LAST SECTION
OF THE PRESENTATION ON CAREERS,
CRITICALLY IMPORTANT AREA.
I WANT TO HIGHLIGHT A NEW REPORT
FROM THE NATIONAL ACADEMIES OF
SCIENCE ENGINEERING AND
MEDICINE.
THERE WERE EIGHT RECOMMENDATION
AND I'M HIGHLIGHTING THREE AREAS
AND IMPORTANCE OF DEVELOPING AND
PLANS TO PROMOTE AN ACCESSIBLE
CULTURE AND ADDRESS BIAS.
COLLECTING DATA ON DEMOGRAPHICS
AND AND REDRESSING BIAS AND
DISCRIMINATION IN ORGANIZATIONAL
PROCESSES.
THAT REPORT IS ENTITLED
ADVANCING ANTI RACISM DIVERSITY,
EQUITY AND INCLUSION AND STEM
ORGANIZATIONS BEYOND BROADENING
PARTICIPATION, I CON SEN ANXIOUY
REPORT.
I REFER YOU TO THEIR WEBSITE FOR
MORE INFORMATION.
THROUGH THE NIH ADVISORY
COMMITTEE TO THE DIRECTOR HAS
EMBARKED ON A WORKING GROUP TO
ADDRESS REIN-VISIONING U.S.
POSTDOCTORAL RESEARCH EXPERIENCE
AND CAREER PROGRESSION WITHIN
THE BIOMEDICAL RESEARCH ENDER
PRICE AND THAT ACD WORKING GROUP
HAS FACILITATED FOUR LISTENING
SESSION THIS IS MARCH AND THEY
WERE INTERNATIONAL TRAINING
CONCERNS AND THE STRUCTURE AND
VALUE CONNECTS ON UNDER
REPRESENTED POPULATIONS AND
COMPENSATION AND BENEFITS TO
POSTDOCS INCLUDING CHILDCARE AND
DEPEDEPENDENT CARE, JOB SECURITD
CAREER PROSPECTS AND QUALITY OF
LIFE.
AN RFI IS AVAILABLE ON THIS
TOPIC.
WITH LOWER TIME YO MORE TIME YOL
RESPOND.
WE'RE INTERESTED IN ANYONE'S
CONCERNS AND ANYONE EFFECTED BY
THIS CHALLENGES IN THIS SPACE TO
ADDRESS THE FUNDAMENTAL
OBSTACLES FACED BY THE POSTDOC
TRAINEE EXPERIENCE SO PLEASE DO
RESPOND TO IT THIS RFI REQUEST
FOR INFORMATION WITH YOUR
THOUGHTS.
I'M EXCITED TO ALSO SHARE WITH
YOU THE PROGRESS ON OUR GENDER
R25 AND FIRST EVER R21 CALLED
GALVANIZING HEALTH EQUITY
THROUGH NOVEL AND DIVERSE
EDUCATIONAL RESOURCES OR GENDER
AND WE HAD OUR FIRST RECEIPT
DATE TO MEET THE NEED FOR GENDER
SPECIFIC TRAINING AND SCIENCE
MEDICINE AND ALLIED HEALTH
PROFESSIONALS AND TO SUPPORT THE
DEVELOPMENT OF GENDER FOCUSED
COURSES FOR METHODS FOR THE
EXTRA COMMUNITY AND PARTNERSHIP
WITH OUR ICOs AND ESPECIALLY I
WANT TO GIVE A SHOUT OUT TO THE
NATIONAL LIBRARY OF MEDICINE FOR
TAKE THE LEAD ON ADMINISTERED
THIS PROGRAM WITH ORWH.
THE NEXT APPLICATION DATE IS
JUNE 27th.
YOU HEARD LAST YEAR AT THE
VIVIAN PIN SYMPOSIUM ORWH
INTEREST IN CHAR IT TERRIZING
CONSISTENT WITH LATCH LER ETAL.
PEOPLE TAKE MANY PATHS THROUGH
CAREERS WHETHER IT'S TAKING CARE
OF THEIR FAMILIES OR LEAVING FOR
MILITARY SERVICE OR REENGAGING
IN FORMAL EDUCATION.
THESE PATHS ARE ALL PART OF THE
BRAIDED RIVER THAT REPRESENTS A
MORE CONTEMPORARY META FOR FOR
CAREER PATHS AND THESE
EXPERIENCES OF INDIVIDUALS WHEN
WE HAVE AN I AM CONCLUSIVE STEM
WORKFORCE UNDERPINNING THIS AND
MENTORSHIP AND HOLISTIC SUPPORT
ACROSS THE BOARD PROVIDE NEW
IDEAS THAT ARE MORE CREATIVE AND
PRACTICAL TO OFFER INTERNET
DISCIPLINARY SOLUTIONS TO
SCIENCE.
ALONG THOSE LINES, AT THE LAST
MEETING HERE, IT WAS MY
PRIVILEGE, ALONG WITH THE
DIRECTOR OF NATIONAL INSTITUTE
AND SKIN DISEASES HIGHLIGHT A
NEW PROGRAM IN WOMEN'S HEALTH
AUTO MANY UNION AND IMMUNE
MEDIATED DISEASES A PILOT
PROGRAM TO SUPPORT AND TRAIN
WOMEN'S HEALTH SCHOLARS HELPING
THEM TO ACQUIRE IN HOME SKILLS
FOR COMPLEX TEAM SCIENCE
LEADERSHIP AND INCLUDING ACROSS
TOPICS LIKE DATA SCIENCE AND
OTHERS THAT INVOLVE LARGE MULTI
COMPONENT EFFORTS.
THIS IMMERSIVE COST SECTOR
COLLABORATIVE EXPERIENCE IN THE
LEADERSHIP SCHOLARS PROGRAM WILL
ENABLE THESE INDIVIDUALS TO BE
WELL PREPARED TO BE LARGE
CONSORTIUM TEAM LEADERS.
AND IS BEING CONDUCTED THROUGH H
THE ACCELERATING ON AUTOIMMUNE
AND AMP AIM A PUBLIC-PRIVATE
PARTNERSHIP AT NIH.
I LOOK FORWARD TO PROVIDE YOU
WITH UPDATES ON THIS PROGRAM.
MORE UPDATES GOING FORWARD.
I ALSO WANT TO HIGHLIGHT FOR YOU
AN OPPORTUNITY ON O ADVANCING
GENDER INCLUSIVE EXCELLENCE THAT
GREW OUT OF THE NIH WORKING
GROUP ON WOMEN AND BIOMEDICAL
CAREERS THAT I CO-CHAIR WITH THE
NIH DIRECTOR.
THEY HAVE PARTNERED WITH KIDNEY
DISEASE AND I WANT TO HIGHLIGHT
THEIR LIP I LEADERSHIP IN THIS
SPACE.
THERE IS A U24 COORDINATING
CENTER.
THE PURPOSE TO PROVIDE THE
ORGANIZATIONAL FRAMEWORK FOR THE
MANAGEMENT DIRECTION AND OVER
ALL COORDINATING ACTIVITIES
AIMED AT INVESTIGATING
STRATEGIES, APPROACHES AND
INTERVENTIONS TO PROMOTE GENDER
EQUITY AND ADDRESS BARRIERS FOR
WOMEN AT FACULTY AND LEADERSHIP
LEVELS IN MANY AREAS OF SCIENCE
AND TECHNOLOGY AND ENGINEERING
AND MEDICINE.
THE NEXT RECEIPT DATE IS MAY
FIRST.
IF YOU ARE INTERESTED IN
APPLYING FOR THIS COORDINATING
CENTER, THIS AMAZING
OPPORTUNITY, PLEASE DO TAKE A
LOOK AT WEBSITE HERE.
LAST YEAR AT THE NIH WORKING
GROUP IN WOMEN AND BIOMEDICAL
CAREERS WE TALKED ABOUT
REIMAGINING WOMEN IN THE BIO
ENGINEERING TECHNOLOGY AND DATA
SCIENCE ECOSYSTEM.
THE SUMMARY FROM THAT REPORT IS
NOW AVAILABLE ON OUR WEBSITE AND
I'M JUST HIGHLIGHTING ONE OF THE
SKETCHES FROM THAT MEETING.
WOMEN AND THEN IMPORTANCE OF
WOMEN AS INNOVATORS AND
INVENTORS AND ENTREPRENEUR.
THE GOOD NEWS THAT WOMEN ARE
CERTAINLY OUTPERFORMING IN
VARIOUS WAYS, 40% WERE
ENTREPRENEURS IN 2020.
THERE ARE FUNDING GAPS IN THIS
SPACE AND WE NEED TO ADDRESS THE
STICKY FLOOR ISSUES AND AS WELL
AS HEALTH EQUITY AND SOCIAL
IDENTITY AND THIS M-SHAPED
CAREER PATH AND THE NEED FOR
CULTURE CHANGE WHERE THE THEMES
HIGHLIGHTED IN THE PARTNERSHIP
SUMMIT AND I WAS EXCITED WHEN
Dr. SUZANNE GREGRICK FOR DATA
SCIENCE AND THE DIRECTOR OF
OFFICE OF DATA SCIENCE STRATEGY
ODSS HERE AT NIH HIGHLIGHTED
WOMEN AND DATA SCIENCE AND HER
WOMEN'S HISTORY BLOG AND IT WAS
MY PLEASURE TO BE INCLUDED IN
THAT BLOG POST TALKING ABOUT
WOMEN IN DATA SCIENCE.
I'M VERY CONCERNED WE SEE DATA
GOING IN THE WRONG DIRECTION
WITH A REDUCTION OF WOMEN
RECEIVING COMPUTER SCIENCE
DEGREES AT THE UNDER GRADUATE
LEVEL WHEN DATA SCIENCE JUST
TAKING OFF CLEARLY AS CRITICALLY
IMPORTANT ESPECIALLY IN
BIOMEDICAL AND BEHAVIORAL
RESEARCH IN THE ECHO SYSTEM SO
TAKE A LOOK AT THE BLOG FOR
INFORMATION ON AMAZING WOMEN AND
NIH AND DATA SCIENCE INCLUDING
Dr. GREGRICK AND OTHERS.
I WANT TO HIGHLIGHT AGAIN, AS I
ROUND UP HERE, THE FEW EVENTS.
NIDCR IS COMING ON THEIR 75t
75th ANNIVERSARY AND THEY'RE
LAUNCHING THE EFFORTS AND I WANT
TO CONGRATULATE THEM FOR 75
YEARS OF RESEARCH ON DENTAL AND
CRANIAL FACIAL DISEASES.
IT WAS OUR PRIVILEGE TO
COLLABORATE WITH THEM DURING
BLACK HISTORY MONTH TO HOST A
FIRESIDE CHAT WITH ALLEGE, Dr.
JEAN SINKFORD WHO WAS A FORMER
MEMBER AND LEDGE END AT THE FOR
FRONT OF EQUITY AND ORAL HEALTH
AND HUMAN CAREER DEVELOPMENT AND
IN MANY OTHER SPACES AND SHE
TELLS HER STORY AND THIS BOOK ON
DOTTED TRAILBLAZERS MINORITY
WOMEN LEADERS IN ORAL HEALTH.
AND WE CHOSE TO FEATURE WOMEN'S
ORAL HEALTH AS A THEME IN A
RESENT ISSUE WOMEN'S HEALTH IN
FOCUS ON A QUARTERLY BASIS WE
WOULD SELECT A THEME AND
HIGHLIGHT NIH WIDE EFFORTS IN
THIS SPACE.
IF IF YOU MISSED THAT, TAKE A
LOOK AT IT AND YOU CAN SEE ON
OUR WEBSITE THIS YEAR FORT
SEVENTH ANNUAL VIVIAN W. PIN
SYMPOSIUM OUR EVENT TOLL
RECOGNIZE NATIONAL WOMEN'S
HEALTH WEEK WE ARE FOCUSING ON
MENOPAUSE AND OPTIMIZING MID
LIFE HEALTH OF WOMEN HELD ON MAY
16th.
OUR INFORMATION IS AVAILABLE ON
OUR WEBSITE.
THE KEYNOTE WILL BE DELIVERED BY
Dr. JOANNE MANSON PROFESSOR OF
MEDICINE AT HARVARD MEDICAL
SCHOOL AND THE CHIEF OF THE
DIVISION OF PREVENTATIVE
MEDICINE AT THE DEPARTMENT OF
MEDICINE THE TITLE IS PEN A MENL
THERAPY.
JOIN US ON MAY 16th, WE HAVE
AN AMAZING LINEUP OF INCREDIBLE
PRESENTATIONS ON A VERY
IMPORTANT TOPIC.
AND OUR ORWH LECTURE SERIES
CALLED DIVERSE VOICES I'M JUST
HIGHLIGHTING OUR RECENT
PRESENTATIONS AND TALKS ON
CANCER DISPARITIES, METHODS AND
MEASURE ON INTERSECTIONAL STIGMA
AND MENTAL HEALTH AND UPCOMING
IN JULY AND SEPTEMBER ON
INTERSECTIONAL APPROACHES TO
SUBSTANCE USE AND MISUSE AND
SOCIAL DETERMINANTS AND UP TAKES
OF INFECTIOUS DIS SEES CONTROL
MEASURES SO YOU OF CAN GET
INFORMATION ABOUT THOSE BY
SIGNING UP FOR OUR EVENTS.
YOU CAN GET OUR MONTHLY E-MAILS,
THE PULSE, AND OUR QUARTERLY
PUBLICATIONS AND LEARN MORE
ABOUT OUR E-LEARNING FORCES AT
OUR WEBSITE WITH THAT, I AM
GOING TO STOP SHARING.
AND TURN THE PODIUM BACK OVER TO
Dr. NOURSI.
I KNOW WE'RE THREE MINUTES OVER.
>>Samia Noursi: YOU ARE GREAT
ON TIME.
YOU ARE ONLY FOUR MINUTES.
CAN YOU HEAR ME?
>>I WOULD JUST LIKE TO WELCOME
DR. PHIL IS SHARPS WHO JOINED US
SINCE IN THE LAST HOUR AND Dr.
AMANDA BREGAL.
Dr. JUTTER IS WITH US SO YOU
WANT TO TAKE QUESTIONS NOW OR DO
YOU WANT TO DO IT LATER FOR THE
DISCUSSION SO WE STAY ON TIME?
>>YES, LET'S GO AHEAD.
IF YOU HAVE QUESTIONS OR
THOUGHTS FROM MY PRESENTATION,
JUST DROP THEM DOWN OR YOU CAN
PUT THEM IN THE CHAT SO WE CAN
TEE THEM UP FOR OUR DISCUSSION
TIME LATER.
I DO WANT TO GO A HAPPENED AND
IGO AHEAD AND INTRODUCEJOANNIE M
ADVANCING TRANSLATIONAL SCIENCES
AND FONDLY KNOWN AS N CATS AND
SHE'S PLANNING OF THE COMPLEX
AND MULTIFACETED CLINICAL
RESEARCH PROGRAMS AND OF COURSE
THE PRIMARY OBJECTIVE THERE SHE
HAS IS DIRECTOR IS TO USE
TRANSLATIONAL SCIENCE AS A MEANS
TO PROVIDE ALL PEOPLE WITH MORE
TREATMENTS, MORE QUICKLY AND
EFFICIENT LEASE AND AS I
MENTIONED BEFORE, JOANNIE,
BEFORE SHE JOINED NCATS SHE WAS
THE DIRECTOR OF SCIENTIFIC
PROGRESS WITH ALL OF US PROGRAM
AND AT THE PRECISION MEDICINE
INITIATIVE AND BEFORE THAT AS
DIRECTOR OF DIVISION OF
NEUROSCIENCE AND BEHAVIOR AT
NATIONAL INSTITUTE OF DRUG ABUSE
SO IT'S MY OF PLEASURE TO DO
WELCOME Dr. JOANNIE RUTTER.
>>THANK YOU SO MUCH.
TO TALK A LITTLE BIT MORE TO THE
COUNCIL.
IT'S A PLEASURE TO BE HERE AND
YOU ARE GOING TO SEE MY DOG'S
TAIL WAGGING IN THE BACKGROUND
BECAUSE SHE'S EXCITED TOO.
I'M GOING TO TALK ABOUT
TRANSLATIONAL SCIENCE AND
WOMEN'S HEALTH BUT BEFORE I GET
INTO SOME OF THOSE ASPECTS, I
WANT TO START OFF WITH A LITTLE
BIT MORE BACKGROUND OF NCATS.
SO YOU CAN GO TO THE NEXT SLIDE.
N CATS.
THE NATIONAL CENTER FOR
ADVANCING TRANSLATIONAL SCIENCES
OR NCATS,.
>>IT'S FULLY IN THE
TRANSLATIONAL RESEARCH AND
SIDISTUDYING THE SCIENCE OF
TRANSLATIONAL RESEARCH SO WE CAN
BE EFFECT IT TIVE AND EFFICIENT
IN GOING FROM BENCH TO BEDSIDE.
WITH THAT WE DON'T HAVE A
SPECIFIC DISEASE OR ORGAN THAT
WE FOCUS ON.
WE FOCUS ON ALL OF THEM.
SO I'LL TELL YOU HOW WE FOCUS ON
ALL OF THEM A LITTLE BIT MORE
APPROXIMATE WHAT WE DO.
I'LL START OFF BY SETTING THE
STAGE.
THERE ARE THOUSANDS OF DISEASES,
WE THINK THERE ARE OVER 10,000
DISEASES AND ACTUALLY WE KNOW
THAT THERE ARE 10,000 RARE
DISEASES ALONE.
THERE ARE THOUSANDS OF DISEASES.
WHEN YOU LOOK A LOT THE BURDEN
OF DISEASES AND HERE IN THIS
PARTICULAR IMAGE FROM OUR WORLD
AND DATA, THE BURDEN IS MEASURED
BY THE DISABILITY ADJUSTED LIFE
YEARS ALSO KNOWN AS DALLY AND
THIS IS BASICALLY MEASURING THE
TOTAL BURDEN OF DISEASE BOTH
FROM YEARS OF LIFE LOST DUE TO
PREMATURE DEATH, AS WELL AS
YEARS OF LIFE LIVED WITH THE DIS
A LOT.
SO ONE DALLY EQUALS ONE LOST
YEAR OF HEALTHY LIFE.
AND SO IN THIS GRAPHIC THIS WAS
DONE IN 1990 AND YOU CAN SEE THE
DIFFERENT DISEASES THAT HAVE
BEEN THE PERSISTENT DISEASES AT
THE TOP HERE AND I WANT YOU TO
JUST PAY ATTENTION TO THE
RIGHT-HAND SIDE NUMBERS AND THE
RED LINE IN THE MIDDLE.
BECAUSE I WANT TO KNOW WHAT YOU
EXPECT TO SEE AS YOU GO FORWARD
TO 2017 ON THE RIGHT-HAND SIDE.
IF YOU CLICK THAT DOT RIGHT
THERE, CAN YOU GO BACK ONE?
SEE IF YOU CAN HIT THAT PLAY
BUTTON.
SO, NOW YOU ALREADY JUMPED TO
THE END BUT YOU CAN SEE HOW THIS
HAS CHANGED OVER THE YEARS SO IF
YOU GO TO THE NEXT SLIDE, WE'RE
MOVING IN THE WRONG DIRECTION.
DESPITE THE FACT THAT WE HAVE
MORE TOOLS AND TECHNOLOGIES TO
BE ABLE TO EYE FIVE AND MITIGATE
THESE DISEASES SO WHY IS THAT?
HOW CAN WE START TO TRY TO TURN
THE CURVE IN THE OTHER WAYS SO
IF APPROXIMATE YOU GO TO THE
NEXT SLIDE, THE PUBLIC-HEALTH
CHALLENGE FOR US AT NCATS IS
THINKING ABOUT ALL OF THESE
DISEASES, THE OVER 10,000
DISEASES.
WHEN WE THINK ABOUT THAT, WHERE
IS A PLACE TO START IN WELL,
ONLY 5% HAS A TREATMENT FOR A
CURE.
NOT ONLY THAT, AS SORT OF A
BLEAK NUMBER, THE TIME FROM
DEVELOPING A PARTICULAR THEY ARE
DEVELOP PARTICULAR THERAPEUTIC,
NINE OUT OF 10 FAIL AT THAT
PHASE 1 AND PHASE 2 CLINICAL
TRIAL PHASE, IT'S 80% THAT FAILS
AT THAT PHASE AND THE REST THAT
HAVE IS BUSINESS DECISIONS ARE
OTHERWISE HOW THEY FAIL.
BUT MOST OF THESE ARE FAILING IN
THE SAFETY AND EFFICACY OF THESE
MEDICATIONS.
HIGHLIGHTING THIS A LITTLE BIT
MORE, THIS IS WHERE WE'RE
REFERENCING THESE NUMBERS, 55
FAILED DUE TO EFFICACY AND 28
FAILED IN TOXIC EFFECTS AND S
SO -- IT TAKES $2.6 BILLION TO
DO THIS.
WHAT CAN WE DO DIFFERENTLY?
RIGHT NOW THE CURRENT TOOLS WE
USE FOR THE DEVELOPMENT INVOLVE
TWO DIMENSIONAL CELLS THAT WE
PUT ON A PETRI DISH TO ANALYZE
SAFETY AND EFFICACY.
WE USE ANIMAL MODELS TO ANALYZE
SAFETY AND EFFICACY SO THESE ARE
AREAS THAT I THINK THAT WE HAVE
A OF CHANCE AND ACTUALLY
STARTING TO EFFECT OTHERWISE AND
SO RATHER THAN USING A
ONE-SIZE-FITS-ALL APPROACH HOW
DO WE TACKLE THIS IN OTHER WAYS
SO I'LL TALK ABOUT HOW WE'RE
ADDRESSING THAT.
NOT JUST ACROSS NCATS AS A WHOLE
BUT ALSO SPECIFICALLY IN WOMEN'S
HEALTH AND AS YOU ALL KNOW,
THERE'S A REASON WHY IT'S
IMPORTANT TO SPECIFICALLY FOCUS
ON WOMEN'S HEALTH.
SO GOING TO THE NEXT SLIDE AND
ESSENTIALLY, OUR MISSION AT
NCATS IS TURN RESEARCH INTO
HEALTH SOLUTIONS AND DOING THIS
THROUGH TRANSLATIONAL SCIENCE SO
IF YOU GO TO THE NEXT SLIDE, THE
TRANSLATIONAL SCIENCE PIPELINE
IS DEPICTED HERE AND FOR ANY
TRANSLATIONAL PROJECT WHEN YOU
FIND PERHAPS A DRUG TARGET AND
YOU NEED TO MAKE A THEY ARE
YOU'D THAT I CAN WOULD HIT THAT
DRUG TARGET AND IT'S EARLY IN
THE PRECLINICAL PHASE AND YOU GO
STEP WISE THROUGH THE
TRANSLATIONAL SCIENCE PIPELINE
TO MOVE IT TO CLINICAL USE OR
CLINICAL TESTING AND CLINICAL
APPLICABILITY.
SO NCATS IS REALLY HERE TO BE
THINKING ABOUT HOW WE CAN
ADDRESS THESE SORT OF
LONGSTANDING BOTTLENECKS IN THIS
PIPELINE SO WE CAN USE THE
PROCESS TO TRAVERSE THE PIPELINE
MUCH MORE EFFECTIVE AND MUCH
MORE EFFICIENTLY.
AND THAT IS THE WAY WE'RE GOING
TO GET MORE TREATMENTS TO PEOPLE
FASTER.
SO THIS IS SORT OF THE IDEA.
IF YOU GO TO THE NEXT SLIDE, I
HAVE A VARIETY OF WAYS THAT I
SHOW YOU WHERE THESE PURPLE
BOTTOM REPRESENT THE BOTTLENECK.
THEY CAN BE OPERATIONAL,
ADMINISTRATIVE, WORKFORCE
DEVELOPMENT, OR SCIENTIFIC
BOTTLENECKS.
SOMETIMES THE SCIENTIFIC
BOTTLENECKS ARE MORE TRACTABLE
THAN SOME OF THE OTHER ONCE SO
THEY'RE A RA VI TEE OF ASPECTS
THAT WE'RE TRYING TO EVALUATE
HERE BUT TRANSLATIONAL SCIENCE
IS LOOKING AT THE HOLISTIC
PROBLEM TO HELP BREAKDOWN THOSE
BOTTLENECKS SO WE CAN MOVE
THROUGH THAT PIPE LYNN BETTER
AND FASTER AND MORE EFFECTIVE
AND MORE EFFICIENTLY.
SO, I'LL SHOW YOU SOME OF THE
IDEAS HERE.
THE FIRST ONE THAT I UNDERLINE
ON THE RIGHT-HAND SIDE IS THAT
ONE OF THE THINGS WE'RE TRYING
TO DO IS DEVELOP PLATFORM BASED
APPROACHES FOR DEVELOPING TISSUE
AND ORGANS ON A CHIP EX DOING 3D
BIO FABRICATION TO UNDERSTAND A
DISEASE PROCESS BETTER AND WHAT
MIGHT BE MORE SPECIFIC IN
EFFECTING THE PREDICTABILITY OF
UNDERSTANDING MORE OF THE SAFETY
AND EFFICACY OF COMPOUNDS THAT
MIGHT BE GOING INTO PHASE 1 AND
PHASE 2 CLINICAL TRIALS.
IF IF WE USE MODEL SYSTEMS THAT
MIGHT BE A LOT BETTER THAN USING
ANIMAL MODELS OR 2D CELL CULTURE
MODELS.
I'LL TALK ABOUT THAT IN A
MOMENT.
THIS IS TO SAY IF IF YOU GO TO
THE NEXT SLIDE, WE HAVE THREE
AMBITIOUS GOALS HERE AND Dr.
CLAYTON HIGHLIGHTED THOSE.
TO BRING MORE TREATMENTS FOR ALL
PEOPLE MORE QUICKLY.
WE WANT TO METRO SIZE THIS IN A
WAY.
WE HAVE 5% OF THE TREATMENTS FOR
THE NORTHBOUND OF DISEASES NOW
THAT HAVE TREATMENT AND WE WANT
TO CHANGE THAT NUMBER FROM 5% TO
25%.
SO IT'S A BIG JUMP BECAUSE IT'S
BEEN AT 45% F 5% FOR A LONG TIM.
WE THINK WITH THE TOOLS THAT WE
HAVE CURRENTLY WITH THE
OPPORTUNITIES AROUND THERAPY AND
EDITING WE HAVE A BIG
OPPORTUNITY TO MAKE A DENT HERE
OVER THE NEXT 10 YEARS.
EVEN IF WE FAIL WITH 25%, I
WOULD RATHER FAIL AT 25% THAN
MEET THE GOAL OF GOING FROM 5%
TO 6% SO THAT'S THE
AUDACIOUSNESS BEHIND THAT GOAL.
FOR ALL PEOPLE, THIS IS REALLY
EXACTLY WHAT IT NEEDS.
IT'S INCREASING INCLUSIVITY
ACROSS EVERY AREA WE SUPPORT.
WHETHER IT'S WORKFORCE
DEVELOPMENT, WHETHER IT'S CAREER
TRAINING, WHETHER THAT'S MAKING
SURE THAT WE HAVE THE PIPELINE
IN PLACE FOR UNDER REPRESENTED
INDIVIDUALS IN SCIENCE AND IN
CLINICAL TRIALS AND IN CLINICAL
RESEARCH AND ALL OF THOSE AREAS
IS SOMETHING THAT WE WANTED TO
BE FOCUSED ON.
AND THIRDLY, MORE QUICKLY.
WE WANT TONE ABLE DIAGNOSTICS
AND THERAPEUTICS TO REACH PEOPLE
TWICE AS FAST.
I MENTION THAT 10 TO 15 YEAR
PIPELINE AND IT'S ON THE
DEVELOPMENT SIDE AND SO WHEN WE
INCLUDE THE BENCH TO BEDSIDE
MODEL AS A WHOLE, IT CAN BE EVEN
LONGER.
AND SO HOW CAN WE START TO
REALLY CUT THAT TIME IN HALF?
AND THAT GOES SOME OF THE KEY
GOALS THAT WE HAVE AND I HOPE
THAT WITH SOME OF THE VEN YETS I
TELL YOU ABOUT TODAY YOU WILL
SEE THE POSSIBILITIES TO MEET
THESE GOALS.
SO THE NEXT SLIDE IS JUST REALLY
TALKING ABOUT HOW NCATS APPLIES
THESE KEY APPROACH AND OUR
EFFORTS TO BRING MORE TREATMENTS
FOR PEOPLE MORE QUICKLY AND
ESSENTIALLY WHAT WE DO IS
BECAUSE WE CAN STUDY OVER 10,000
DISEASES, THAT MEANS THAT WE
HAVE TO UNDERSTAND WHAT SIMILAR
ACROSS DISEASES TO SPUR THOSE
MULTIPLE TREATMENTS AT A TIME.
AND SO IF WE CAN FIND PARTICULAR
PATHWAYS OR AREAS THAT ARE
COMMON ACROSS DISEASES, HOW CAN
WE LEVERAGE THAT TO HELP BRING
TREATMENTS TO THOSE DISEASES
MORE QUICKLY.
WE WANT MODELS THAT BETTER
PREDICT A PERSON'S REACTION TO
TREATMENT.
THAT'S THE PREDICTIVE MODEL
APPROACH I'LL TALK ABOUT LATER
TODAY TOO AND THEN ENHANCING
CLINICAL TRIALS SO THAT THE
RESULTS MORE ACCURATELY REFLECT
PATIENT POPULATION.
AND WE'RE DOING SO MUCH BETTER
IN BRINGING AND MAKING SURE WE
HAVE INCLUSIVITY FOR WOMEN IN
CLINICAL TRIALS AND THAT'S A
GOOD THING.
IT'S A NECESSARY THING BUT IT'S
NOT SUFFICIENT AND I'LL TALK
ABOUT THAT TOO.
AND FINALLY, HOW CAN WE MAKE
SURE WE'RE LEVERAGING ALL OF THE
REAL WORLD DATA AND DATA SCIENCE
APPROACHES TO ADDRESS
PUBLIC-HEALTH NEEDS AND I'M SO
GLAD Dr. CLAYTON MENTIONED THE
IDEA OF SUSAN AND HER WORK HERE
AT THE NIH AT THE OFFICE THE
DATA STRATEGY AND SCIENCE TO
REALLY MAKE SURE THAT WE'RE
DOING THIS IN A STRONG AND
ROBUST BAY.
THE NEXT SLIDE IS REALLY JUST
KIND OF ROUNDING OUT THESE WHOLE
IDEA OF TRANSLATIONAL SCIENCE
AND AGAIN IT'S THE FIELD THAT IS
MEANT TO ADDRESS THE SCIENTIFIC
AND THE OPERATIONAL INNOVATIONS
TO OVERCOME THE LONGSTANDING
BARRIERS ALONG THE TRANSLATIONAL
RESEARCH PIPELINE AND WE DO THIS
BASICALLY BY IDENTIFYING
ESSENTIALLY EIGHT KEY PRINCIPLES
THAT FOCUS ON WHAT MAKES AN
EFFECTIVE TRANSLATIONAL SCIENCE
PROGRAM GO VERY WELL AND MUCH OF
IT IS REALLY ABOUT THAT
UNDERSTANDING OF COM ON
CHALLENGES AND ROADBLOCKS TO
TRANSLATION AND DETERMINING THE
SCIENTIFIC AND OPERATIONAL
PRINCIPLES THAT CAN BE SORT OF
BUILT OR UTILIZED TO REMOVE
THOSE ROADBLOCKS AND DEVELOPING
THOSE SOLUTION THAT'S CAN EMPLOY
THESE PRINCIPLES THAT CAN BE
APPLICABLE TO A VARIETY OF
DIFFERENT DISEASES AND
CONDITIONS SO BY USING THESE
DIFFERENT PRINCIPLES WHEN
THEY'RE NEEDED AND WE TALKED
ABOUT THE IMPORTANCE OF TEAM
SCIENCE AND IT'S A KEY PRINCIPLE
HIGHLIGHTED HERE IN THE MIDDLE
IN THE TEAM SCIENCE BADGE.
SO THESE ARE IMPORTANT
CHARACTERISTICS FOR PEOPLE
WORKING IN THIS SPACE SO THAT WE
CAN REALLY BRING EVERYBODY THAT
WE HAVE TO THE TABLE TO ADDRESS
THOSE BOTTLENECKS IN THE
TRANSLATION SCIENCE PIPELINE.
AND THE NEXT SLIDE I JUST WANTED
TO GIVE YOU A SENSE OF THE
NCATS' BUDGET AND ESSENTIALLY WE
SPEND MOST OF OUR BUDGET ON THE
CLINICAL SIDE OF THE
TRANSLATIONAL SCIENCE PIPELINE
THROUGH THE CLINICAL AND
TRANSLATIONAL SCIENCE AWARD THAT
MAKES UP 70% OF OUR BUDGET AND
IT'S A LINE ITEM IS SO THAT GOES
TO THE CTSA PROGRAM AND THE 30%
THAT REMAINS IS REALLY WHAT THE
NCATS PROGRAMS DO ACROSS THE
TRANSLATIONAL SCIENCE PIPELINE
AND THAT WORK IS IN THE
PRECLINICAL SPACE AND RARE
DISEASES AS WELL.
SO NEXT SLIDE, I'M GOING TO
START TO TRANSITION INTO SOME OF
THE KEY AREAS THAT WE'RE WORKING
IN FOR HIGHLIGHTING THESE
TRANSLATIONAL SCIENCE PRINCIPLES
FOR ADDRESSING WOMEN'S HEALTH
AND I WANTED TO JUST START OFF
WITH THIS PAPER HERE, DRUGS AND
MEDICAL DEVICES AND IMPACT ON
WOMEN'S HEALTH AND I ABOUT THE
WAY I TYPICALLY USE QR CODES SO
YOU CAN JUST TAKE A POINT YOUR
CAMERA AT THE QR CODE AND IT
WILL TAKE YOU TO THE REFERENCE.
BUT THIS PARTICULAR PAPER TALKS
A LITTLE BIT ABOUT DATA FROM THE
FDA'S OFFICE OF WOMEN'S HEALTH
AND TALKS ABOUT THE IDEA THAT
FEMALES HAVE DOUBLE THE RISK OF
DEVELOPING DRUG ADVERSE
ACCORDING TO MEN.
I WANT TO SORT OF HIGHLIGHT THAT
AS SORT OF A KEY FEATURE HOW
WE'RE ABLE TO ATTACK THAT
PARTICULAR NUMBER.
I WILL SPEND TIME TALKING ABOUT
THE PRECLINICAL SPACE THAT WE
WORK IN AS WELL AS THE CLINICAL
SPACE THAT WE WORK IN.
WHEN WE CONSIDER SEX AS A
BIOLOGICAL VARIABLE, WOMEN
COMPROMISE HALF OF PARTICIPANTS
IN NIH FUNDED CLINICAL TRIALS.
LARGELY BECAUSE OF THE EFFORTS
OF Dr. CLAYTON AND HER TEAM
AND THE SAME NOT NECESSARILY
TRUE FOR THE PRECLINICAL SPACE
AND PRECLINICAL RESEARCH AND
MORE MUCH THAN NOT, PRECLINICAL
RESEARCH IS CONDUCTED IN MOSTLY
MALE DERIVED CELLS IN MALE
ANIMALS AND THESE PRACTICES HAVE
RESULTED IN A LACK OF
INFORMATION IN WOMEN'S HEALTH
AND THERE'S NO DOUBT IT'S
CONTRIBUTING TO THE HIGHER RISK
IN THE ADVERSE DRUG REACTION
STATISTICS THAT I JUST TALKED
ABOUT IN THIS REPORT.
AND IN ADDITION OF COURSE, AND
LARGELY FOR ETHICAL REASONS, BUT
AS YOU KNOW, PREGNANT WOMEN ARE
NOT ALLOWED TO PARTICIPATE IN
STUDIES OF NEW DRUGS AND IN
ADDITION TO THAT THERE ARE MANY
YEARS WHEN ALL WOMEN WHO HAD THE
POTENTIAL TO GET PREGNANT WERE
EXCLUDED FROM NUMEROUS RESEARCH
STUDIES SO WE'RE MAKING HEAD WAY
THERE BUT THESE APPROACHES
CREATED A LACK OF INFORMATION
ABOUT WOMEN'S HEALTH AND FEMALE
PHYSIOLOGY AND WE STILL HAVE A
LOT TO LEARN IN THIS SPACE AND I
WANT TO TALK ABOUT THOSE
OPPORTUNITIES WHERE NCATS IS
TRYING TO CHANGE THAT NARRATIVE
IF YOU WILL AND HE'LL TALK AGAIN
ABOUT THE PRECLINICAL AND THE
CLINICAL SIDE.
I'LL START HERE ON THE CLINICAL
SIDE.
SO YOU CAN GO TO THE NEXT SLIDE.
IT SHOULDN'T BE THE CLINICAL AND
TRANSLATIONAL SCIENCE AWARD
PROGRAM ALSO KNOWN AS THE CTSA
PROGRAM AND THIS IS A
INTERNATIONAL NETWORK THAT IS
THE LARGEST PROGRAM WITHIN THE
NIH TO SUPPORT CLINICAL
RESEARCH.
WE HAVE -- IT WAS FIRST
ESTABLISHED IN 2006 AND WE HAVE
NOW OVER 60 AWARDEE INSTITUTIONS
WITHIN A RUBRIC OF THE CTSA
PROGRAM AND THERE ARE GOALS TO
DEVELOP, DEMONSTRATE AND DES SEM
NATURE THESE INNOVATIONS THAT
SCIENCE HELPS FASTER AND THEY
PROMOTE IMPACTFUL PARTNERSHIPS
AND CONDUCT A LOT OF TEAM
SCIENCE AND TRAIN THEIR TRAINEES
IN TEAM SCIENCE.
THEY WORK IN ADDRESSING HEALTH
DISPARITIES DOING INNOVATING AND
COMMUNITY ENGAGEMENT AND
PRACTICES AND THOSE SORTS OF
THINGS AND THEY PROCEED PROVIDE
URGENT HEALTH NEEDS AND THEY
CREATE A ROLE DURING THE
PANDEMIC FOR PROVIDING WAYS IN
WHICH WE CAN CONDUCT CLINICAL
TRIALS FOR ALL THE DIFFERENT
STUDIES THAT NEEDED TO BE DONE
DURING THE PANDEMIC.
THEY PROMOTE TRAINING AND CAREER
SUPPORT AND ESSENTIALLY REALLY
HELP US PRACTICE THE FIELD OF
TRANSLATIONAL SCIENCE AND THEY
HAVE REALLY BEEN INSTRUMENTAL IN
HIGHLIGHTING AND GENERATING
THOSE EIGHT TRANSLATIONAL
SCIENCE PRINCIPLES THAT I
MENTIONED BEFORE SO THIS IS NO
DOUBT UP WITH OF THE BIGGEST AND
I THINK MOST BENEFICIAL PROGRAMS
THAT WE'VE HAD AT THE NIH AND IF
YOU GO TO THE NEXT SLIDE AND
I'LL ASK YOU TO GO AHEAD AND
CLICK TWICE.
ESSENTIALLY EACH PARTICULAR
INSTITUTION WITHIN THE CTSA
PROGRAM HAS THEIR OWN LOCAL
STRENGTHS BUT TOGETHER, THEY CAN
REALLY ENABLE A RAPID AND ROBUST
PUBLIC RESPONSE TO A VARIETY OF
ACTIVITIES AND THEY'VE BEEN
INVOLVED IN THE HEAL PROGRAM,
THE HELPING END ADDICTION
LONG-TERM PROGRAM AND THE ACTIVE
PROGRAM FOR THE CLINICAL TRAILS
FOR THE PANDEMIC AND DOING A LOT
OF THE COMMUNITY ENGAGEMENT
EFFORTS THAT NEEDED TO BE
CONDUCTED, DECENTRALIZED
CLINICAL TRIALS, MOBILE APP
DEVELOPMENT THAT HAS BEEN ON
GOING EVEN BEFORE THE PANDEMIC
AND SO THERE HAS BEEN A VARIETY
OF ACTIVITIES THEY HAVE
SUPPORTED THAT WE HAVE OF A KEY
COMPONENT FOR TELEHEALTH AND
TELEMEDICINE AND WE HAVE A LOT
OF ACTIVITIES AND RARE DISEASES
AND EVEN I GUESS ONE OF THE
THINGS THAT I WOULD LIKE TO
HIGHLIGHT HERE IS IT'S NOT JUST
THE SCIENTIFIC SIDE BUT THE
OPERATIONAL SIDE AND THE CTSA
PROGRAM HAS BEEN INSTRUMENTAL IN
DEVELOPING SOMETHING CALLED THE
SMART IRB AND THIS IS BEEN
ESSENTIALLY A WAY IN WHICH WITH
THAT WE CAN SPEED UP THE TIME IT
TAKES FOR IRB APPROVALS TO
HAPPEN TO STUDIES CAN BE
INITIATED MORE QUICKLY.
WE HAVE REDUCED THAT TIME IN
HALF.
THIS IS ONE ASPECT WHERE WE'RE
ABLE TO SPEED THINGS UP AND WE
HAVE A LONG WAY TO GO IN OTHER
SPACES.
THE NEXT SLIDE IS A FEW NIP ET
CETERA OF SOME OF THE ACTIVITIES
FROM THE CTSA PROGRAM AND THEIR
INVOLVEMENT IN WOMEN'S HEALTH
AND THIS EXAMPLE HERE IS JUST
SHOWING THAT WE HAVE A PILOT
AWARD PROGRAM IN THE CTSA
PROGRAM AND THE PILOT AWARD
PROGRAM PROVIDES SEED MONEY FOR
A LITTLE BIT OF SUPPORT FOR NEW
OR INNOVATIVE IDEAS OR
APPROACHES AND THEN THAT SEED
MONEY CAN REALLY HELP PROVIDE
THE VALUABLE PRELIMINARY DATA
FOR YOUNG INVESTIGATORS THAT
DEVELOP A RATIONAL FOR DOING A
R01 BASED PROJECTOR SOME OTHER
TYPE OF NIH AWARD PROJECT.
AND CURRENTLY WE HAVE ABOUT 15%
OF THE PILOT AWARDS ARE IN THE
AREA OF EMPHASIZING ASPECTS OF
WOMEN'S HEALTH AND MOST OF THOSE
ARE SPECIFICALLY FOCUSED ON
WOMEN'S HEALTH AND SOME OF THEM
ARE SPATIA PARTIALLY FOCUSED ONS
HEALTH.
UNDERSTANDING AND EVALUATING
SERVICES FOR IN CARS RATED AND
PREGNANT IN POSTPARTUM WOMEN,
IMPROVING CARDIOVASCULAR RISK IN
WOMEN AND ALSO TRYING TO THINK
ABOUT WAYS OF INTEGRATING
SMOKING SECESSION INTO
BREASTFEEDING PROGRAMS
SPECIFICALLY TO REDUCE CANCER
DISPARITIES BUT IT WILL HAVE
LONGER TERMS EFFECTS THAN JUST
IN CANCER SO THIS IS THAT MANY
DISEASES AT A TIME PREVENTION
STUDY THAT IS DONE IN THE
PROGRAM TOO.
THIS IS ANOTHER AREA I WANTED TO
MENTION.
THERE'S A PROGRAM CALLED THE
TRIAL INNOVATION NETWORK AND
THIS IS AN INITIATIVE THAT IS
BEING USED WITH ITS CTSA PROGRAM
AND IT'S BEING USED SPECIFICALLY
WITHIN THE HELPING ENDS
ADDICTION LONG-TERM OR THE HEAL
PROGRAM TO LOOK AT PAIN AND
OPIOID MANAGEMENT SPECIFICALLY
SO THIS IS MEANT TO REALLY
COMPARE THE EFFECTIVENESS OF
EXISTING NON ADDICTIVE PAIN
THERAPEUTICS AS WELL AS EXISTING
NOVEL APPROACHES FOR PAIN
PREVENTION AND MANAGEMENT SO WE
WANT TO MAKE NEW APPROACHES FOR
PAIN THERAPIES THAT ARE NON
ADDICTIVE AND THAT'S THE KEY
THING.
WE'RE COMPARING THE
EFFECTIVENESS OF SOME OF THESE
PARTICULAR THERAPEUTICS THAT ARE
EXAMINING DOWN THE PIPELINE FOR
THOSE IDEAS.
AND SO THERE'S A LARGER EFFORT
WITHIN THE CTSA PROGRAM TO
REALLY NOT A PART OF THIS
PARTICULAR ACTIVITIES AND
ANOTHER AREA FOR PREVENTION OF
THE POSTMA SEC TOMMY PAIN DIN
TROM AND HOW THAT CAN BE USED IN
A NON WAY AND IF WAYS THAT
THEY'RE CONDUCTED ARE VERY
IMPORTANT.
NEXT SLIDE IS JUST
HIGHLIGHTING -- DURING THE
PANDEMIC THERE WAS ONE KEY AREA
I THINK THAT NCATS HAS BEEN
REALLY ABLE TO CONTRIBUTE AND
IT'S IN THE AREA OF DATA SCIENCE
AND WE'VE BEEN, SINCE THE
PANDEMIC HIT, WITH THE CTSA
PROGRAM, THERE ARE AN
OPPORTUNITY FOR US TO UNDERSTAND
HOW WE CAN IDENTIFY OF AND
COLLECT THE ELECTRONIC HEALTH
RECORDS TO STUDY POTENTIAL
OUTCOMES FOR INDIVIDUALS WHO ARE
DEALING WITH THE PANDEMIC.
AND INSPECTED WITH SARS-CoV-2
AND WE'RE COMPARING THEM TO
PEOPLE WHO AREN'T INFECTED SO WE
RECEIVED THE ELECTRONIC HEALTH
RECORDS IN A WAY THAT WE CAN
COMPARE THEM APPLE TO APPLES
WAY.
IF YOU GO TO ONE INSTITUTION FOR
A CLINICAL VISIT AND THAT MIGHT
BE INFECTIOUS DISEASE AND YOU GO
TO ANOTHER HOSPITAL FOR CLINICAL
VISIT FOR GETTING SOME SORT OF
ASSESSMENT ON YOUR ANKLE THAT'S
VERY SORE, THESE ARE TWO VERY
DIFFERENT HOSPITALS OR UNITS.
THEY MIGHT BE ACROSS THE STREET
BUT THEY ARE DIFFERENT HEALTH
RECORDS WHICH IS FUNNY.
NOT IN A GOOD WAY.
SO, THIS A BIG DATA SCIENCE
PROBLEM AND WHAT THE NATIONAL
COVID COHORT COLLABORATIVE HAS
DONE IS WE'VE TAKEN IT OFF THE
TABLE FOR ELECTRONIC HEALTH
RECORD RESEARCH ANALYSIS AND NOW
WE'RE ABLE TO COMPARE, NO MATTER
WHERE THOSE ELECTRONIC HEALTH
RECORDS ARE FROM THEY COMPARE
THEM APPLES TO AMS O RIGHT NOW
WE HAVE 77 DIFFERENT SITES
CONTRIBUTING THESE RECORDS TO A
SECURE ENCLAVE.
WE HAVE OVER 17 MILLION PEOPLE
WITHIN THE ENCLAVE AND OVER
7 MILLION OF THOSE HAVE BEEN
COVID POSITIVE OVER THE LAST
COUPLE OF YEARS AND THIS
TRANSLATES TO 22.1 BILLION ROWS
OF DATA.
IF YOU PUT THAT IN A SPREAD
SHEET IN ONE LINE, IT WOULD
WOULD WRAP AROUND THE EARTH
THREE-TIME.
IT'S A LOT OF DATA AND WE DON'T
HAVE TO USE SPREAD SHEETS TO DO
THIS.
IT'S A VERY SOPHISTICATED WAY OF
EVALUATING THE DATA AND IT TAKES
A TEAM SCIENCE APPROACH TO DO
THAT BUT WE'VE BEEN ABLE TO
INFORM ON AREAS OF PUBLIC-HEALTH
QUESTIONS LIKE HOW IT'S IMPACTED
LONG COVID RISK AND THE USE OF
ANTIBODY EFFECTIVENESS ACROSS
DIFFERENT VARIANTS OF THE
PANDEMIC, AS WELL AS
UNDERSTANDING THE PAXLOVID USE
CHARACTER AND I CAN TALK ABOUT
THESE IF YOU ARE INTERESTED.
I WANTED TO GIVE YOU A SENSE OF
THE DASHBOARD AND THE QR CODE
SHOWN ON THE RIGHT.
YOU CAN LOOK AT SOME OF THE DATA
THAT ARE THERE NOW.
WITHIN THESE ELECTRONIC HEALTH
RECORDS IT'S A REAL WORLD DATA
ENTERPRISE WHERE WE HAVE CMS
DATA, MEDICARE, MEDICAID,
VACCINE, AND THIS UPDATED EVERY
TWO WEEKS SO WE CAN REALLY
MONITOR THE WE'LL SPAN OF THE
PANDEMIC.
THIS A TIME TO LIMITED RESEARCH
AND SO, WE WERE GOING THROUGH
FY24 AND SEE WHAT WE NEED TO DO
BUT WE'RE HOPING THAT THE
PANDEMIC WOULD BE ENDING BY THEN
AND THAT REMAINS TO BE SEEN
ESPECIALLY THE LONGER TERM
EFFECTS OF SOME OF THAT SO HOW
ARE WE MOVING FORWARD WE'RE
STILL EVALUATING THAT.
THIS IS BEEN AN IMPORTANT
PROGRAM.
I WANTED TO TELL YOU THE
BACKGROUND OF THIS BECAUSE SOME
OF THE WORK THAT'S BEEN
CONDUCTED WITHIN OF SARS-CoV-2
INFECTION SO, AN QUANTIFY BY
THIS GROUP BY VIEW IT ALL AND
THE EVENTS DETECTOR FOR
PREGNANCY HERE FOR 10PM IS THE
ALGORITHM IDENTIFIED AND THE
FIRST FOR THE EXACT GESTATIONAL
LINK WITH EVERY CLINICAL EVENT
FROM AN ELECTRONIC HEALTH RECORD
AND THE TIMING OF SARS-CoV-2
INFECTION IN PREGNANT WOMEN SO
THIS CAN BE USED IN IMPORTANT
WAYS TO HOPEFULLY FOLLOW THOSE
MOVING FORWARD.
WE SEE WAS TO EXAMINE CAN COHORT
BIOMARKERS IMPACTED COVID-19
DIFFERENTLY AND THEN IN MEN AND
WOMEN IN THIS WAY WE LOOKED AT
570,000 ADULT PATIENTS WHO WERE
ADMITTED FOR COVID-19 AND
BETWEEN 2020 AND 2021 AND THE
TOP FOUR FAILED CO MORBID TEASE
IN BOTH SEXES WERE RENAL
DISEASE, LIVER DISEASE, CANCER
AND HEART DISEASE AND WOMEN HAD
A HIGHER RISK.
IMPORTANT TO UNDERSTAND THAT
THOSE CHARACTERISTICS AND HOW
SARS-CoV-2 MIGHT HAVE SORT OF
WORSEN THE THE CHARACTERISTICS
AND WHY IS THAT AND THOSE ARE
QUESTIONS WE HAVE.
WE HAVE HINTS BECAUSE WHAT THEY
FOUND THERE WERE LEVELS OF
SEVERAL PROTEINS AND THEY WERE
ABLE TO IDENTIFY MY VALUES AND
THESE WERE STRONGER IN WOMEN,
THEN IN MEN SO SO THE NEXT SLIDE
I WANT TO GET INTO SOME
PRECLINICAL CAN BE I DIDN'T
MENTION TOO I GUESS HERE.
I AM FROM A RULE COMMUNITY IN
KANSAS AND SO I ALSO HAVE THE
RURAL POPULATION IF LINE AND
THIS IS JUST A STUDY THAT CAME
OUT AND IT WAS THE PAPER OF
Dr. LEAD AUTHOR THAT HIRED
HOSPITALIZATIONS AND MORTALITY
RATES OF SARS-CoV-2 INFECTED
PEOPLE IN RURAL AMERICA AND WERE
HIGHER THAN NOT ROLE AND
PATIENTS AND SO THERE WAS A SORT
OF RURAL THAT WAS ESTABLISHED IN
THIS PUBLICATION AND SO IT'S
REALLY IMPORTANT NOT JUST TO
STUDY SOME SORT OF THE EFFECTS
OF MEN AND WOMEN BUT THE EFFECTS
OF MEN AND WOMEN IN DIFFERENT
ENVIRONMENT INCLUDING THE RURAL
ENVIRONMENT SO I THINK THIS IS
ONE IMPORTANT PIECES OF
INFORMATION THAT WE'VE SEEN AND
SO GO TO THE NEXT SLIDE, PLEASE.
I WANT TO MOVE INTO SOME OF THE
PRECLINICAL ELEMENTS TOO BECAUSE
AS WE THINK ABOUT THE PREDICTED
NATURE IN THE HIGH FAILURE RATE
THIS IS AN AREA OF OPPORTUNITY
WHERE WE SHOULD SEE BIGGER
CHANGE IF WE TAKE A DIFFERENT
APPROACH AND SO WE ROUTINELY
HAVE BEEN USING 2D CELL LINES OR
MOUSE MODEL TO REFLECT WHAT IT
MEANS TO BE HUMAN AND I NEED A
FEMALE VERSION OF THE FIGURE
HERE TOO O THIS ISN'T ENOUGH.
WE NEED NEW TECHNOLOGY AND TOOLS
As COULD THE LANCETATIONAL
PIPELINE TO DO THIS BETTER SO WE
ABOUT TO THE NEXT SLIDE AND WE
STOP WITH THE CELL LINES AND
MOUSE MODEL AND THINK HOW CAN WE
REFLECT IT BETTER AND A LOT OF
THAT IS TO IMPROVE SOME OF THIS
3D CELL PHONE APPROACH AND AS WE
DO THAT YOU TEND TO LOSE THE
SORT OF ABILITY TO SCREEN
HIGH-THROUGHPUT WAY BECAUSE
THESE ARE COMPLEX AND WE CAN'T
SCREEN THEM IN THESE HIGH PLACE
AND SO THAT THE SCREENING IS
DIFFICULT BUT THE PHYSIOLOGICAL
COMPLEXITY AS WE START TO
EVALUATE TISSUE OR TISSUES ON A
CHIP IT'S MUCH MORE VALUABLE AND
SO THAT TRADE OFF IS REALLY
WORTH THE DIFFERENCE OF AT LEAST
THAT'S WHAT WE'RE PETTING ON AND
I THINK THAT AZTEC KNOWLEDGE
INVOLVES WE'LL START TO GO BACK
AND ADDRESS THE NATURE OF THAT
IS NEEDED SO THAT WE CAN DO THIS
AT SCALE.
THIS IS AN EXAMPLE OF WHAT THIS
MEANS AND WE HAVE THE ABILITY TO
TAKE BLOOD FROM ANY INDIVIDUAL
AND TAKE THE PATIENT CELLS OR
THE PARTICIPANTS CELLS AND
RESOURCE THEM INTO STEM CELLS
AND FROM THAT WE CAN
REDIFFERENTIATE NEEM VIRTUALLY
ANY CELL TYPE SO WE'RE ABLE TO
USE THE TECHNOLOGY TO MAKE CELLS
THAT REPRESENT LEADERS THAT MAKE
UP OUR ORGANS SO WE CAN CREATE
SKIN TISSUE AND WE CAN PUT THESE
CELLS ON AND THIS IS DEPICTION
SHOWN HERE BECAUSE IT'S
IMPORTANT TO HAVE VACUUM SECTION
THERE SO YOU CAN EXPAND AND
CONTRACT THE ABILITY OF THOSE
CELLS TO MIMIC MORE BLOOD CELLS
AS YOU BREATH IN AND BREATH OUT
SO IT'S AN IMPORTANT WAY OF
DEVELOPING THESE MODEL IN SORT
OF PARALLEL AND YOU CAN IMAGINE
NOW THAT THE NEXT STEPS AND
CREATE YOU ON A CHIP AND THIS IS
A AND THAT BEV AND TO PER STEP
FORWARD AND I'LL GET BACK TO
THIS IN A MOMENT.
IF YOU ARE THE NEXT SLIDE, I
WANT TO TALK SPECIFICALLY ABOUT
HOW WE'RE DOING THIS IN THE
FEMALE SYSTEM AND SO THIS IS
WORK DONE BY THERESA WOODRUFF
AND JOY AS WELL AS MANY OTHERS
BUT THEY WERE WORKING ON THESE
SORTS OF APPROACHES FOR VARIOUS
ASPECTS OF THE FEMALE
REPRODUCTIVE SYSTEM AND LET'S
GET TOGETHER AND BUILD SOMETHING
TOGETHER THAT CAN BE EVEN BETTER
AND -- AND ORGANOID MODEL SO WE
CAN TEST DIFFERENT THERAPIES
THAT MIGHT BE HELPFUL FOR THOSE.
THESE HAVE ALSO BEEN USED TO
THINK ABOUT OVARY DISEASE AS
WELL SO THEY HAVE BEEN VALUABLE
IN HELPING THE RESEARCH AND
APPROXIMATE PUSHING THE RESEARCH
FORWARD AND THIS IS THE SAME
TEAM AS I SHOWED YOU BEFORE AND
IF YOU GO TO THE NEXT SLIDE
THEY'VE GOT THEIR DEVELOPMENT
WHAT THEY CALL AN EVEN TON WHICH
I LOVE THAT NAME AND IT'S NOT
"AVATAR" BUT IT'S AN EVATAR.
THIS IS THE FEMALE REPRODUCTION
SYSTEM ON A CHIP AND ESSENTIALLY
WE HAVE PRODUCTS THE
REPRODUCTIVE SYSTEM ON A CHIP
AND HOW THEY TRAVEL FROM ONE
COMPARTMENT TO THE NEXT WHAT
HAPPENS DOWNSTREAM WHEN THOSE
CHANGES HAPPEN SO IT'S A WAY TO
REALLY I'LL EIGHT THE ISSUES AND
WE HAVE BEEN ABLE TO DO THIS
THREE MONTHS AND THE CELLS TEND
TO FAIL SO THEN OUR GOAL IN THE
FUTURE ARE TO HAVE THEM GO
LONGER AND IF WE ANOTHER LIP IT
SHOULD START TO PLAY THIS IS
ESSENTIALLY YOU CAN SEE THE
LITTLE SILLIA IN WHERE THE WHERE
IT TAKES THE EGG AND THROUGH THE
MOVEMENT THROUGH THE SILLIA SO
THIS IS HOW THE THEY SHOULD WORK
AND NEXT SLIDE HERE SHOWS YOU
WHERE WE'VE BEEN CONDUCTING IN
COP ABERRATION WITH THE AND I
WANT TODAY THANK Dr. LAYTON
FOR HER HERE AND THIS IS
REMARKABLE WORK AND IT CAN HELP
US FOR INDIVIDUAL TREATMENTS TO
LEARN MORE HOW FEMALES MAY
METABOLIZE DRUGS DIFFERENTLY
FROM MALES THERE ARE A COUPLE OF
EXAMPLES HERE AND ACTUALLY, THIS
IS A STUDY THAT WAS JUST
PUBLISHED AND SO, IF YOU GO TO
THE NEXT SLIDE AND YEAH, THIS
ESSENTIALLY G. TO THE NEXT
SLIDE.
THIS IS ESSENTIALLY A INTERFACE
AND SO THAT BOTTOM DEPICTION
THOSE THE DIFFERENT LAYERS OF
THE MATERNAL SIDE ON THE TOP
THAT IS IN THE TOP IN THAT THE
GREEN SECTION I DON'T KNOW IF IF
I CAN SHOW MY POINTER HERE BUT
IT'S THE GREEN SECTION ON THE
TOP IF THAT FIGURE SO THAT IS
THE MATERNAL SIDE AND THERE ARE
LAYER UNDER THAT START TO GET
INTO THE FETAL SIDE AND SO WE'RE
ABLE TO BE ABLE TO CAPTURE THAT
INTERFACE OF IN TERNAL AND FETAL
CELLS TO UNDERSTAND HOW THE
STRUCTURE AND FUNCTION AND
RESPONSES FOR DIFFERENT
EXPOSURES OR INFLAMMATION FOR
EXAMPLE HIGH THE HAVE THAT
EFFECT SO THIS IS REALLY GREAT
WORK FROM THE UNIVERSITY OF
TEXASAL GALVESTON AND THIS IS
EXCITING AND BUT THAT PAPER ON
THE PREVIOUS SLIDE IT'S FOR THE
REPORTER STUDY THAT IS PUBLICLY
AVAILABLE SO WE'LL GO TO THE
NEXT SLIDE.
I WANTED TO SORT OF ALSO TALK
ABOUT SOME OF THE OPPORTUNITIES
THAT YOU THINK ARE KIND OF
EXCITE NORTH THIS SPACE AND WE
LEARNED THAT OVER TIME, PEOPLE
HAVE GONE INTO SPACE OVER WE'VE
SEEN THIS WITH RENAL PROBLEMS
AND IMMUNITY PROBLEMS, ET
CETERA.
SO, WE KNEW THAT THESE THINGS
POSSESS AND WE WANT CELLS IN THE
MICROENVIRONMENT WHERE THEY
ACTUALLY AGE FASTER SO WE CAN
STUDY THOSE EFFECTS OF AGING AND
SO A GOAL OF OURS OUR TISSUE
SPACE PROGRAM JUST ENDED LAST
MONTH AND I WANT TO SHOW YOU AND
YOU CAN CLICK ON THE NEXT SLIDE
HERE AND YOU CAN REALLY HEAR THE
ROCKET BLASTING OFF AND HERE WE
HAVE TWO TISSUE PROGRAMS GOING
UP INTO SPACE AND THEY'RE BEING
EVALUATED ON THE SPACE STATION
AND SO AND I HOPE WE CAN DO IT
IN THE FUTURE, SO THIS IS ONE
AREA WHERE I'D LIKE TO SEE US
CONTINUE TO WORK IN THIS SPACE.
IF YOU GO TO THE NEXT SLIDE, I
MENTION THIS IDEA OF YOU WANT TO
CHIP AND CREATING ESSENTIALLY
DIGITAL PLANS YOU CAN IMAGINE
THAT YOU HAVE A CHIP AND THERE
WAS AN ARTICLE RECENTLY TALKING
ABOUT THE FUTURE OF CLINICAL
TRIALS FOR PROGNOSTIC DIGITAL
TWINS THAT HAVE EXTERNAL CONTROL
AND IF IF YOU ARE YOUR OWN
CONTROL, AND YOU CAN TEST
DIFFERENT APPROACHES, BECAUSE
YOU HAVE A DIGITAL TWIN, THAT
MIGHT BE REALLY VALUABLE AND I
THINK IT'S SOMETHING THAT WE'RE
TRYING TO WORK TOWARDS.
IN 2025 WE'RE GOING TO THE MOON.
THAT'S WHAT ARTEMIS III IS ALL
ABOUT AND WE CAN FIGURE HOUT TO
GET A DIGITAL TWIN OF ONE OF THE
FEMALE ASTRONAUTS.
IT'S TO SHOW YOU THERE MIGHT BE
OTHER OPPORTUNITIES FOR THAT
SPACE EXPLORATION AND WOVE IDEAS
OF HOW WE CAN EXPAND THE LODGE
GEOFF TEE OF THE CELLS TO STUDY
THEM LONGER AND ALSO REPRESENT
MORE TYPES OF ORGANS AND SPACE.
SO THE IDEA HYPED THIS TOO IS
THERE IS A LIMITED AND THEY HELP
US FOR EXAMPLE THE FEMALE
REPRODUCTIVE TRACK THIS IS A
PHYSIOLOGICAL SYSTEM AND WE CAN
UNDERSTAND MORE FOR DIFFERENT
CELL TYPES AND EXPOSURE TO ORAL
TREATMENT OR WELCOME STUDY
DISEASE AND OUR CAUSES AND WE
CAN ALSO FIGURE OUT HOW TO
COMBINE THAT WITH OTHER ORGANS
AS WELL OF THAT TOO AND ALSO
UNDERSTAND PERHAPS CONCEPTION
AND PREGNANCY AT SOME POINT IN
TIME SO THESE ARE IDEAS THAT
WE'RE TRYING TO BUILD TO WORK.
I'M GOING TO END ON A FEW MORE
THINGS.
ONE IS WE'RE ALSO WORKING IN A
SMALL MOLECULE SPACE AND THAT IS
A LOT OF THE WORK WE DO AND I'M
JUST WANT TO GO HIGHLIGHT THE
MORE PREDICTIVE BASED APPROACHES
FOR THIS PARTICULAR AUDIENCE BUT
I DIDN'T WANT TO HIGHLIGHT THAT
WE'RE WORKING ON SMALL MOLECULE
SPACE FOR WOMEN'S HEALTH AND
SPECIFICALLY HERE UNDERSTANDING
BRAIN MATAS SIS FOR BRAIN CANCER
AND WE'RE GOING TO MAKE SURE AND
WE'RE GOING TO FIGURE OUT
DRAWINGMINIMIZINGTHE RISK OF A .
ANOTHER AREA THAT WE TEND TO
WORK ON QUITE A BIT IS ON RARE
DISEASES AND WE DO KNOW THAT
THERE ARE A VARIETY OF RARE
DISEASES THAT EFFECT FEMALES
SPECIFICALLY.
TURNER SYNDROME AND TRIPLE X
SYNDROME AND ET CETERA AND SO
IT'S VERY IMPORTANT THAT WE
THINK ABOUT WAYS AND
UNDERSTANDING SORT OF THAT WORK
AND ONE DISEASE AT A TIME
APPROACH BUT ALSO NEW
THERAPEUTIC MODALITY AND THAT'S
WHAT I'LL FOCUS ON HERE AND IF
YOU GO TO THE NEXT SLIDE, IT'S
REALLY IMPORTANT BECAUSE RARE
DISEASES ARE QUITE A
PUBLIC-HEALTH CHALLENGE AND WE
KNOW WE DID NCATS THAT PEOPLE
WITH RARE DISEASES PAY THREE TO
FIVE TIMES MORE IN DIRECT
MEDICAL COSTS THAN PEOPLE
WITHOUT RARE DISEASES AND THAT
TRANSLATES, GIVEN THE FACT THERE
ARE 35 OR 40 MILLION PEOPLE WITH
A RARE DISEASE IT TRANSLATES TO
$400 BILLION A YEAR FOR DIRECT
MEDICAL COSTS FROM PEOPLE WHO
ARE DISEASES.
THAT'S A BIG PUBLIC ECONOMIC
BURDEN IN THIS SPACE SO THIS IS
AN AREA THAT IS SOMETHING WE'RE
INTERESTED IN IN PURSUING
PRIVATE MORE.
IF YOU GO TO THE NEXT SLIDE.
SOME OF THE WAYS WE'RE DOING
THIS ARE REALLY IN THE AREAS OF
GENE THERAPY AND GENE EDITING
AND WE HAVE OUR VARIETY OF
PROGRAMS IF THE SPACE THAT ARE
IN 30 STAGES OF DEVELOPMENT SOME
ARE EARLIER IN DEVELOPMENT AND
IN CLINICAL TRIAL PHASE BUT MORE
IN IND ENABLING PHASES AND SOME
ARE IN THE CLINICAL TRIAL SPACES
SO WE HAVE A PROGRAM AND EDITING
THAT ON BEHALF OF THE COMMON
FUND PROGRAM AND PROVIDING
TOOLKIT TOOLKITS AND MAKING DELT
CAN ARE EFFECTIVE OR AND THE
GENE THERAPY CONSORTIUM SO
THERE'S ONE THAT Dr. CLAYTON
TALKED ABOUT ON THE IMMUNE
SYSTEM OR IMMUNITY AND THIS IS
ON GENE THERAPY AND WHAT WE'RE
DOING HERE IS WE'RE ENHANCING
MANUFACTURING AND TRYING TO MAKE
SURE THAT WE CAN GET THE RIGHT
DELIVERY TO THE RIGHT CELLS AND
AT DEVICES ARE AS FULLY LOADED
AS POSSIBLE WITH THE THERAPEUTIC
GENE SO HOW DO WE ENHANCE THAT
GREEN EXPRESSION WITHIN THE
DELIVERY DEVICE AND THESE ARE
LARGELY ASSOCIATED VIRUS THAT'S
WE'RE LOOKING INTO FOR DELIVERY
BUT ULTIMATE LEASE THERE WILL BE
OTHER APPROACHES AS WELL.
AND THEN WE HAVE OUR FINAL
PROGRAM THAT I'LL TALK ABOUT IS
THE PLATFORM GENE THERAPY
PROGRAM AND THIS IS A SINGLE
ASSOCIATED VIRAL VECTOR AS A
PLATFORM FOR MULTIPLE
THERAPEUTIC GENES SO MULTIPLE
DISEASES, MULTIPLE THERAPEUTIC
GENES COULD BE USED IN ONE
SINGLE AAB VECTOR AND THIS IS
THE PROCESS THAT WE'RE TESTING
AND TRYING TO FIND WHAT IS
COMMON IN TERMS AND WE WANT TO
BE ABLE TO TEST THE ABILITY TO
USE THESE IN A WAY TO MAKE THE
DATA THAT WE FIND PUBLIC AND WE
HOPE THAT ULTIMATELY THIS WILL
INCREASE EFFICIENCY TO CLINICAL
TRIALS START UP AS WELL FOR
OTHER THERAPIES THAT I CAN SEE
DOWN THE PIKE BEING ON THIS
PROGRAM.
SO THOSE ARE SOME OF THE KEY
AREAS WE'RE WORKING ON IN TERMS
OF GENE EDITING AND GENE
THERAPY.
IF YOU GO TO THE NEXT SLIDE,
THIS IS TWO MORE SLIDES HERE AND
ONE IS HOW WE'RE THINKING ABOUT
ADVANCEMENT OF WOMEN AND
BIOMEDICAL CAREERS AND I
MENTIONED THAT THE WORKFORCE
DEVELOPMENT IS A KEY AS POTH OF
WHAT WE DO AND SO WE HAVE
SOMETHING CALLED THE WOMEN'S
SCIENTIST ADVISER GROUP WITH THE
INTRAMURAL PROGRAM AND WE ENGAGE
LOCAL COMMUNITIES PARTICULARLY
STUDENTS IN GRADES K-12 AND WE
HAVE THEM DO TOURS AND SEE WHAT
WE DO AND WE DO THIS IN
DIFFERENT WAYS DEPENDING ON
WHERE THEY ARE IN THEIR
PROGRAMS.
AND SO THIS IS AN ISSUE THAT
INCREASES THE VISIBILITY OF OUR
SCIENTIST AND ENCOURAGING THEM
AND THEN THE NEXT SLIDE IS JUST
THE LAST SLIDE WHERE WE'RE
UNDERGOING A STRATEGIC PLAN
PROCESS AND YOU CAN CLICK FROM
HERE AND I HOPE THAT THIS
COMMUNITY STAYS TO AND WE'LL
REACH OUT FOR REQUEST FOR
INFORMATION FAIRLY SOON AND I
WANTED TO MAKE SURE YOU WERE
AWARE OF THAT SO THAT WHEN IT IT
COMES OUT IT WILL BE READY TO GO
AND HELP US HIGHLIGHT AND MANY
YOU WOULD LIKE TO SEE US MAKE
SURE THAT OUR STRATEGIC PLAN.
AND WITH THAT, I WILL STOP THERE
AND SEE IF THERE ARE ANY
QUESTIONS.
>>THANK YOU SO MUCH, JONI FOR
THAT WHIRLWIND.
THAT WAS A WHIRLWIND.
I REALLY APPRECIATE YOUR
HIGHLIGHTING EVATA.
>>Debra: BECAUSE IT WAS
EXCITING AND I REMEMBER WHEN WE
FIRST TALKED THE FOLKS ABOUT
THIS EFFORT AND WE WERE THRILLED
TO BE ABLE TO SUPPORT THAT A LOT
THE BEGINNING AND TERESE AND
OTHERS HAVE DONE AN INCREDIBLE
JOB MOVING THINGS FORWARD AND
HELPING US SEE THE APPLICATIONS
OF THOSE POTENTIAL APPROACHES
WHERE I LIMITLESS AT THIS POINT.
>>THANK YOU SO MUCH FOR THAT.
I WANT TO SEE IF COUNCIL MEMBERS
HAVE QUESTIONS.
I'M NOT SEEING ANY.
WHILE YOU ARE THINKING OF YOUR
QUESTIONS, I ALSO REALLY WANT TO
GIVE YOU AN INCREDIBLE SHOUT OUT
FOR THE SEX DIFFERENCES
PUBLICATION THAT CAME FROM N3C.
WE TALKED ABOUT THAT AND YOU AND
I TALKED ABOUT IT AND WHY THINK
THAT PAPER WAS OUT WHEN WE
TALKED.
>>IT WASN'T.
>>Janine A. Clayton: YOU WOULD
HAVE TOLD ME.
JONI WHERE ARE THE SEX --
>>THE RURAL HEALTH PAPER TOOK A
YEAR TO GET PUBLISHED AND FOR
SOME REASON IT WAS THE PAPER OF
THE YEAR.
WE'VE SEEN THERE'S BEEN DELAYS
OF PUBLISHING JUST BECAUSE OF
THE REVIEW TIMES, ET CETERA.
SO IT'S BEEN A WHILE.
>>Janine A. Clayton: RIGHT.
SO THANK YOU FOR HIGHLIGHTING
THAT AND THERE'S A LOT OF
POTENTIAL TO BUILD ON NC3 FOR
APPLICATIONS AND WE'VE DISCUSSED
THAT BUT I SEE THAT MY COLLEAGUS
HER HAND UP.
>>THANK YOU VERY MUCH.
IT WAS VERY EXCITING AND SO
PLEASED TO BE INTRODUCED TO THE
NCATS IS DOING.
IT BRINGS ME BACK TO MY EARLIER
DAYS AS A PHYSICALLOLOGIST.
O MY QUESTIONS ARE I USED TO DO
A LOT OF IN VIVO HIGH HOW DO YOU
MIMIC THE POSITIVE AND NEGATIVE
FEEDBACK SYSTEM WHICH ARE
OPERATIVE IN AN ENTIRE ORGANISM
AND VERSUS THE LIMITED
ENVIRONMENT THAT YOU HAVE IN A
CHIP.
>>THAT'S A GREAT QUESTION.
WE HAVEN'T SOLVED IT YET.
FOR EXAMPLE, WE WOULD REALLY
LIKE TO SOLVE IT.
IF WE CAN, WE CAN GET TO THE
LONGER ANALYSIS OF THESE KINDS
OF TISSUES NOT CHIPS FOR
EXAMPLE, IN THE SPACE WE SEND
THOSE CHIPS UP INTO SPACE,
THEY'RE GOOD ABOUT THREE TO FOUR
WEEKS BUT THEN THEY DIE OFF SO
WE HAVE TO BRING THEM DOWN AND
WE MEASURE THEM AND THAT IS
BECAUSE WE DON'T HAVE A ABILITY
TO GET RID OF THE TOXICITIES
THAT ARE BUILDING UP IN THE
CELLS AND THE WAYS THEY BUILDUP.
WE DON'T HAVE THAT COMPLETE SORT
OF SYSTEM.
AND SO THOSE ARE THE INNOVATION
THAT'S WE'RE STILL NEEDING TO
FIGURE OUT AND CREATE AND IT
WILL NEVER BE PERFECT BUT THESE
ARE SOME OF THE AREAS THAT I
THINK WE'RE WORKING ON NOW.
SO IT'S A GREAT QUESTION.
AND IF APPROXIMATE YOU HAVE
IDEAS, LET US KNOW.
ALSO THE BIOLOGICAL RHYTHMS THAT
ARE INHERENT.
>>THAT'S RIGHT.
THAT'S RIGHT.
CIRCADIAN RHYTHMS ARE IMPORTANT.
>>ABSOLUTELY.
>>THE OTHER THING THAT I WAS
INTERESTED IN YOUR OBSERVATION
IN SPACE PEOPLE AGE FASTER WHICH
IS LIKE A CONTRADICTION TO
EINSTEIN THEORY.
PEOPLE TRAVEL IN SPACE WHEN
PARADOX THAT THE TWIN IN SPACE.
>>THAT'S RIGHT, YEAH.
SO IT'S THE -- FOR IT'S THEORY
OF RELATIVELY TO RELATES TO THE
SPEED OF LIGHT.
IF YOU GO INTO HYPER DRIVE, IT
WOULD BE YOU WOULD GET YOUNGER.
>>YEAH.
>>BUT IN MICRO GRAVITY, IT'S
THAN LACK OF THE GRAVITATIONAL
COUND RECOGNIZE ARE POLE THAT
SEEMS TO HAVE THIS SORT OF
EFFECT, WE DON'T KNOW WHY, YET
BUT THE GRAVITY IS DOES SERVE AS
SORT OF THIS LIKE QUANTUM
ACTIVITIES IF OUR CELLS AND SO
IT'S AN IMPORTANT ENVIRONMENT
THAT TO BE INCLUSIVE WHEN WE
WANT TO THINK ABOUT THAT PROCESS
AND AGING.
>>THANK YOU VERY MUCH.
>>THESE DIFFERENCES ARE ALL
PUBLICATIONS IN THAT SPACE AND
ESPECIALLY AROUND SOME OF THE
BONE CONSEQUENCES SO WE ALREADY
KNOW THEIR SEX DIFFERENCES IN
BONE LOSS AND JUST IN
OSTEOPOROSIS FOR EXAMPLE SO IT'S
GREAT TO BE ABLE TO -- I WOULD
NOT HAVE THOUGHT Dr. RUTTER
THAT SPACE EXPLORATION WOULD BE
APPROPRIATED TO THE NCATS AND
WOMEN'S HEALTH PRESENTATIONS SO
WE ARE REAL HE'S EXCITED TO HEAR
JUST OF YOUR VISION AND YOUR
PERSPECTIVE THAT YOU ARE
BRINGING TO NCATS.
THERE IS A QUESTION IN THE CHAT
OF Dr. TEMPLETON.
SHE'S ASKING A QUESTION.
DO YOU WANT TO ANSWER HER
QUESTION ABOUT THE PARTICULAR.
>>YEAH, YEAH.
THAT WAS AN AWESOME
PRESENTATION.
THIS IS HAVE NARRO NAR THEIR OWY
FOCUSED AND WE IT'S CARTILAGE IN
PATIENTS WITH WEIGHT BEARING AND
YOU CAN SEE DIFFERENCES ON MRI
WHICH MAY OR MAY NOT WAGE MORE
PROGRESSIVE OSTEOARTHRITIS, HAVE
YOU THOUGHT OF LOOKING THAT IN
IN SPACE AND LOOKING AT CHANGES
IN BONE AND LOOKING AT CHANGES
IN THES CARTILAGE?
>>YES IN DEED.
IN FACT WE HAVE TISSUE CHIP THAT
MIMICS THAT JOINT, THE
CARTILAGE.
IT'S A KNEE JOINT THAT WE HAVE
IN SPACE.
WE ARE STUDYING THAT FOR THAT
VERY REASON.
YEAH.
I DON'T HAVE SPECIFIC FINDINGS
AT THIS POINT BUT IT'S SOMETHING
THAT IS OF INTERESTING AND VERY
IMPORTANT TO STUDY AND I HOPE
THEY HURRY BECAUSE, MY RIGHT
KNEE IS AWFUL.
>>AND I APPRECIATE THAT.
I APPRECIATE YOU LOOK AT
CARTILAGE BECAUSE IT GETS LOST.
I'M ORTHOPEDIC SURGERY WHEN WE
HAVE PEOPLE THAT HAVE BEEN
PROLONGED CANNOT WAIT BECAUSE OF
A JURY IT'S ALWAYS THE QUESTION.
HOW SOON DO YOU LET THEM PUT
WEIGHT ON THAT CARTILAGE BECAUSE
WE DON'T KNOW WHAT CHANGES THE
CARTILAGE IS UNDERGONE AND IF
TOUCHDIF ITHAS UNDER GONE CHANGE
YOU NEED TO CHANGE PROTO.
>>IN A WAY, BIOLOGY IS SUPER
ORGANIZED.
I MEAN, THE WAY THAT WE DEVELOP
THESE CHIPS AND ORGANOIDS IS
THERE A LAYER.
YOU HAVE THE CARTILAGE AND BONE
LAYER AND THEY ARE ALL LAYERS SO
IT IT'S ORGANIZED TO BE ABLE TO
DEVELOP THESE TISSUES ON A CHIP
AS WELL AND THEN YOU KNOW,
LOOKING AT THAT EPIDEMIOLOGY
FURTHER, HOW DO YOU CREATE THAT
STRESS AND THAT FORCE FOR WHEN
THOSE JOINTS ARE ACTUALLY
PRESSING ON ONE ANOTHER AND
UNDERSTANDING WHAT IT MEANS.
SO THESE ARE THE KINDS OF
QUESTIONS THAT WE'RE INTERESTED
IN ASKING AND I HOPE THAT WE CAN
FIND SOME GOOD PATHS FORWARD AN-
>>WE HAVE TWO KANSAS ON HERE.
>>I CAN'T EITHER.
[LAUGHTER]
>>Janine A. Clayton: CONTINUING
ON THE CHIP THING, I KNOW WE'RE
AT 11:37 SO WE HAVE THREE
MINUTES FOR THIS REST OF THIS
Q&A.
JONI, I LOVE THE FEMALE
REPRODUCTIVE CHIP ISSUES AND YOU
HIGHLIGHTED IN YOUR GOING INTO
THE WOMEN'S HEALTH SECTION OF
THE PRESENTATION, THE SEVERE
AEs THAT WE SEE IN WOMEN
COMPARED TO MEN IN THE FDA
PAPER.
I WANT TO ASK YOU FOR EXAMPLE,
DELIVER ON A CHIP PROJECT
BECAUSE SO MANY DRUGS PASS
THROUGH THE LIVER.
ARE YOU TRYING TO INCORPORATE
DIFFERENCES IN THE ORGANS ON A
CHIP THAT REPEAT REPRODUCTIVE
RELATED?
>>YES, EXACTLY.
SO THAT IS PRECISELY THE IDEA
AND DOING THAT BECAUSE WE CAN
TAKE PRIMARY CELLS AND WE CAN
CREATE THOSE STEM CELLS SO IF WE
HAVE APP OPPORTUNITY NOT JUST
MEN AND WOMEN BUT ALSO DIVERSE
POPULATIONS.
AND SO THAT IS DEFINITELY A
FEATURE THAT WE WANT TO
INCORPORATE A LOT MORE.
AS WE GET INTO MORE OF THE
DEVELOPMENT MODE NOW WE'RE INTO
SORT OF A FIGURING OUT HOW TO
TEST THEM MODES AND SO THAT
MEANS WE'RE GOING TO BE ABLE TO
SCALE THOSE UP.
AS WE START TO SCALE UP, WE'LL
SEE A LOT MORE OF THAT DIVERSE
TEASE IN THE TEXAS STUDIES.
IT'S A VERY IMPORTANT POINT.
I'M GLAD YOU ASKED IT.
IT'S CRITICAL TO HAVE THE SYSTEM
COMPONENTS ON THERE AND
UNDERSTANDINGINGS IF THERE'S A
METABOLIC FROM THE THERAPEUTIC
IN THE LIVER THAT MIGHT EFFECT
THE DOWNSTREAM EFFECTS OF IT
THAT WE'LL LEARN THAT BETTER
ESPECIALLY SUPPOSE IT'S
IMPORTANT TO KNOW.
>>Janine A. Clayton: ABSOLUTELY
AND IT CAN GENERATE MORE
RESEARCH QUESTIONS TO EXPLORE
THE SEX DIFFERENCES SO THAT CAN
ACTUALLY BE DATA USED TO WRITE
INVESTIGATOR INITIATED
APPLICATIONS SO YOUR GENERATING
NEW KNOWLEDGE THAT IS POPULATING
OUR ECOSYSTEM AND YOU
HIGHLIGHTED AT THE BEGINNING HOW
IMPORTANT IT IS, THE FACT THAT
THIS OVER RELIANCE ON MALE
APPROXIMATE HAVE RESULT INSIDE
OUR GAPS ABOUT FEMALE BIOLOGY
AND WOMEN'S HEALTH IN GENERAL SO
THESE ARE SOME OF THE WAYS YOU
MAY NOT THINK OF TRANSLATIONAL
RESEARCH AS WOMEN'S HEALTH
RESEARCH BUT THESE ARE VERY
FOUNDATIONAL EFFORTS SO I DO
WANT TO HIGHLIGHT AND JUST
APPLAUD NCATS FOR IN CORPORATING
IT INTO YOUR WORK.
>>I WAS GOING TO SAY THANK YOU
BACK BECAUSE WITHOUT YOU, Dr.
CLAYTON AND ORWH WE WOULD BE
STRUGGLING O WE ABSOLUTELY
CHERISH THE RELATIONSHIP THAT WE
HAVE WITH YOU AND YOUR TEAM AND
THE SCIENTIFIC COMMUNITY.
IT'S TEAM SCIENCE.
WE NEED ALL OF US AT THE TABLE
SO THAT'S IMPORTANT.
THANK YOU FOR THEIR HELP AND
LEADERSHIP IN GUIDING THIS.
>>THANK YOU SO MUCH FOR THAT
JONI.
YOU ARE RIGHT, SCIENCE IS A TEAM
SPORT FOR SURE.
EVEN THOUGH THE SPORT THAT I
PLAY IS AN INDIVIDUAL SPORT,
SCIENCE A TEAM SPORT AND WE'RE
JUST EXPANDING THE TEAM AND
GETTING MORE PLAYERS ON THE
TEAM.
EXACTLY.
>>BEFORE WE GO, YOU WANT TO
GIVE MEMBERS ONE MORE SECOND A
CHANCE TO MAKE ANY COMMENTS OR
QUESTIONS.
YOU ALSO ARE IN THE CHAT JONI
THERE WAS POSITIVE FEEDBACK ON
YOUR K-4 PROGRAM AND YOUR WSAs
AND THAT'S GREAT AND THAT'S
FANTASTIC TO SEE IT AS WELL AND
GREAT TO SEE YOUR INTRAMURAL
SCIENTISTS GETTING VISIBILITY IN
THAT PROGRAM SO CONGRATULATIONS
ON THAT.
>>Samia Noursi: THANK YOU,
Dr. RUTTER.
I APPRECIATE YOU JOINING US.
I'D LIKE TO MAKE SURE WE WELCOME
Dr. SIMON WHO JOINED US A LOT
WAY FROM GREECE.
I CAN'T BELIEVE WITH YOU ARE US
AND NOT ENJOYING THE BEACHES
THERE.
THANK YOU FOR JOINING US WE
APPRECIATE YOU BEING ABLE TO DO
SO AND Dr. CLAYTON WE CAN MOVE
TO THE NEXT SEGMENT.
>>Janine A. Clayton: YES, I
WILL TURN THE VIRTUAL MICROPHONE
TO Dr. JULIE AN.
>>THANK YOU Dr. CLAYTON.
CAN YOU HEAR ME OKAY?
>>WE CAN HEAR YOU GREAT.
I WOULD NOW LIKE TO INTRODUCE
OUR FINAL SPEAKER OF THE MORNING
MY COLLEAGUE DAWN CORBETT SHE'S
THE NIH INCLUSION POLICY OFFICER
AND THE OFFICE OF EXTRAMURAL
RESEARCH OER WHERE SHE PROVIDES
OVERSIGHT OF NIH WIDE EFFORTS TO
ENSURE I AM CONCLUSION OF WOMEN,
MINOR TEASE AND INDIVIDUALS As
COULD THE LIVES SPAN IN NIH
DEFINED CLINICAL RESEARCH AND
PRIOR TO JOINING OER SHE LED
EFFORTS TO INCREASE EFFICIENT'
AND TRANSPARENCY OF CLINICAL
RESEARCH THROUGH ENHANCE
RECRUITMENT MONITORING AND
INCREASE COMPLIANCE EFFORTS AS A
HEALTH SCIENCE POLICY ANNALIST
IF APPROXIMATE THE NATIONAL
INSTITUTE OF MENTAL HEALTH AND
AND OFFICE OF CLINICAL RESEARCH,
CLINICAL TRIAL OPERATIONS AND
STATISTICS BRANCH THERE AND SHE
BEGAN HER FEDERAL CAREER AT NIH
IN THE NI IN PH OFFICE FOR
RESEARCH IN DISPARITIES IN
GLOBAL MENTAL HEALTH.
Ms. CORBETT HAS A MASTER
DEGREE IN PUBLIC-HEALTH FROM
JOHNS HOPKINS SCHOOL FOR
PUBLIC-HEALTH AND A BACHELOR'S
DEGREE IN POLITICAL SCIENCE FROM
THE UNIVERSITY OF ILLINOIS.
WELCOME Ms. CORBETT.
>>BEFORE I START MY
PRESENTATION I WANT TODAY IF I
ARE MINOR SURGEON MY FACE
YESTERDAY SO I'M WEARING A MASK
SO I'M GOING OFF CAMERA DURING
THE PRESENTATION BUT I'LL COME
BACK FROM THE Q&A TO MAKE SURE
YOU CAN CLEARLY HEAR ME.
BUT I'M GOING TO GO AHEAD AND
GET STARTED NOW.
AND SO TODAY I WANTED TO GIVE
YOU AN UPDATE ON NIH INCLUSION
EFFORTS.
WE TOUCHED BASE LAST YEAR TO
TALK ABOUT WHERE WE WERE WITH
INCLUSION OF WOMEN AND AND
MEMBERS OF RACIAL AND ETHNIC
MINORITY GROUPS AND INDIVIDUALS
ACROSS THE LIFESPAN AND I WANT
TODAY GIVE YOU AN UPDATE OF
WHERE WE ARE CURRENTLY.
JUST TO ORIENT YOU AND GIVE YOU
A TIMELINE OF NIH INCLUSION
POLICIES, THERE WAS INCLUSION
POLICY ON THE BOOKS SINCE 1986
WHEN NIH BEGAN INCLUSION OF
WOMEN IN NIH CLINICAL RESEARCH
STUDIES IN 1994, IT WAS NAH
POLICY IN RESPONSE TO THE 1993
REVITALIZATION ACT THAT MANDATED
THE CONCLUSION OF WOMEN AND
RACIAL AND ETHNIC GROUPS AND
CLINICAL RESEARCH STUDIES SO IT
WAS REQUIRED IN 1994 AND THEN IN
1998, AT THAT TIME, WE REALIZE
THAT A NUMBER OF CONCERNS ABOUT
INCLUSION OF WOMEN AND MEMBERS
OF RACIAL AND ETHNIC MINORITY
GROUPS ALSO APPLIED TO INCLUSION
OF CHILDREN ALSO REPRESENTING --
UNDER REPRESENTED IN NIH FUNDED
CLINICAL RESEARCH SO IN THE
1998, WE BEGAN REQUIRING
INCLUSION OF CHILDREN AND NIH
RESEARCH AND IT WAS PRETTY MUCH
THE SAME AND IN 208.
WE BEGAN IMPLEMENTING SOME
ADDITIONAL REQUIREMENT AND THE
21st SEPTEMBER RECURES ACT
WHICH WAS PASSED IN DECEMBER OF
2016 AND INCLUDED A NUMBER OF
NEW REQUIREMENTS FOR NIH AND
CLINICIAN.
SOME OF THIS REQUIREMENTS
INCLUDED NEW REQUIREMENTS FOR
RECORDING VALID FOR SEX, GENDER
RACE AND CLINICAL TRIALS.GOV AND
PHASE 3 CLINICAL TRIALS SO THAT
THIS IMPLEMENTED ON THE 2017 AND
IN 2019, THE NIH INCLUSION
ACROSS THE POLICY WAS INCLUSION
OF CHILDREN POLICY NOW INCLUDING
THE INDIVIDUAL ALL AGES AND NIH
FUNDED CLINICAL RESEARCH STUDIES
INCLUDING HEALTH AND OLDER
ADULTS AND THERE'S A SCIENTIFIC
OR ETHICAL REASON FOR THEIR
INCLUSION AND MOST RECENTLY IN
2022 WE CLARIFIED OUR
INSTRUCTIONS FOR PROGRESS
REPORTS AND ON INDICATING THAT
NIH DEFINED WHICH IS PUBLICLY
AVAILABLE ON THE NIH REPORT SITE
AND SO WE'LL GO OVER THESE IN A
BIT MORE DETAIL BUT I WANT TO
ACKNOWLEDGE DESPITE THE NUMBER
MANY DECADES OF EFFORTS, WE
ACKNOWLEDGE THERE IS STILL MORE
TO BE DONE.
WE STILL HAVE NOT REACHED THE
LEVEL OF CLINICAL RESEARCH
STUDIES AND TO THE EXTENT WE SEE
WOULD LIKE AND NIH COMMISSION A
REPORT OF THE NATIONAL ADD
ACADEMY OF MEDICINE THAT REPORT
CAME OUT LAST YEAR.
ABOUT A PARADIGM SHIFT THAT
LOOKS ON TACTICS AND PROCESS
CHANGES AND DISPARITIES AND
RESEARCH ACCESS WILL INSIST AT
POPULATION SUBGROUPS AND -- AND
THEN KINDLY IF IT'S SPOKEN
CLINICAL TRIAL AND IT'S
APPLICABLE CLINICAL TRIAL, WHICH
IS REFERRED TO OUR FDA REGULATED
DRUG DEVICE STUDY THOSE STUDIES
MUST ALSO REPORT THE RECORDS OF
THIS ANALYSIS IN CLINICAL TRIALS
IN ADDITION TO REQUIREMENT THAT
INFORMATION IN THE PROJECT
OUTCOME SECTION.
AND I MENTIONED WE EXPANDED OUR
INCLUSION OF CHILDREN POLICY IN
2019 T.S.X. EFFECTIVE THEN AND
WHICH REQUIRES THAT INDIVIDUALS
OF ALL AGES INCLUDED AND NIH
HUMAN SUBJECTS RESEARCH UNLESS
THERE'S SCIENTIFIC REASONS NOT
TO DO SO.
IF YOU HAVE A NIH GRANT YOU MAY
BE FAMILIAR WITH THE TABLES WE
REQUIRE BY SEX OR GENDER AND
RACE AND ETHNICITY AND WE KNOW
PRIORITY WITH INDIVIDUAL LEVEL
DATA WHICH SHOWS THE SEX OR
GENDER, RACE, ETHNICITY AND THE
AGE OF ENROLLMENT OF EACH
PARTICIPANT IN NIH FUNDED
CLINICAL RESEARCH STUDIES.
SO, I BRIEFLY SUMMARIZED OUR
REQUIREMENTS AND I KNOW WHEN WE
TALK ABOUT THE STATUS OF WHERE
WE ARE IN IMPLEMENTATION OF OUR
POLICIES.
I'VE TALKED PREVIOUSLY ABOUT THE
JAR REPORT TA CAME OUT IN 2015
WHICH INDICATED THAT BETTER
OVERSIGHT WAS NEEDED TO HELP
ENSURE CONTINUED PROGRESS
INCLUDING LIMITED HEALTH
RESEARCH.
THIS REPORT INCLUDED FIVE
RECOMMENDATIONS INCLUDING
IMPROVEMENTS TO REPORTING, ALSO
IMPROVEMENT TO TRANSPARENCY OF
DATA BY MAKING IC LEVEL REPORTS
AVAILABLE AND BY TRACKING THE
NUMBER OF STUDIES THAT REQUIRE
ANALYSIS BY SEX OR GENDER RACE
AND ETHNICITY AND MAKING THAT
INFORMATION PUBLICLY AVAILABLE.
SO, WE ARE REPORTING ALL OF THE
RECOMMENDATIONS FROM THE GAO
REPORT ARE CLOSED AND WE HAVE
IMPLEMENTED THE IMPROVEMENT
THAT'S GAO REQUESTED AND WE
CLOSED THAT OUT LAST YEAR.
THIS REPORT WAS PUBLISHED IN
DECEMBER OF 2022 AND NCI WAS
INVOLVED IN THIS AUDIT AS WELL
AS MY OFFICE.
THIS AUDIT FOUND THAT FEDERAL
AGENCIES HAD TAKEN AGENCY TO
FACILITATE DIVERSITY OF PATIENTS
AND NIH FUNDED CANCER CLINICAL
TRIALS.
THE REPORT MENTIONED ACTIONS
FEDERAL AGENCIES HAD TAKEN WITH
RESPECT TO ELIGIBILITY CRITERIA
AND OTHER PRACTICES AND SO THERE
WERE NO RECOMMENDATIONS FROM
THAT REPORT FOR NIH TO
IMPLEMENT.
WE'LL TALK A LITTLE BIT MORE
ABOUT THINGS THAT WE'VE BEEN
DOING IN RECENT YEARS TO IMPROVE
OUR MONITORING AND ENFORCEMENT
OF NIH INCLUSION POLICIES.
AMONG THOSE EFFORTS INCLUDE THE
DEVELOPMENT OF A HUMAN SUBJECT
SYSTEMSIS.
THIS IS A ERA MODULE THAT WORKS
WITH PROGRAM MODULES AND ALSO
ASSIST FOR THOSE OF YOU WHO USE
THAT TO SUBMIT NIH GRANTS.
AND ANY IDEA OF THE HUMAN
SUBJECT SYSTEM AND THAT IT
INCLUDES ALL HUMAN SUBJECTS AND
CLINICAL TRIAL INFORMATION ALL
IN ONE PLACE SO OUR APPLICANTS
AND RECIPIENTS AND OUR STAFF CAN
SEE ALL OF THE INFORMATION IN
ONE PLACE.
WE ALSO HAVE SYNCHRONIZED SYSTEM
CLINICAL TRIALS AND WE CAN
VALIDATE THE INFORMATION IS
CONSISTENT AND APPROPRIATE
ACROSS SYSTEMS THEY CAPTURE THE
INDIVIDUAL LEVEL DATA WHICH I'VE
MENTIONED.
WE ARE ALSO USING THIS SYSTEM TO
MONITOR THE NUMBER OF STUDIES TA
REQUIRE ANALYSIS BY SEX OR
GENDER, RACE AND ETHNICITY SO IT
ALLOWS OUR PROGRAM OFFICERS TO
SEE AT A GLANCE, THE REQUIREMENT
FOR EACH STUDIES AND THEIR
ENROLLMENT GOALS AND PROGRESS.
IN ADDITION.
NIH HAS CONTINUED TO ENHANCE ITS
REPORTING OF INCLUSION OF
INDIVIDUALS AND NIH RESEARCH.
MOST RECENTLY, LAST YEAR IN 2022
WE DEPLOYED A NEW REPORT, WHICH
SHOWS NIH INCLUSION DATA BY
RESEARCH CONDITION OR DISEASE
CATEGORY AND INCLUDES AGE FOR
THE FIRST TIME.
A FEW YEARS IT DEPLOYED DATA AND
WE CAN THAT INITIALLY FOR SEX OR
GENDER RACE AND ETHNICITY
BECAUSE WE HAD BEEN COLLECTING
THIS DATA FOR SOME TIME SO IT'S
AVAILABLE BY AGE AND IT'S
AVAILABLE ON OUR WEBSITE AND YOU
CAN GO TO THE WEBSITE AND CLICK
ON ANY RESEARCH DISEASE OR
CONDITION AND MEDIUM PREPORTION
AND THE PEOPLE AND WE CAN ALSO
LOOK BY IC FOR THOSE DATA SO
THERE'S A WEATHER OF INFORMATION
ABOUT PARTICIPATION AND OUR
RESEARCH AVAILABLE.
ONE NOTE ABOUT THE AGE DATA
THAT'S AVAILABLE, WE ONLY HAVE
AGE DATA FOR THOSE THAT FOLLOW
UNDER THE INCLUSION OF LIFESPAN
AND INCLUDING APPLICATIONS
SUBMITTED JANUARY 25th, 2019
OR LATER.
THIS IS A SNAPSHOT OF THE DATA
AND WE DON'T HAVE ALL OF OUR
GRANTS AND CONTRACTS THAT
CURRENTLY FULL UNDER THIS
POLICY.
FINALLY, WE CONTINUE TO WORK ON
COLLABORATION BUT WITH OUR
FEDERAL PARTNERS ALSO PUBLIC AND
PRIVATE PARTNERS NEXT SUN AND IN
WORKING TO IMPROVE INCLUSION AND
WORKING IN CLINICAL TRIALS AND
AND ORGANIZATIONAL LEVEL
STRATEGIES TO INCLUDE THAT
INCLUSION.
THIS IS FROM OUR RECENT PAPER
THAT CAME OUT WHICH I WAS A
CO-AUTHOR OF THIS PAPER ALONG
WITH MY COLLEAGUES ON THE OTHER
TEAM LEADS ON THE DIVERSITY
PROJECT.
ONE OF THE QUOTES YOU CAN SEE
HERE IS ALL THEY MUCH WORK HAS
FOCUSED ON STUDY LEVEL
STRATEGIES, RESEARCH
ORGANIZATIONS MUST MAKE SYSTEMIC
CHANGES TO HOW CLINICAL TRIALS
ARE ENVISIONED IN IMPLEMENTED
AND CHIEF SUN TAPE ABLE SUPPORT
FOR DIVERSITY AND INCLUSION
TIMES.
THIS IS SOMETHING WE'VE BEEN
THINKING ABOUT A LOT AND OUR
OFFICE IS HOW CAN ORGANIZATIONS
CREATE A SUSTAINABILITY
INFRASTRUCTURE TO SUPPORT
INCLUSION OVER THE LONG-TERM
RATHER THAN LACTAID LOOKING STUY
SIDE AND THIS REQUIRES EFFORTS
FROM EFFORTS TO CREATE SOMETHING
THAT IS ALREADY BEEN CREATED AND
IT'S DIFFICULT TO SUSTAIN
RELATIONSHIPS OVER TIME.
AND ADDRESS ISSUES GOING
FORWARD.
AS I ACKNOWLEDGED AT BEGINNING,
WE KNOW WE STILL HAVE MORE TO DO
SO MOST RECENTLY ON MARCH 30th
AND THE 31st, THE NATIONAL
INSTITUTE OF HEALTH AND HEALTH
DISPARITIES HELD A WORKSHOP ON I
AM CONCLUSIVE PARTICIPATION AND
RESEARCH AND THIS WAS A VERY
INTERESTING MEETING AND WE
TOUCHED ON A LOT OF IMPORTANT
TOPICS.
FOR BEFORE AND DURING AND AFTER
THE STUDY MANY OF WE TALKED
ABOUT ISSUES SUCH AS
PARTICIPANTS COP PENNIZATION AND
HOW WE THINK OF THIS IN TERMS OF
INCLUSION IN CLINICAL RESEARCH
AND THE NUMBER OF POPULATIONS
THAT NEED TO BE CONSIDERED TO
HAVE TRULY DIVERSE AND INCLUSIVE
CLINICAL RESEARCH STUDIES THAT
ARE GENERALIZABLE UP TO THOSE
WHO CAN BENEFIT FROM THE
RESEARCH IF YOU DIDN'T HAVE A
CHANCE TO CATCH THIS MEETING
IT'S AVAILABLE.
WE LOOK FORWARD TO THE REPORT
COMING OUT OF THIS MEETING.
I WOULD LIKE TO TALK ABOUT OUR
DATA.
I HAVE TWO YEARS PRESENTED HERE.
WE HAVE DATA FROM FISCAL YEAR
2021 AND 2022.
I'VE ALSO INCLUDED A JUSTED DATA
FOR 2022 ON WHICH I'LL.
IF YOU LOOK AT OUR OVER ALL
PORTFOLIO, 2021 WE HAD ABOUT
13 MILLION PARTICIPANTS IN
CLINICAL RESEARCH AND THE VAST
MAJORITY IS 77% WERE U.S.
RESEARCH AND 23% OF RESEARCH
CONDUCTED OUTSIDE THE U.S.
WE SEE THIS BIG JUMP WHEN YOU
LOOK AT 2022 FROM 13 MILLION TO
97 MILLION.
THIS IS LARGE SOCIAL MEDIA STUDY
THAT WE HAD FOCUSED ON COVID-19
CATEGORIES.
I'M GOING TO FOCUS ON THE 2022
ADJUSTED DATA WHICH EXPLAINED
THAT STUDY ON THE 86 MILLION
PARTICIPANTS SO WE CAN GET A
BETTER SENSE OF WHAT THE I AM
CONCLUSION LOOKS LIKE ACROSS THE
PORTFOLIO.
SO WE HAD ABOUT 11 MILLION
PARTICIPANTS AND 81% OF THOSE
FROM U.S. STUDIES AND ABOUT 19%
STUDIES OUTSIDE THE U.S.
WHEN WE LOOK AT NIH DEFINED
PHASE 3 CLINICAL TRIALS MUCH
SMALLER NUMBER OF PAR ANTS.
WE HAVE IN 2021 AND IT JUMPED UP
WHEN WE LOOKED AT AT JUSTED DATA
FROM 2022.
AGAIN, MOST PARTICIPANTS WE SAW
AN INCREASE IN U.S. PARTICIPANTS
FROM 2021 TO 2022 FROM 66% TO
ABOUT 82% IN 2022 AND WHEN WE
LOOK AT FOREIGN STUDIES AGAIN WE
SAW IT WAS A DECREASE FROM ABOUT
34% OF STUDIES OUTSIDE THE U.S.
IN 2021 UP TO 19% IN 2022.
I'D LIKE IT O TO SHOW GENDER AG
CLINICAL TRIALS AND NON TRIALS.
WE LOOK AT FISCAL YEAR '21 WE
CAN SEE ABOUT 39% OF OUR
PARTICIPANTS ARE MALE AND ABOUT
59% OF OUR PARTICIPANTS WERE
FEMALE AND THIS IS BEEN A TREND
OVER TIME AND WE'VE INTEND TODAY
SEE FEMALE PARTICIPANTS AND THE
MALE PARTICIPANTS AND FAIRLY
ABOUT TWO AND A HALF PERCENT
IDENTIFIED AS EITHER CATEGORY OR
UNKNOWN OR NOT RECORDED.
I'M GOING TO SKIP THE 2022 AND
DISCUSS TO THE 2022 ADJUSTED AND
THE TRENDS ARE SIMILAR WHERE
WHAT IS ADJUSTED ON ABOUT 56%
ABOUT 45% MALE AND 2.8% UNKNOWN
ARE NOT RECORDED.
SO WHEN YOU LOOK AT THESE FREE
CLINICAL TRIALS WE SEE MORE
FEMALES IN THE NIH TIME PHRASE
CLINICAL TRIALS THAN THE NIH
CLINICAL RESEARCH PORTFOLIO AS A
WHOLE AND THIS IS A TREND AGAIN
WHERE WE'VE TENDED TO SEE OVER
TIME.
WE HAVE FEMALE ONLY STUDIES AND
MALE ONLY STUDIES AND IT'S ONE
REASON WHY WE TENDS TO SEIZE
THIS SO IT CAN BOTH 2021 AND IN
2022 A JUSTED UP 61% FEMALES AND
THEN WE SAW JUST A BIT OF AN
INCREASE IN THE UNKNOWN THAT ARE
NOT RECORDED FROM ABOUT 1% IN
THE NEAR 2021 TO 2004 IN 2022.
LOOKING AT RACE, AGAIN, I'LL
FOCUS ON THE 2021 AND THE 2022
ADJUSTED.
NO MAJOR JUMPS IN AMERICAN
INDIAN OR ALASKA NATIVE ADJUSTED
A BIT TO 1%.
DECREASE IN EACH PARTICIPANTS
FROM 5% IN 2021 TO 3.4% SO THIS
IS AN AREA WE'VE BEEN FOCUSED ON
LOOKING AT WHY ARE WE SEEING A
DECREASE IN PARTICIPANTS.
WE ALSO SEE WHEN WE LOOK AT
BLACK OR AFRICAN AMERICAN
PARTICIPATION THAT STUDY AT
ABOUT 13% AND NATIVE HAWAIIAN OR
OTHER PACIFIC ISLANDER DECREASED
.8% IN 2021 TO 3% IN 2033 AND
WHITE PARTICIPATION INCREASED A
BIT FROM 64% TO 68%.
WE HAD ABOUT 2% IN 2021 AND THAT
INCREASED TO TWO AND A HALF
PERCENT IN 2022 AND WE DID SEE A
BIT OF A DECREASE AND UNKNOWN OR
NOT RECORDED FROM 14% TO 12.2%
SO IT'S HIGH BUT WE'RE SEEING A
DECREASE.
WHEN WE LOOK AT NIH DEFINED
PHASE 3 CLINICAL TRIAL
ENROLLMENT, THEY'VE BEEN FAIRLY
STUDIES AND WE TEND TO SEE MORE
JOBS BECAUSE THERE ARE FEWER
STUDIES AND THEY'RE QUITE LARGE
BUT WE DIDN'T SEE A LOT OF JUMPS
WHEN WE ADJUSTED IN 2022 DATA
AND SO I'LL DECREASE AND
AMERICAN INDIAN OR ALAS ALASKA E
AND ASIAN PARTICIPANTS SO IT'S
2.1% IN 2022.
AND WE ALSO WITH WE LOOK AT
WHITE IT'S 75% TO 76% IN 2022
AND A DECREASE IN IDENTIFIED AS
MORE THAN ONE RACE AND IT'S 4%
IN 2021 TO 1% IF 2022 AND WE SAW
AN INCREASE OF UNKNOWN OR NOT
RECORDED IN THE CLINICAL TRIALS
WHICH IS NOW ABOVE 8.6% IN 2022.
MOVING OR NOT TO ETHNICITY WHEN
WE LOOK AT ENROLLMENT OF
HISPANIC OR LATINO WE SAW AN
INCREASE FROM 10.5% TO 2021 TO
12% IN 2022.
WE LOOK AT PHASE 3 CLINICAL
TRIALS THEY JUMPED AROUND QUITE
A BIT DUE TO ONE LARGE STUDY
WITH HISPANIC OR LATINO
PARTICIPANTS THAT ENDED SO WE
HAD LARGE NUMBER OF HISPANIC
LATINO PARTICIPANTS ALMOST 40%
OF 2021 THAT IS A DECREASE TO
ABOUT 12% WHICH IS MORE TYPICAL
OF WHAT WE'VE SEEN IN TERMS OF
ENROLLMENT OF HISPANIC OR
ENROLLMENT PARTICIPANTS.
WE HAVE SOME DATA ON AGE FOR
THOSE STUDIES THAT FALL UNDER
THE INCLUSION ACROSS THE
LIFESPAN POLICY AND FOR THE
FIRST TIME WE GET A SENSE OF
WHAT OUR PORTFOLIO LOOKS LIKE IN
TIMS OF AGE.
WE CAN SEE WE SAW A DECREASE ON
CHILDREN UNDER THE AGE OF 18
FROM 20% IN 2021 TO 14% IN 2022.
THESE ARE STILL EARLY AND IT'S
ONLY A SNAPSHOT OF DATA SO WE'LL
SEE THESE TRENDS OVER TIME.
WE SAW AN INCREASE IN ADULTS
18-64 AND WE SAW AN INCREASE IN
OLDER ADULT 0 ABOUT 19% TO 21%
IN THIS 2022 AND MUCH IT'S LOW
ABOUT 3% IN 2021 AND TO JUST
UNDER 5% IN 2022.
I WOULD LIKE TO MENTION WE HAVE
A NUMBER OF TRAINING AND
RESOURCES AVAILABLE ON OUR
WEBSITE WHICH I LINKED TO HERE.
WE HAVE PODCASTS ON HOW TO
DEVELOP INCLUSION PLANS WHICH WE
PRODUCED AND WE HAVE OTHER
PODCASTS ABOUT NIH DEFINED
CLINICAL TRIALS AND I HAVE
INVESTIGATOR TRAINING WHICH I DO
EVERY YEAR THAT WE UPDATE FROM
OUR NIH GRANTS WHICH WE MAKE
AVAILABLE ON OUR WEBSITE WHICH
COVERS THESE TOPICS IN MORE
DEPTH AND WE HAVE INVESTIGATORS
CAN USE WHICH INCLUDES RESOURCES
AND TOOLS THAT FOLKS CAN USE AS
WE THINK ABOUT INCLUSION OF
VARIOUS GROUPS AND INCLUDE
INDIVIDUALS IN THE STUDIES.
SO WITH THAT, WE HAVE TIME, I'M
HAPPY TO TURN IT OVER TO ANY
QUESTIONS.
>>THANK YOU, DAWN.
THANK YOU Dr. CORBETT.
I'LL TURN IT TO Dr. CLAYTON TO
MODERATE A Q&A SESSION IF YOU
HAVE ANY QUESTIONS FOR Ms.
CORBETT, OUT ARE CAN UTILIZE THE
CHAT.
FEEL FREE TO COME BACK ON
CAMERA.
THANK YOU.
Dr. SIDEMAN.
>>HI, THIS IS GREAT.
FIRST, I ASKED IF WE CAN PLEASE
HAVE A COPY OR SOMEHOW THE
SLIDES IT WOULD BE VERY HELPFUL
AND I ALWAYS HAVE A QUESTION
THAT I'M SORRY IF YOU OF MAY
HAVE ANSWERED IT OR IT'S BEEN
DISCUSSED BEFORE BUT WHEN WE
TALK ABOUT INCLUSION IN FOR
SECTIONS OF BIOLOGICAL VARIABLE
OR WOMEN AND WE'RE TALKING ABOUT
GENERALLERGENDER AND SEX ARE WEG
ALL-INCLUSIVE?
IS THAT CLEAR IN HOW WE'RE
COUNTING AND INCLUDING WITH
RESPECT TO NIH RESEARCH WHEN
WE'RE TALKING ABOUT SEX AND THEN
GENDER?
HOW ARE WE REALLY
OPERATIONALIZING THAT CAN
COUNTING THAT?
>>I CAN TALK ABOUT THIS FROM
PERSPECTIVE OF INCLUSION POLICY
AND I WELCOME MY COLLEAGUES IN
ORWH.
IN TERMS OF THE INCLUSION POLICY
THE MANDATE THAT WE HAVE BY-LAW
IS THAT WOMEN (INAUDIBLE) AND
NIH FUNDED FROM THE RESEARCH AND
THIS WAS CAME OUT OF CONCERNS
THAT INDIVIDUALS TOUT THEIR
POTENTIAL WERE BEING
SYSTEMATICALLY EXCLUDED FROM
RESEARCH STUDIES, NIH HAVE TAKEN
A FLEXIBLE POSITION THAT EITHER
SEX OR GENDER MAY BE CONSIDERED
FOR THE PURPOSES OF INCLUSION
INCLUDING WOMEN, DEPENDING ON A
SCIENTIFIC QUESTION BEING ASKED
AND WHAT IS MISSED IMPORTANT AND
FOR THAT QUESTION IF YOU REPORT
IT SO IT WAS EITHER SEX OR
GENDER WE ENCOURAGE THEM TO, FOR
EXAMPLE, PROVIDE A POINT IN TIME
OVER TIME BUT WE PROVIDE A GREAT
DEAL OF FLEXIBILITY HOW IT'S
REPORTED AND WE HAVE CONCERNS
FROM THE EXTERNAL COMMUNITY AND
IN TERMS OF IF APPROXIMATE IT'S
CLEAR INDIVIDUALS WHO ARE
TRANSGENDER OR NON BINARY
UNDERSTAND OR ARE INCLUDED IN
THESE NUMBERS AND IT'S SOMETHING
THAT WE'RE UNDER DISCUSSION.
WE WANT TO MAKE SURE THAT PEOPLE
SEE THEMSELVES IN OUR DATA AND
THAT WE INCLUDE ALL THE
INDIVIDUALS THAT NEED TO BE
INCLUDED BUT THE WAY WE
CURRENTLY COLLECT THE DATA IS
REALLY FLEXIBILITY.
>>SO WHEN WE'RE TALKING ABOUT
WOMEN, ANYONE WHO HAD
REPRODUCTIVE CAPACITY OR WILL
HAVE REPRODUCTIVE CAPACITY AT
ANY POINT IN THEIR LIFETIME?
IS THAT KIND OF -- FEMALE
SEXUALITY BIRTH?
>>WE DO NOT HAVE THAT FOR THE
RESEARCH COMMUNITY.
WE ALLOW INVESTIGATORS TO USE
SEX OR GENDER AND ORWH HAS
DEFINITIONS WHICH THEY HAVE ON
THEIR WEBSITE OF THOSE CONTEXT.
WE DO RECOGNIZE THERE ARE
SEVERAL CONTEXT AND WE DON'T
LIMIT THE INCLUSION OF WOMEN
CURRENTLY TO SEX FOR THE
PURPOSES OF I AM CONCLUSION
POLICY.
>>THANK YOU.
>>Janine A. Clayton: SALON
McGREGOR.
>>THANK YOU.
AND IT'S AN EXTENSION OF Dr.
SIMON'S QUESTION.
I WAS LOOKING A LOT THE FIGURES
OF CLINICAL TRIAL ENROLLMENTS
AND YOU USE THE TERMINOLOGY
MALES AND FEMALES.
SO IS THAT AN ASSUMPTION THAT IS
BEING MADE ON NIH'S PART JUST
FOR SIMPLICITY?
AND THEN LIKE WHAT APPROXIMATE
THE NOT REPORTED?
HOW DOES THAT GET THROUGH THE
PROCESS?
>>SO, WHAT WE KEEP IN MIND IS
ALL THE DATA WE COLLECT ARE
(INAUDIBLE).
INVESTIGATORS CAN USE
TERMINOLOGY THAT IS APPROPRIATE
TO THEIR STUDY IN TERMS OF THE
DATA THAT THEY COLLECT.
WE DO USE FOR THE REPORTING, WE
ALSO DO NOT SPECIFY WHETHER THAT
SEX OR GENDER.
IT CAN BE EITHER SEX OR GENDER.
FOR INDIVIDUALS WHO DID NOT
IDENTIFY AS EITHER MALE OR
FEMALE, THEY WOULD BE REPORTED
AND UNKNOWN OR NOT REPORTED.
AGAIN, WE DON'T DEFINE WHAT
INVESTIGATORS TO USE TO COLLECT
DATA FROM PARTICIPANTS, WE ALLOW
EITHER SEX OR GENDER TO BE
REPORTED BUT THE TERMINOLOGY WE
USE DOES INCLUDE THOSE
CATEGORIES OF MALE, FEMALE OR
UNKNOWN AND NOT REPORTED.
>>THANK YOU.
SO YOU'VE HEARD YOU ARE HEARING
FROM AN INCLUSION POLICY
PERSPECTIVE, WHAT'S THE POLICY?
HOW THE POLICIES ORIGINATE AND
THEY ORIGINATED WHEN WOMEN WERE
BEING EXCLUDED SO THERE'S A
POLICY FOR IN CONCLUSION OF
WOMEN AND THAT RACIAL AND ETHNIC
PRIORITY POPULATIONS BUT WE'RE
ALSO NOW TALKING ABOUT EVOLVING
CONCEPTS OF BOTH SEX AND GENDER
AND HOW IMPORTANT THEY ARE
BECAUSE WE KNOW THAT THEY HAVE
AN IMPACT ON HEALTH OUTCOMES AND
CAN BE HIGHLY RELEVANT TO THE
RESEARCH QUESTIONS UNDER STUDIED
SO WE HAVE A POLICIES ASPECT BUT
WE ALSO HAVE A RESEA RESEARCH AT
BECAUSE WE KNOW KNOW MORE ABOUT
THESE CONCEPTS AND SO AS A
RESULT OF THAT, ONE OF THE
REASONS WHY WE HOSTED EARLIER
THIS YEAR THE GENDER AND HEALTH
WORKSHOPS TO START TALKING ABOUT
HOW THE WAYS THAT -- THE MANY
WAYS THAT GENDER CAN EFFECT
HEALTH AND HAVE ALSO EXPANDED
OUR WEB PAGE WITH
CONCEPTUALIZATIONS OF THOSE
CONCEPTS AND SUPPORTING RESEARCH
ON GENDER MEASUREMENT BECAUSE WE
NEED ADDITIONAL TOOLS WITH MORE
RIGOR AND RANGE TO ASCERTAIN
GENDER BECAUSE ALISON, I THINK
YOU ASKED EARLIER, OR I CAN'T
REMEMBER WHO IT WAS, I'M SORRY,
IF APPROXIMATE YOUR COLLECTING
SEX YOU IS SHOULD SAY WHAT YOU
ARE COLLECTING AND HOW YOU
COLLECT IT.
WHATEVER YOU ARE DOING, RIGHT.
THAT'S A METHOD ISSUE RIGHT AND
SO IT IF YOU DON'T, IT'S VERY
CHALLENGING TO BE ABLE TO
UNDERSTAND THE DATA.
IT LOOKS LIKE -- I'M SOON SURE
WHOSE HAND WAS UP NEXT.
WAS IT MELISSA OR JUDY?
>>OKAY.
ALL RIGHT.
>>QUICK COMMENT AND QUESTION
THAT WAS A VERY IMPORTANT
SESSION AND I'M ALWAYS GRATEFUL
TO BE PART OF THE GROUP.
CURRENTLY TO MY UNDERSTANDING
AND IT'S NOT COLLECT DATA ON
GENDER MINORITIES AND FOR
INSTANCE, WITH THE VIRTUAL
THERE'S TRANSGENDER AND WITHOUT
THE DATA THAT WE DO ON OTHER
MINORTIZIED POPULATIONS SUCH AS
BLACK, NATIVE AMERICAN, ET
CETERA, THEN I THINK IT HURTS US
IN KNOWING THE MAGNITUDE OF
ISSUES THAT SHOULD BE ADDRESSED
AND IT'S ALSO A RECOGNITION OF
THE IMPORTANCE OF BEING FOR
PEOPLE WHO ARE A GENDER MINORITY
IN ONE WAY OR ANOTHER.
IS THERE A THOUGHT TO COLLECT
THIS DATA?
>>I THINK WE CERTAINLY
ACKNOWLEDGE THE IMPORTANCE OF
COLLECTION OF DATA ON SEXUAL
GENDER MINORITY POPULATIONS.
THE QUESTIONS IS, THE METHODS
FOR COLLECTING AND REPORTING
THIS DATA AND WHAT IS MOST
USEFUL FOR THE SCIENTIFIC
COMMUNITY AND THE DATA THAT I
SHOWED YOU HERE ARE REALLY TO
DEMONSTRATE COMPLAINTS WITH OUR
POLICIES AND SOEL OUR POLICY ON
I AM CONCLUINCLUSION OF WOMEN AY
GROUPS ARE CURRENTLY FOUND AS A
POLICY ON INCLUSION OF SEXUAL
AND GENDER MINORITY POPULATION
AND SO YOU COME CLEAR IN TERMS
OF WHAT MIGHT BE THE BEST METHOD
OF REPORTING THAT.
I THINK WHAT WE FOUND OVER THE
YEARS THERE'S BEEN SOME
INTERESTING PAPERS AND
COLLECTING THE DATA AT NIH
LEVEL.
IT DOESN'T GET THE DATA INTO
PUBLICATION AS WE WOULD EXPECT
AND WHERE THEY CAN BE UNDERSTAND
OR THEY CAN BE USED IN THE
CONTEXT OF HEALTH OUTCOMES O I
THINK IT'S SOMETHING WE NEED TO
KEEP IN MIND AS WE THINK ABOUT
WHAT KIND OF INFORMATION IS THE
MOST USEFUL AND HOW CAN IT BE
USED IN THE SCIENTIFIC
COMMUNITY.
>>AND I THINK I CAN ALSO ADD
THAT JUDY, YES, WE ARE THINKING
ABOUT THESE ISSUES AS TO WHERE
WE NEED TO GO AND WE ARE
COLLABORATING WITH THE SEXUAL
GENDER MINORITY RESEARCH OFFICE
AND WE HAVE SUPPORTED EFFORTS
INCLUDING FUNDING RESEARCH
AROUND ASCERTAINING AND GENDER
IDENTITY AND OTHER MEASURES AND
WE ARE AWARE OF THE RESENT
NATIONAL ACADEMIES REPORT ON SEX
GENDER IDENTITY AND SEXUAL
ORIENTATION AND THEIR
RECOMMENDATIONS WHICH WE ARE
CONSIDERING INTERNALLY TO BEST
UNDERSTAND WHERE WE CAN GO IT TO
MOVE THIS SCIENCE FORWARD AND
ORWH HAS TAKEN A PROACTIVE
APPROACH AND WE HAVE MADE FUNDS
AVAILABLE TO SUPPORT RESEARCH TO
EXPAND THE RIGOR AND
AVAILABILITY OF VARIOUS TOOLS
AND INSTRUMENTS TO MEASURE
GENDER BECAUSE THERE'S NOT A
SINGLE TOOL THAT IS AGREED UPON
OR SO THAT IS AN IMPORTANT PIECE
OF MOVING THIS FIELD FORWARD IS
GETTING THE TOOLS TO MOVE THE
FIELD FORWARD AND THEN THERE'S
ALSO A DIFFERENCE BETWEEN
COLLECTING DATA ABOUT
INDIVIDUALS MORE PARTICIPATING
IN A RESEARCH STUDY VERSUS
SURVEY OR OTHER TYPES OF DATA
WORKFORCE RELATED DATA.
THESE ARE FOR DIFFERENT PURPOSES
SO WE ALWAYS HAVE TO KEEP IN
MIND WHY WE'RE COLLECTING THE
INFORMATION AND AS DOUG SAID,
IT'S SOMETIMES VERY SURPRISING
THAT EVEN WITH DATA COLLECTED
YOU ARE NOT ABLE TO SEE
INTERPRETATIONS FOR POPULATIONS
AS WOULD EXPECT AND WE'LL
HIGHLIGHT FOR THIS GROUP, I
THINK YOU KNOW THIS VERY WELL,
THAT FOR SEX FEWER THAN
ONE-THIRD OF THE PHASE 3
CLINICAL TRIALS THAT ARE NIH
DEFINED HAVE ANY SEX SPECIFIC
RESULTS EVER PUBLISHED IN
LITERATURE SO WE HAVE ALSO NEED
TO WORK WITH OUR JOURNAL EDITORS
AND PUBLISHING COLLEAGUES ABOUT
THEIR GUIDELINES AND THEIR
MANUSCRIPT GUIDELINES PROMOTING
SEX AND GENDER EQUITY AND
SIDELINES AND BECAUSE THIS IS A
ECOSYSTEM ISSUE NOT JUST APP NIH
INCLUSION POLICY ISSUE.
DOES THAT ANSWER YOUR QUESTION,
JUDY?
>>YEAH.
THANK YOU, DAWN AND JANINE.
Dr. SIMON.
>>THANK YOU.
SO, THE REASON WHY I KEEP ASKING
THIS QUESTIONS JUST TO PIGGYBACK
ON WHAT YOU JUST MENTIONED Dr.
CLAY TOMCLAYTON, I AM NEW FOR WN
THE DEI AND THE WOMEN'S HEALTH
STUFF AND THIS IS THE FOREFRONT
OF MY MIND BECAUSE HOW TO HELP
SHIFT HOW THINGS ARE REPORTED
AND REQUIRED FOR REPORTING AND
THINGS LIKE THAT AND WHAT I
WORRY ABOUT IS WHEN WE JUST TALK
ABOUT SEX AS A BIOLOGICAL
VARIABLE.
I KNOW IT'S THE TAGLINE, SABB,
YOU CHAMPIONED THIS AND IT'S
INGRAINED IN STUDY SECTION AND
REVIEW, ET CETERA.
IT'S SEX IS A BIOLOGICAL
VARIABLE AND GENDER IS A SOCIAL
CONSTRUCT OR SOCIAL CONSTRUCT
IMPACTS BIOLOGY AS WELL AS WE
KNOW.
SO I'M WONDERING IF THERE COULD
BE OPPORTUNITIES TO -- WHY WANT
TO THINK I'M COMMITTING HARASSY
BUT TO CHANGE THE TAGLINE OR
MODIFY THE TAGLINE OF SEX IS A
BIOLOGICAL VARIABLE.
IT'S LIKE OKAY SEX IS A
BIOLOGICAL VARIABLE AND WE'RE
NOT INCLUDING THE WORD GENDER
AND SOCIAL THINGS AND IDENTITY
IS IN GENERAL WE'RE JUST KIND OF
THING THAT YOU CLICK ON THE TAB
WHEN YOU COMPLETE IT NIH REVIEW
NEAR THE END ABOUT INCLUSIONS.
ADEQUATE, RIGHT.
SO THE WAY REVIEW HAPPENS STILL
IS NOT REALLY MINDFUL GRANT
REVIEW AND MANUSCRIPT REVIEW
IT'S NOT STILL MINDFUL OF
INCLUDING THINGS LIKE HOW SEX
AND OTHER EYE DEN FEES GENDER
INCLUDING RACE ETHNICITY AND
OTHER IDENTITIES ACTUALLY PLAY
INTO THE RESEARCH.
SO I'M WONDERING IF THERE'S AN
OPPORTUNITY PERHAPS IN -- JUST
IF YOU THINK ABOUT NIH REVIEW OF
THAT REVIEW FORM THAT WE ALL
HAVE TO FILL OUT, FOR ALMOST ALL
THE REVIEWS, EXCEPT FOR THE
RESENT COMPASS REVIEWS THERE WAS
NOTHING THERE FOR SEX OR GENDER
OR IDENTITIES IS THERE APP
OPPORTUNITY TO THINK THROUGH HOW
THAT COULD BE MODIFIED OR BETTER
INCOMPETENT GREATED INTO GRANT
REVIEW AT NIH?
I HOPE IT MAKES SENSE AND IT'S
LATER HERE AND MY BRAIN MIGHT
NOT BE FULL BECAUSE I'M IN
GRACE.
>>THANK YOU, Dr. SIMON.
DO YOU WANT TO MAKE COMMENTS
ABOUT THAT?
>>I WOULD JUST SAY THAT WE
APPRECIATE THE FEEDBACK AND I
THINK THESE ARE ALL THINGS THAT
NIH IS CAREFULLY CONSIDERING
WITH ALL OF OUR DATA COLLECTION
AND WE'RE WORKING ALSO WITH THE
DEPARTMENT AND MAKING SURE THAT
WE HAVE CONSISTENCY WITH FEDERAL
AGENCIES AS WELL.
>>TO ADD TO THAT, MELISSA, I
COMPLETELY AGREE THAT OF COURSE
BOTH SEX AND GENDER AFFECT
HEALTH.
THE SABB POLICY WAS SEEKING
PRIMARILY, BUT NOT ONLY, TO
ADDRESS NOT SOME OF THE GAPS AND
KNOWLEDGE IN THE PRECLINICAL
SPACE BECAUSE SEX WAS NOT BEING
CONSIDERED AT ALL AND THERE WAS
A OVER LINE ON MALE ANIMALS AND
MALE CELLS HOWEVER IT WAS
CLEARLY STATED IN THE POLICY IT
DOES A PLAY TO HUMAN STUDIES AND
THERE WAS A LINK PROVIDED IN THE
POLICY, THE ORIGINAL POLICY THAT
WEPT TO A LONGER DOCUMENT THAT
INCLUDED DESCRIPTION THAT GENDER
WAS IMPORTANT FOR HUMAN STUDIES
AND A LOT OF PEOPLE THAT DON'T
GOAT THAT SECOND DOCUMENT, BUT I
HEAR YOU AND WE AGREE WITH YOU.
AS AN APPLICANT IS MAKING THE
CASE FOR THEIR RESEARCH QUESTION
UNDER STUDY, WE ARE LOOKING AT
HOW THESE OTHER ASPECTS SHOULD
BE CONSIDERED SO WE'RE LOOKING
TO THE CONTEXT OF THE SCIENCE
UNDER STUDY BUT I HEAR YOU ABOUT
RAISING YOUR CONCERNS ABOUT
ABOUT THE PEER REVIEW PROCESS
AND CONCERNS ABOUT ADDRESSING
BOTH SEX AND GENDER.
>>THIS IS ONE LITTLE BIT I
APPRECIATE THAT.
THAT ONE LAST THING IS BECAUSE
IN STUDY SECTION AND REVIEW IT'S
CLEAR AMONGST REVIEWERS FOR MY
SCIENTIFIC EXPERIENCE IT'S MORE
BEING COUNTING WILL INCLUSIONS
THAN ABOUT INCORPORATEING AND
BEING THOUGHTFUL ABOUT THE
SCIENCE AND HOW THIS RESEARCH
PROJECT ACTUALLY -- HOW
DIFFERENT IDENTITIES PLAY OUT
WITH THE PHENOTYPES OF THE END
POINTS IN THESE PARTICULAR
RESEARCH STUDIES.
THAT'S WHAT I'M TRYING TO
EXPRESS.
MORE COUNTING THAN INTEGRATION
INTO THE SCIENCE AND IF THERE'S
A WAY TO DO THAT AT THE CSR OR
AT THAT LEVEL OF THE NIH REVIEW
FORM, OR REVIEWERS THAT WOULD BE
HIGHLY IMPACTFUL.
>>THANK YOU, Dr. SIMON.
ABSOLUTELY FROM MY PERSPECTIVE
IT'S CRITICAL TO THE SCIENCE
BEING CONDUCTED AND SO IT SHOULD
BE INCORPORATED FOR INTO THE
ASSESSMENT OF A RIGOR AND
SUITABILITY OF THE SCIENCE AND I
HEAR THE IMPACT AND I APPRECIATE
THE INPUT.
WE CAN ALSO DO, Dr. NOURSI
WILDNURSEUNTIL 12:30.
WE CAN GIVE YOU AN OPPORTUNITY
TO MAKE MY BRIEF CLOSING REMARKS
AND WE CAN USE THAT 15 MINUTES
FOR QUESTIONS FROM THE EARLIER
REPRESENTATIONS.
SO DAWN, WOULD YOU LIKE TO GO
AHEAD AND GIVE CLOSING REMARKS.
>>SURE.
THANK YOU.
SO MUCH SO I REALLY APPRECIATE
YOUR ATTENTION AND ALL OF THE
FEEDBACK THAT YOU'VE GIVEN US.
I WILL SAY THAT WE ARE REALLY
WORKING TO MAKE SURE THAT
INCLUSION MEANINGFULLY
CONSIDERED, MY OFFICE HAS BEEN
DOING QUITE A LOT TO TRY TO MAKE
SURE THAT PEOPLE KNOW HOW TO
DEVELOP INCLUSION PLANS.
WHAT NEEDS TO BE IN THIS.
SO THEY ARE THOUGHTFUL AND THEY
GO BEYOND BEING COUNTING BUT
THEY ADDRESS MANY OF THE ISSUES
THAT YOU'VE MENTIONED ON HERE
TODAY'S AND SO WE CONTINUE TO
WORK ON THIS AND I APPRECIATE
YOUR IDEAS THAT YOU'VE BROUGHT
TO US.
I HAVE TO MAKE THE SLIDES
AVAILABLE TO YOU ALL AND THANK
YOU SO MUCH FOR ALL OF YOUR
FEEDBACK.
>>Samia Noursi: THANK YOU SO
MUCH.
>>Janine A. Clayton: I WANT TO
MENTION THAT DAWN DOES AN
OUTSTANDING JOB AS A INCLUSION
OFFICER AND SUPPORTS US AT ANY
WAYS AT THE NIH INCLUSION
GOVERNANCE COMMITTEE AND Dr.
NOURSI IS THE SUPERVISOR AND
PLAYS A CRITICAL ROLE IN ALL THE
SCIENCE POLICY ACTIVITIES AS
ASSOCIATE DIRECTOR FOR SCIENCE
AND POLICIES AND SO I WANT TO
THANK THEM ALL FOR THEIR SUPPORT
FOR HAVING THE GREAT DATA.
THANK YOU, DAWN FOR AN AMAZING
PRESENTATION.
MORE DATA THAN WE'VE HAD BEFORE
AND WE APPRECIATE THAT.
WITH THAT, I THINK WE CAN TAKE A
LITTLE BIT OF TIME, IF THERE ARE
QUESTIONS OR COMMENTS OR
FEEDBACK WE ALWAYS LIKE TO KNOW
FROM OUR ADVISORY COMMITTEE
MEMBERS YOUR THOUGHTS AND GET
YOUR FEEDBACK ON ORWH EFFORTS
AND IDEAS AND I SAW A HAPPENED.
>>THANK YOU Dr. CLAY TOP.
CLAYTON.YOU SHOWEDS VERY EXCITIA
REALLY HAPPY TO SEE ALL OF THAT.
THE DATA ON THE MORTALITY IN THE
RISE THAT YOU SHOWED IN THE
BEGINNING OF YOUR TALK ARE
REALLY CONCERNING.
WHAT I WANT TODAY ASK YOU, I
THINK A LOT OF THE RECENT
INCREASE WE SAW IS ATTRIBUTE
TODAY COVID-19.
HAVE YOU SEEN ANY RELIABLE DATA
FROM OTHER COUNTRY TO SEE WHAT
THE EVENT OF COVID-19 ON O
VARIOUS INCIDENTS OF MATERNAL
MORTALITY MIGHT HAVE BEEN LOWER
THAN OURS BUT WAS THERE A 30 TO
35% INCREASE IN WHAT WE SAW
HERE?
>>Janine A. Clayton: IT'S A
GREAT QUESTION.
>>I WOULD HAVE TO PULL THAT TO
TAKE A LOOK AT IT ONE OF THE
THINGS AND IN PARTICULAR, AS YOU
ARE AWARE.
RATES OF COVID-19 WERE
PARTICULARLY HIGH IN SOME
HISPANIC POPULATIONS AND IN
INDIVIDUALS IN WOMEN IN
PARTICULAR.
AND SO, I'M WONDERING WHETHER
IT'S A PIECE OF THAT HISPANIC
INCREASE THOSE NUMBERS OR IS
THIS JUST EXACERBATING PREGNANCY
ASSOCIATED COSTS LIKE SUICIDE
AND HOMICIDE.
I THINK WE NEED -- IT TELLS ME
WE NEED TO LOOK AT THIS IN A
HOLISTIC WAY AND ACCOUNT FOR
MORE EVERYTHING THAT A PERSON IS
EXPERIENCING DURING A PREGNANCY
AND AFTER AND BEFORE THE
PREGNANCY FOR THAT MATTER.
BUT I DON'T HAVE A DATA POINT TO
GIVE YOU ON THAT.
I APPRECIATE YOUR INSIGHTS THAT
LOOKING AT THAT MIGHT GIVE US
SOME MORE CLOSE WHERE WE FOCUS
ON IN THE UNITED STATES AND WHAT
WAS NOTABLE HOWEVER, WAS THE
REDUCTION IN THE MATERNAL
MORTALITY SEEN IN EASTERN YOU'RE
NOT.
AT FIRST PART ON THE LEFT, I HAD
TO ABOUT BACK TO THE DATA AND
SAY IS THIS CORRECT.
WAIT.
AND I WENT BACK TO THE DATA AND
IT'S ABSOLUTELY CORRECT BECAUSE
THIS IS AN AREA THAT'S BEEN
RECOGNIZED BY THE ADMINISTRATION
ASS.
>>THANK YOU, AGAIN.
I FEEL SO FORTUNATE TO BE PART
OF THIS GROUP AND PROVIDE INPUT
AND THIS DOES TALK ABOUT
SOMETHING THAT YOU SPOKE OF
Dr. CLAYTON WAS THE NEW OFFICE
FOR AUTOIMMUNE DISEASE RESEARCH
AND AS YOU WERE DESCRIBING THAT
I THOUGHT, THAT IS INCREDIBLE
BECAUSE THAT'S A HUGE AREA THAT
WE KNOW VERY LITTLE ABOUT.
IT AFFECTS WOMEN IN PARTICULAR.
IT STARTED MAKING ME THINK ABO
ABOUT, WE SILO A LOT OF THESE
CONDITIONS THAT IMPACT WOMEN AND
MORE SO THAN MEN AND WITHOUT
HAVING SORT OF THE COLLECTIONS
THAT THE INTEGRATION COMES.
MORE WOMEN UTILIZE THE EMERGENCY
DEPARTMENT AND IT WAS JUST PART
OF A STUDY WE PUBLISHED WHEN WE
LOOKED AT THE TIMING THAT A
PATIENT GOES THROUGH FROM START
TO FINISH AND WOMEN WAIT LONGER
AND IT'S LONGER TO BE DIAGNOSED
AND TO HAVE THE TEST ORDERS AND
THROUGHOUT THE WHOLE PROCESS AND
SO, I'M WONDERING IF IF THE
OFFICE COULD LOOK AT ACUTE CARE
PRESENTATIONS OR AN INCOMPETENT
GREATED PROCESS WHERE WE CAN
IDENTIFY THESE CONDITIONS FOR
WOMEN AND AT THE BREAK OF WHEN
THEY ARE MOST VULNERABLE MANY
OF.
>>YOU ARE ABSOLUTELY RIGHT THE
FRAGMENTATION OF CARE IS
IMPORTANT FOR WOMEN'S HEALTH AND
IT'S CLEAR ABOUT THE DELAY OF
DIAGNOSIS AND TYPE OF TREATMENT
AND THIS WELL DOCUMENTED THAT
THERE ARE DIFFERENCES AND
HEALTHCARE DELIVERY.
SO, THOSE ARE KINDS OF STUDIES
THAT ARE ALSO IMPORTANT FOR US
TO BE ABLE TO SUPPORT AUTOIMMUNE
DISEASES.
THEY'RE A SET OF DISEASES THAT
ARE VERY IMPORTANT FOR WOMEN'S
HEALTH AND THERE ARE OTHER
DISEASES THAT ARE ALSO IMPORTANT
FOR WOMEN'S HEALTH AND WE TAKE A
HEAD-TO-TOE APPROACH.
EVERYTHING THAT AFFECTS A WOMAN
HEAD-TO-TOE SO WE NEED TO WORK
MORE CLOSELY WITH THE INSTITUTES
AND CENTERS TO BE ABLE TO BRING
THEIR RESOURCES TO BEAR ON THESE
PROBLEMS BUT FOR ACUTE CARE AND
EMERGENCY MEDICINE, I'M TRYING
TO THINK OF WHICH INSTITUTES IT
FALLS UNDER AND ALISON I'M
HAVING TROUBLE BECAUSE THERE'S
AN OFFICE OF EMERGE EMERGENCY -A
AND EMERGENCY WHICH I THOUGHT
WAS IN THE NIGMS AND YOU KNOWING
I'M NOT SURE WHERE THAT IS AND
SO THAT MEANS YOU HAVE GIVEN ME
SOMETHING TO TAKE BACK TO MY
COLLEAGUES HERE TO FIND WHO
WOULD BE THE FOLKS THAT WE
SHOULD TALK TO ABOUT BRINGING A
SEX AND GENDER PERSPECTIVE AND A
WOMEN'S HEALTH PERSPECTIVE TO
THAT WORK, DID I INTERPRET THAT
CORRECTLY?
BRINGING THAT PERSPECTIVE TO THE
WORK IS THERE AN OPPORTUNITY TO
BRING THAT PERSPECTIVE TO THAT
WORK FROM A RESEARCH VANTAGE
POINT.
>>EXACTLY.
>>I WILL WORK ON THAT.
I DON'T HAVE AN ANSWER FOR YOU
RIGHT NOW AND WE WILL GET BACK
TO YOU.
Dr. JONES.
>>THANK YOU FOR A REALLY
EXCITING PRESENTATION THIS
MORNING AND IT'S ALWAYS PACKED
WITH SO MUCH INFORMATION AND I
WANT TO GO BACK TO THE MATERNAL
MORTALITY DATA AT THE END AND
LOOKING AT THE COVID-19 PANDEMIC
AND WONDERING HOW MUCH OF THAT
DATA IS SORT OF MOVED ALSO IS
RELATED TO OPIOID OR OTHER DRUG
OVERDOSE AS WELL AS SUICIDES AND
ALSO LOOKED AT ITEL THROUGH A
LENS OF GENDER AND ETHNICITY.
-- RACE AND ETHNICITY.
>>Janine A. Clayton: THAT IS
CDC DATA AND IT'S TOM A AND
CLERK AND I HAVE NOT EXAMINED
THAT DATA IN THAT WAY.
I WILL PUT THE LINK IN THE CHAT
IN A FEW MINUTES O TH SO THAT YN
LOOK AT THAT DATA.
YOUR POINT ABOUT SUBSTANCE USE
AND OVERDOSE REALLY VERY WELL
TAKEN AND WE ARE KEENLY AWARE OF
THE VERY DISTURBING RATES FOR
PREGNANT AND POSTPARTUM PEOPLE
AND IT'S A CRITICAL ASPECT OF
MATERNAL HEALTH AND WE NEED TO
MAKE SURE WE INCORPORATE IN FACT
THOSE ISSUES WERE PART MENTAL
HEALTH IN HEALTH WAS PRIORITIZED
IN THE SECOND YEAR OF
IMPROVEMENT INITIATIVE AND MOST
SALIENT GOING FORWARD AS
COVID-19 AND THE CONSEQUENCES,
HEALTH CONSEQUENCES OF RACIAL
DISCRIMINATION.
I DON'T HAVE THAT DATA TOP OF
MIND BUT I'M GOING TO SHARE THE
LINK TO THE CDC DATA AND THE
PAPER IN THE CHAT FOR THE GROUP.
>>THANK YOU.
>>THANK YOU FOR THOSE
QUESTIONS.
Dr. TEMPLETON.
>>GREAT WORK AND AMAZING
PRESENTATIONS TODAY.
THE QUESTION I HAD WAS EARLIER
TALKING ABOUT THE VIOLENCE
AGAINST WOMEN RESEARCH.
IS THERE GOING TO BE EMPHASIS OR
CARVE OUT REGARDING VIOLENCE
AGAINST WOMEN IN STEM?
BECAUSE AS WE KNOW I THINK ONE
IT'S AN ISSUE THAT KEEPS WOMEN
OUT OF STEM BECAUSE IT IMPACTS
THE CULTURE THAT WOMEN DON'T
WANT TO ENTER.
WOMEN PHYSICIANS IN PARTICULAR I
THINK IT'S SOMETHING THAT ISN'T
RECORDED BECAUSE WE'RE
EMBARRASSED WHILE SERVICE IS
SUPPORT FOR WOMEN IN STEM IN
GENERAL AND NEGATIVE CAREER
AGENTS IF YOU DO REPORT IT BUT
MAYBE IF THERE'S FOCUSED OR
TARGETED RESEARCH ON THAT THAT
MIGHT HELP REDUCE SOME OF THE
STIGMA THAT MAY BE GET PEOPLE
TALKING ABOUT THIS AND FIGURING
OUT HOW WE ADDRESS VIOLENCE
AGAIN WOMEN AND ALL AREAS OF
STEM.
>>THANK YOU FOR THAT COMMENT.
THE DATA ON HARASSMENT AND
SEXUAL HARASSMENT OF WOMEN AND
STEM IS VERY DISTURBING AND IT
IT DIDN'T SHOW THE DATA TODAY
AND I'VE SHOWN IT BEFORE THAT WE
SEE VERY HIGH RATES AND LIFE
SCIENCES DEGREE GRANTING
ORGANIZATIONS AND IN STEM IN
GENERAL MEDICAL STUDENTS HAVE A
MUCH HIGHER RATE THAN IN OTHER
GRADUATE PROGRAMS AND THAT ARE
ARE NOT STEM CREE LATED SO IT IT
IS AN AREA OF SIGNIFICANT
CONCERNS.
YOU MAY RECALL THE NIH DIRECTOR
HAD AN ADVISORY COMMITTEE TO THE
DIRECTOR WORKING GROUP FOCUSED
ON ADDRESSING THE CU CULTURE TOD
SEXUAL HARASSMENT AND I WAS PART
OF THE WORKING GROUP AND ONE OF
THE RECOMMENDATION 0 THAT
WORKING GROUP, ALL OF WHICH WERE
ACCEPTED BY THE NIH DIRECTOR
FRANCIS COLLINS AND HAVE BEEN
PUT INTO PRACTICE SOME OF WHICH
HAVE BEEN PUT INTO PRACTICE
GOING FORWARD ONE OF THEM LOST
FUND RESEARCH ON INTERVENTIONS
AND RELATED TO SEXUAL HARASSMENT
INCORPORATING GENDER HARASSMENT
AND SO SEXUAL APPROPRIATE GENDER
HARASSMENT IN STEM AND NIGMS HAS
A FUNDING OPPORTUNITY
ANNOUNCEMENT ON INTERVENTION TO
ADDRESS SCIENTIFIC WORKFORCE
ISSUES AND THEY ISSUED A NOTICE
OF SPECIAL INTEREST TO THAT
FUNDING OPPORTUNITY SPECIFICALLY
FOCUSED ON RESEARCH TO ADDRESS
SEXUAL HARASSMENT AND I AM
PLEASED TO SHARE WITH YOU THAT
THERE WERE TWO APPLICATIONS THAT
WERE FUNDED LAST YEAR ON FOR
THAT PURPOSE AND WE WILL ALSO
PROVIDE THE LINK TO THAT FUNDING
OPPORTUNITY IN THE CHATEAU THATU
CAN GET THE WORD OUT IN THE
OPPORTUNITIES AND IN THE FOCUS
QUARTERLY WE FEATURE THESE TWO
INVESTIGATORS WHO RECEIVED THOSE
GRANTS.
Dr. STOCKDALE AND SALAS SO YOU
CAN LEARN ABOUT THEM AND THEIR
RESEARCH IN OUR IN FOCUS BECAUSE
WE SPOT HEIGHTED THEM TO TELL
MORE ABOUT THE RESEARCH THAT
THEY'RE DOING TO TEST
INTERVENTION THAT'S COULD BE
DEPLOYED ELSEWHERE SO THAT WE
CAN RAMP THEM UP.
AND SO, Dr. TEMPLETON WHAT IS
HELPFUL TO GET THE WORT OUT
ABOUT THE RESEARCH BECAUSE IF IT
WAS KNOWN THERE WAS RESEARCH ON
GOING OR INTERVENTION THAT'S
HAVE BEEN SHOWN TO BE EFFECTIVE
IN THIS REGARD IT COULD EFFECT
THE CULTURE TO SUPPORT PROGRESS.
WE WILL PROVIDE THAT INFORMATION
TO YOU ALSO.
>>THA THANK YOU SO MUCH.
> WE'LL TAKE
THE LAST QUESTION BEFORE THE
BREAK.
>>THANK YOU THIS IS A QUICK
QUESTION COMMENT AND IT WAS
ABOUT THE AUTOIMMUNE DISEASE
RESEARCH WHICH IS VERY EXCITING
AND I'M A DENTIST AND MANY TIMES
PEOPLE DON'T THINK ABOUT THE
IMPACT ON ORAL HEALTHCARE AND I
WAS REALLY GLAD TO SEE THAT
NIAMS HAS SHA ROGEN CLINICAL
TRIAL GOING ON RIGHT NOW AND
REALLY LARGE TRIAL SO THAT'S
GOING TO BE FOCUSING ON DRY
MOUTH FOR DEPARTME DEPARTMENT DD
THE IMPACT ON THE ORAL CAVITY
NOT JUST OF THE DISEASE ITSELF
BUT THE THERAPEUTICS OF THE
DISEASE BECAUSE SOMETIMES THEY
FORGET ABOUT THAT.
>>THANK YOU, VERY MUCH.
YOU KNOW, NIAMS AND NICDS ALSO
HAS A ROBUST PORTFOLIO AND
SHOWGRIN SYNDROME AND WE'VE
FUNDED THAT RESEARCH AND
SUPPORTED THAT.
THANK YOU VERY MUCH.
ORAL HEALTH IS VERY MUCH A PIECE
OF OVER ALL HEALTH JUST LIKE
MENTAL HEALTH AND I THOUGHT YOU
WOULD BE EXCITE TODAY SEE THAT
WE DEDICATED A THEMED ISSUE TO
WOMEN'S HORAL HEALTH AND FOR OUR
IN FOCUS SQUARELY QUARTERLY SO
THANK YOU FOR RAISING THAT ISSUE
THAT IT'S NOT JUST ABOUT DISEASE
MANIFESTATION BUT ALSO
COMPLICATION AND ADVERSE
EFFECTED TREATMENT CAN HAVE
ORGAN SPECIFIC IMPACTS THAT WE
SHOULD CONSIDER AS WELL.
Dr. NOURSI OVER TO YOU.
>>THANK YOU Dr. CLAYTON.
WE WILL BREAK IN A FEW MINUTES
BEFORE WE BREAK, I'D LIKE TO ASK
THE MEMBERS OF THE COMMITTEE TO
TURN ON THEIR CAMERAS.
WELCOME BACK.
I HOPE YOU ALL ENJOYED YOUR
QUICK BREAK AND THE SLIDE SHOW.
I'D LIKE TO CALL THE MEETING TO
ORDER AND HAND IT OFF TO Dr.
LISA BEGG A SENIOR RESEARCH
PROGRAM OFFICER AT ORWH WHO WILL
BE MODERATING OUR AUTOIMMUNE
RESEARCH SPOTLIGHT IN THE NEXT
HOUR.
LISA --
>>THANK YOU Dr. NOURSI AND
GOOD AFTERNOON TO EVERYONE.
I'M HAPPY TO MODERATE THIS
SESSION AND PLEASED TO INTRODUCE
Dr. KAPLAN AND ANDREW MAMME IN
FROM THE NATIONAL ARTHRITIS AND
SKIN DISORDERS AND BETTER NOPE
AS NIAMS.
I WILL INTRODUCE BOTH SPEAKERS
AT THE SAME TIME AND Dr. CAP
KAPLAN WILL LEAD OFF.
Dr. KAPLAN IS THE CHIEFEST
BRANCH AND DEPUTY SCIENTIFIC
DIRECTOR FOR THE INTRAMURAL
PROGRAM AT NIMES.
HER RESEARCH IS IDENTIFYING
MECHANISMS OF THE IMMUNE
DISREGULATION, ORGAN DAMAGE, AND
PREMATURE VASCULAR DISEASE, MORE
SPECIFICALLY, SHE INVESTIGATES
HOW INNATE IMMUNITY AND INTRA
FUR OWNS IN THE CELLS PROMOTE
AUTOIMMUNE RESPONSES AND ORGAN
DAMAGE AND SYSTEMIC LUPUS AND
ARTHRITIS AND OTHER SYSTEMIC
OUGHTN'T IMMUNE DISEASE AND IN
ADDITION TO HER RESEARCH
INTEREST, SHE'S ALSO AN ACTIVE
CLINICIAN AND TEACHER.
SHE SEES PATIENTS AT THE NIH
CLINICAL RESEARCH CENTER AND IS
INVOLVED IN THE DEVELOPMENT OF
VARIOUS CLINICAL TIMES FOR
PATIENTS WITH AUTO 'EM UNION
DISEASES ACROSS THE NIH.
OUR SECOND SPEAKER Dr. ANDREW
MAMMEN A SENIOR INVESTIGATOR AND
LEADS THE MUSCLE DISEASE UNIT AT
NIAMS AND HAD A DEGREE IN PH.D
WHERE HE COMPLETED HIS MEDICAL
INTERNSHIP AND NEUROLOGY
RESIDENCY AND NEURO MUSCULAR.
HE CO FOUNDED THE JOHNS HOPKINS
CENTER WHERE HE AND HIS
COLLEAGUES HAVE DISCOVERED A
FORM OF THE AUTOIMMUNE MY ON A
THEE AND THE CO A REDUCT THE
PHARMACOLOGICAL TARGET OF
STATUS.
Dr. MAMMEN MOVED TO NIH IN
2014 WHERE HE 1 HIS HIGH SCHOOL
ARE FOCUSED ON DEFINING
PATHOLOGICAL MECHANISM AND
THERAPEUTIC TARGETS AND VARIOUS
FORMS OF AUTOIMMUNE MIAWPUKEK.
WE'LL BEGIN THE FIRST
REPRESENTATION.
I'M A RHUMATOLOGIST SO I STUDY
AND TREAT ARE PR PREVALENT IN
WOMEN.
I WOULD LIKE TO TELL YOU HOW SEX
DIFFERENCES MAY IMPACT THE ORGAM
EIGHT IMMUNE SYSTEM AND HOW WE
THINK THIS COULD HAVE A ROLE IN
THE DEVELOPMENT AND OF CERTAIN
AUTO 'EM UNION DISEASES.
I DON'T THINK I HAVE CONTROL
OVER THE SLIDES.
SO THIS IS JUST A LIST OF SOME
OF THE SYSTEMIC AUTOIMMUNE
DISEASES THAT WE DIAGNOSE AND
TREAT AS RUMTOLOGISTS THATTER
HERRER OWE GENEROUS AND HARD TO
DIAGNOSE AND TREAT HOWEVER,
WHILE COMPLEX AND OUTAOUAIS
THERE ARE COMMONALITIES.
AND THIS CAN BE SEEN EARLY ON IN
THEIR LIFE PERHAPS FROM THE
MOMENT OF BIRTH AND THROUGH A
VARIETY OF POORLY UNDERSTOOD
ENVIRONMENTAL FACTORS AND SOONAL
EVENTS AND INDIVIDUAL TRANSITION
FROM A PHASE TO A PHASE OF SUB
CLINICAL ABNORMALITIES IN THE
IMMUNE SYSTEM AND AT SOME POINT
THERE'S A BREAKING TOLERANCE
WHERE VICTIMS WITH POSITION TO
REDEVELOP THE SYSTEMIC OR IMMUNE
DISEASES WILL HAVE INTENTION OF
OR ALAN TEE BODIES IN THEIR
BLOOD THAT TARGET ANTIGENS AND
THESE CAN HAPPEN MANY YEARS
BEFORE THE DISEASE DEVELOPED BUT
WE'LL HAVE A SIGNIFICANT HAVE
THA INDIVIDUAL FROMEMISS
REMISSION BECAUSE OF THE ENGLISH
POSE POSE YOU'RE OF STRESS AND
NOW THESE PATIENTS SLEEP LONGER
BECAUSE WE GOT BETTER TREATMENTS
WE'RE SEEING MORE AND MORE THE
CHRONIC COMPLICATIONS THAT MAKE
MORTALITY CARDIOVASCULAR DISEASE
AND FIBRO SIS AND CANCER, ET
CETERA.
SOMETHING THAT IS DRAMATIC IS
THE PREVALENCE OF SYSTEM I CAN
IMMUNITY IS HIGHER IN WOMEN THAN
MEN AND THIS IS MORE STRIKING
FOR CERTAIN AUTOIMMUNITY
THINKING APPROXIMATE THE
SYSTEMIC IS LUPUS IS A RACIAL
FOR EVERY MAN WITH LUPUS ARE 10
WOMEN WITH LUPUS BUT YOU CAN SEE
FROM THIS SLIDE A NUMBER OF
AUTOIMMUNE BOTH ORGAN SYSTEM I
CAN AND SYSTEMIC ARE MORE PR
PREVALENT IN WOMEN.
THERE'S A KNOWN FACTOR.
THERE'S BEEN A LOT OF RESEARCH
ON THE REASONS FOR THESE WHICH
ARE COMPLEX AND IT'S BETWEEN
GENETIC FACTORS AND PRESENCE TO
X CHROMOSOMES AND HORMONAL
FACTORS THAT HAVE BEEN CITED FOR
MANY YEARS THAT ARE UNCLEAR AND
THEN WHAT MAY HAPPEN DURING
PREGNANCY A FACTOR SUCH AS
ANTIGENS, AND ET CETERA.
NEXT SLIDE.
THEY ARE DESCRIBING WHERE ONE
HAPPENED WOMEN ARE BETTER AT
FIGHTING INFECTIONS BUT MORE
PRONE TO DEVELOP AUTOIMMUNITY
AND THE OPPOSITE IS SEEN IN MEN
AND BOTH INNATE AND ADAPTIVE
HAVE BEEN FOUND TO BE DIFFERENT
IN WOMEN VERSUS MEN AND SO
BETTER THAN OTHERS AND BETTER
UNDERSTOOD THAN OTHERS BUT THE
SPOKE ROLE THAT IS DIFFERENT
THAT THE DIFFERENCE IS PLAYED IN
THE POSITION TO INFECTIONS AND
AUTOIMMUNE IS ALSO NOT
COMPLETELY CLEAR.
SO, THE AUTOIMMUNE DISEASE AND
THE ONE MY LAB HAS BEEN
INTERESTING IN STUDYING FOR A
NUMBER OF DECADES IS SLE.
THIS IS AS I MENTIONED AFFECTS
WOMEN OF CHILD BEARING AGE OR
ANY AGE GROUPS IN MEN AND WOMEN
AND IT'S I A CLINICAL COMPANY WE
THINK IS A SYNDROME RATHER THAN
DISEASE.
THERE ARE IN FACT FORCE SEEN IN
THIS DISEASE BECAUSE IT WILL
HELP BETTER UNDERSTAND THE REST
OF MY TALK.
ONE IS THAT THE PRESENCE OF ORAL
AUTOIMMUNE THAT FOCUS DNA AND
RNA AND PROTEINS THAT LOOK LIKE
SUCH SYSTEMS AND IF WE DON'T SEE
THESE AUTO ANTIBODIES WE REALLY
DOUBT THAT THE DISEASE IS
PRESENT AND THE OTHER IS THAT
THIS REVELATION IN THE PATHWAY,
THE FORMATION OF THIS
INCOMPETENT TRA NEURONS FIGHT
ININFECTIONS AND PLAYING ROLES
IN OUR IMMUNITY IT'S A SURE
FEATURE IN MANY PATIENTS WITH
LUPUS AND THEY MAKE MORE
INTERFERENCE AND THEY MAKE MORE
INTRA NEURONS OR THEY RESPOND
MORE AND THE LASTLY, IS THAT
PREMATURE CARDIOVASCULAR DISEASE
IS A VERY IMPORTANT CAUSE OF
MORBIDITY AND MORTALITY IN LUPUS
AND WE THINK THIS IS I VERY
IMPORTANT IN MORALITY AND IT'S
PROVEN BY THE IMMUNE
DISREGULATION OF LUPUS MORE THAN
BY WHAT WE TYPICALLY THINK WHEN
WE THINK ABOUT HAVING RISK
FACTORS FOR HEART ATTACK SUCH AS
SMOKING, DIABETES, ET CETERA.
SIMILAR TO AUTOIMMUNE DISEASE IN
GENERAL THERE'S BEEN A LOT OF
SPECULATION WHY MORE WOMEN GET
MORE LUPUS THAN MEN AND AGAIN
THIS IS COMPLEX AND OUR GENETIC
MECHANISMS HAVE BEEN PROPOSED IN
ADDITION HORMONAL EXPOSURE AND
THE ROLE OF OTHER FACTORS SUCH
AS DIFFERENCES IN MICROBIOME
BETWEEN WOMEN AND MEN THAT COULD
BE PLAYING A ROLE IN THE
PREDISPOSITION TO LUPUS.
A KEY QUESTION FOR AUTOIMMUNE IS
HOW COME THESE PATIENTS MAKE
ANTIBODIES AGAINST SUCH EXPRESS
MOLECULES SUCH AS THEIR OWN DNA
AND RNA AND WHAT HAPPENS AND HOW
DO DO THESE EXPRESS ANTIGENS
BECOME IMMUNOGENS THAT CAN
TRIGGER AND MAINTAIN STRONG
AUTOIMMUNE RESPONSES AND SO FOR
MANY YEARS, THE THOUGHT WAS THAT
THERE WERE A NORMALITIES IN THE
WAY CELLS DIE AND MAYBE DRIVING
THE AGAIN RACE OF MODIFY ORAL
AUTO AGAIN AND THEY EXPEL THESE
AUTO ANTIGEN AND THEY THINK IT
WAS CALLED A POP TOY SIS AND
THERE ARE MANY WAYS WHICH CELLS
DIE AND THESE MAY BE IMPORTANTS
WE'VE BEEN INTERESTING IN
UNDERSTANDING HOW KNEW TREE FILL
LIVE AND DIE BECAUSE NEUTROPHILS
MAY BE RELEVANT BECAUSE THE THE
MOST AB A BUNT ANT WHITE CELLS.
SO THE NORMALITY IN THE
MECHANISMS OF NEWT ROW FILLS IT
COULD HAVE IMPORTANT
IMPLICATIONS IN HOW THEY AGAIN
RATE AND THE OR ALAN TEE BODIES
GET FORMED AND WAYS WHICH CELLS
CAUSE TISSUE DAMAGE AND I JUST
WANT TO EMPHASIZE THE STUDY OF
NEUTROPHILS HAS LEFT HYPED
COMPARE TO WHAT WE KNOW ABOUT
OTHER IMMUNO CELL TYPES BECAUSE
THEY'RE DIFFICULT TO STUDY.
THEY TIE OFTEN AND THEY'RE
SENSITIVE TO MANIPULATIONS BUT
THROUGH TECHNOLOGICAL ADVANCES
WE KNOW THAT NEUTROPHILS ARE NOT
JUST CELLS THEY GO TO THE
INFECTION AND KILL MICROBES AND
DIE AND THEY PLAY A CENTRAL ROLE
IN SHAPING THE LANDSCAPE IN
HEALTH AND DISEASE AND IN THAT
CONTEXT, MY LAB HAS A
PARTICULARLY INTERESTING
UNDERSTANDING HOW MECHANISMS
NEUTROPHILS MAY BE PLAYING IN A
ROLE IN OUR AUTISM UNITY.
WE KNOW THE FUNCTI FUNCTIONS MAE
HAVING THE KNEW TREE FILL IN THE
MORNING WILL BE DIFFERENT THAN
AT NIGHT AND HOW THEY BEHAVE AND
THE LIFE CYCLE OF HOW IT CHANGES
OVER THE LIFE CYCLE OF BEING A
MAN OR WOMEN.
IT'S BEEN UNDERSTANDING A
CERTAIN TYPE OF NEUTROPHIL
CALLED THE FORMATION OF
NEUTROPHIL NETS OR TRAPS.
IT'S A DRAMATIC PROCESS WHERE IT
EX USED ITS NUCLEAR MATERIAL
BOUND TO A PROTEINS PRESENT
INSIDE THE NEUTROPHIL IN THIS
MESH YOU SEE HERE, THAT CALLED
TERMED TRAPS OR NETS.
WHAT IS IMPORTANT WHEN THESE
NETS FORM, NOT ONLY DO 24th DO O
THE MICROBES BUT THEY EXPOS A
VARIETY OF PHOTO ANTIGENS THAT
ARE NOT TARGETS OF THE SYSTEM
AND ESSENTIALS.
SO THIS TRIGGER THE FORMATION
THESE NETS AND IT'S HAVING THE
ABILITY TO INDUCE NETS AND WE
KNOW THAT THIS PROCESS BECOMES
DIS-REGULATED IN AUTO MANY UNITY
SO PATIENTS WHERE IMMUNE
DISEASES MAKE MORE NETS EVEN IN
THE ABSENCE OF AN INFECTION AND
THEY'RE GETTING RID OF THESE
NETS IN MANY PATIENTS WITH
AUTOIMMUNE DISEASES SO AT ENDS
OF THE DAY.
YOU HAVE THESE NETS NOT
CIRCULATING OR BEING DEPOSITED
IN TISSUE EXPOSING ALL OF THESE
AUTOANTIGEN THAT MAY EXPOS THE
IMMUNE SYSTEM THAT HAS PRONE TO
REACT TO THESE IN THE SHAPE AND
PERPETUATE OUR IMMUNITY.
NEXT SLIDE.
WE'RE NOT GOING TO SPEND MUCH
TIME ON THIS BUT WE KNOW THAT
MAKING NETS IN AN UNCONTROLLED
MATTER IS BAD FOR YOU AND THESE
NETS HAVE THE ABILITY TO
STIMULATE MANY IMMUNE CELLS AND
STIMULATE CLOTS AND DAMAGE BLOOD
VESSELS THE FIELD HAS EXPLODED
AND HERE ON THE LEFT I MENTIONED
A LIST OF DISEASES BOTH SYSTEMIC
AUTOIMMUNE AND FLAMMATORY WHERE
NETS HAVE AN IMPORTANT
PATHOGENIC ROLE AND WE KNOW FOR
EXAMPLE THAT IN COVID-19,
DISREGULATION IS IMPORTANT IN
THOM BOW SIS BUT THERE'S BASED
NOT AUTOIMMUNE AND I AM FLAM
TORI CONDITIONS WHERE ABNORMAL
MALL FORMATION HAS BEEN
IMPLICATED.
IT THIS WAS ALL GENES RELATED TO
NEUTROPHIL BIOLOGY SO THERE WERE
GENES THAT NEUTROPHIL THAT
EXPRESS WE KNOW WOMEN AND MEN
AND WHAT WE FOUND IS THAT THE
NEUTROPHILS IN HEALTHY MEN ARE
MORE IMMATURE THAN NO IN HEALTHY
WOMEN.
THIS WAS THAT VERY PICTURE WE
HAVE OBSERVED IN MULTIPLE
COHORTS THAT WE'VE STUDIED.
THIS MA IMMATURITY IN MALES
COMPARED TO FEMALES TRANSLATED
INTO THE FINDINGS WHEN YOU LOOK
AT NITRO FILLS OF HEALTHY, YOUNG
ADULTS AND COMPARE FEMALES AND
MALES, FEMALE NEUTROPHILS ARE
WAY MORE ACT RATE ISED THAN MALE
NEUTROPHILS.
THEY RESPOND MORE AND THEY
EXPRESS MARKERS THIS THE CELL
SURFACE AT HIGHER LEVELS THAT
MAY HAVE MORE FLAM TORI FEATURES
AND WHAT IS STRIKING OBSERVATION
WAS THAT AT NORMAL CONDITIONS OR
WHEN EXPOSED TO BACTERIA OR
BACTERIA PRODUCTS OR IMMUNE
COMPLEX, THE FEMALE NEUTROPHIL
ARE MORE LIKELY TO MAKE NETS.
THIS IS IMPORTANT BECAUSE THE
MECHANISMS THAT ARE ANTIGENS SO
IF WOMEN ARE BETTER AT MAKING
NETS, THESE MAY BE A FACTOR THAT
INDUCES MORE ANTIGENS AND MORE
PREDISPOSED TO AGAIN EIGHT
ANTIBODIES IF THEY HAVE THE
RIGHT GENETIC MAKE UP.
THEY'RE MORE LIKELY TO MAKE
THESE NETS.
WHAT IS INTERESTING IS THAT
THESE CHANGES IN NEUTROPHILS
MATURATION AND BIOLOGY CHANGE
THROUGHOUT THE PREGNANCY.
SO WHEN WOMEN WERE PREGNANT, WE
FOUND IS THAT THEY ACQUIRED MORE
NEUTROPHIL PHENOTYPE OF MALES.
THEY WERE LESS MATURE AND WHEN
THEY DELIVERED THE BABY THEY
WENT BACK TO HAVE THE PHENOTYPE
OF THE PRE PREGNANCY FEMALES AND
WERE MORE MATURE THAN THE MALE
NEUTROPHILS SO THIS IS JUST TO
ADD THAT PERHAPS A HORMONAL FACT
OR WAS INCOMPETENT INDICATED IN
MATURATION OF ACTIVATION AND
DURING PREGNANCY THERE'S A
GENETIC RESPONSE THAT MAKES THE
FEMALE NEUTROPHIL BEHAVIOR LIKE
THE MALE.
THE METABOLISM OF A MALE AND
FEMALE NEUTROPHIL IS DIFFERENT
AND IT MAY BE TELLING US WHAT
THEY USE AS THEIR SOURCE OF
ENERGY AND HOW PRO FLAM TORI
THEY ARE.
MALE NEUTROPHILS HAVE MORE
MITOCHONDRIA BECAUSE THEY'RE
MORE IMMATURE AND THEY RELY MORE
ON MAESTRO CON AGREE A BY THE
FEMALE WAS RELY MORE ON THE USE
OF GLUCOSE AND GLYCOLYSIS BUT IF
WE ADDED IN THE I DON'T HAVE
ACCESS TO THE POINTER HERE.
IF YOU LOOK AT THE RIGHT GRAPH,
IF WE HAVE A FEMALE HORMONE TO
THE MALE NEUTROPHIL THEY HAVE
THE FEMALE NEUTROPHIL SUGGESTING
THAT SOME OF THE DIFFERENCES AT
LEAST IN THE FEMALES AND MALES
MAY BE RELATED TO SEX HORMONES.
SO WE WENT AHEAD AND WANTED TO
BE MORE SPECIFIC AT WHETHER THE
FIRST DAY THAT SHOW YOU WAS IN
THOSE CELLS BUT WE STARTED TO
PURIFY NEUTROPHILS AND THE GENE
EXPRESSION BETWEEN FEMALE AND
MALE NEUTROPHILS AND WHAT WE SAW
AS YOU CAN SEE ON THE GRAPH ON
THE LEFT, IS THAT THE MAIN GENES
THAT INTEREST DIFFERENTIALLY
REGULATED INTO FEMALES AND MALES
ARE TYPE ONE INTRA FEWER ON
REGULATED GENES THAT ARE
RESPONDING TO CYTOKINES IN
INFECTIONS AND AUTOIMMUNITY AND
COP CONSISTENTLY ALWAYS REGULATE
THE GENES SO JUST IN THEIR HYPER
RESPONDING, TO TYPE ONE
INTERFERENCE AND ON THE RIGHT
GRAPH IT CAN GENERATE A
INTERFERENCE CORE AND IT'S
INTERESTING AND THIS IS THE
RIGHT LOWER GRAPH IS THAT WHEN
WE HAVE DID NOT SINGLE CELL RNA
SEQUENCING IT'S IN NEUTROPHILS
ALL THE OTHER CELL PATH WHEN WE
COMPARE MALE AND FEMALE THEY
DON'T HAVE DIFFERENCES IN THE
GENES BUT THE FEMALE AND MALE
NEWT TREE FILLS ARE SHOWING
DIFFERENCES WITH THE FEMALE
MOWING MORE HYPER RESPONSIVE SO,
JUST TO SUMMARIZE, THESE MAY
HAVE IMPORTANT IMPLICATIONS
BECAUSE IF THE FEMALE RESPONDS
BETTER TO TYPE ONE INTRA NEURONS
THEY ARE MORE LIKELY TO BE
DIS-REGULATED IN THE CONTEXT OF
OUR IMMUNITY AND THEY BE
FIGHTING CERTAIN INFECTIONS
BECAUSE THEY SUCH ADDS THE CASEF
COVID-19 WHERE FEMALES HAVE A
BETTER RESPONSE THAN MEN.
HOW EXACTLY IS THIS HAPPENING
AND THE HINGE FROM THE PREGNANCY
TOLD US, WELL, PERHAPS THIS IS
DIFFERENT IN SEX HOR MONTHS BUT
NOT X CHROMOSOMES AND THERE'S
SUGGESTING THAT THEY CAN
REGULATE NEUTROPHIL FUNCTIONS
AND THEY CAN CHANGE THEIR
NUMBERS AND LINK TO ALL AB
ABNORMALITY WE KNEW LITTLE
DIFFERENCES BETWEEN SEX AND
NEUTROPHIL FUNCTION.
SO, TO TRY TO OF WHETHER THIS IS
SEX HORMONE REGULATED OR X CREM
SO MANXCHROMOSOMES AND WHAT WE F
WE TOOK MALE, YOUNG ADULT MALES
AND YOUNG ADULT FEMALES AND
COMPARED THEIR TYPE OF INTRA
FEWER ON RESPONSE TO MALES WITHK
LIKE MALES BUT THEY HAVE A XXY.
THEY HAVE AN EXTRA X CHROMOSOME
LIKE WOMEN AND WE WILL HAVE
EXPECTED THAT THIS WAS AN EFFECT
OF HAVING TWO X CHROMOSOMES AND
MAY NEUTROPHILS WOULD MORE LOOK
LIKE THE FEMALE INTRO FILL BUT
THEY LOOK SIMILAR TO THE MALE SO
JUST HAVING AN EXTRA X
CHROMOSOME IS NOT DRIVING THE
DIFFERENCE AND SIMILARLY WHEN WE
LOOK AT CHILDREN WHERE THE SEX
HORMONE SHOULD BE MORE
BANKRUPTBLUNTED WEDON'T SEE A DS
AND GIRLS.
THIS IS ON GOING WORK THAT
SECTION HOR MONTHS ARE HORMONESR
TO CERTAIN HOR MONDAYAL
STRATEGIES THAT MAY ALLOW US TO
REGULATE NEUTROPHIL FUNCTIONS IN
CERTAIN EXISTENCE AS A MECHANISM
TO INDUCE AUTOIMMUNITY ET CETERA
AND THIS IS ON GOING WORK THAT
MY LAB IS PERFORMING.
I WANT TO TOUCH UPON BRIEFLY IS
THE EFFECT OF LUPUS ON
CARDIOVASCULAR DISEASE AND WHAT
TYPICAL THING OF CARDIOVASCULAR
DISEASE IS MIDDLE AGE MEN WE
KNOW THAT WOMEN WITH LUPUS HAVE
A SIGNIFICANT INCREASE IN
CARDIOVASCULAR RATES.
THEY HAVE A LOT OF INFLAMMATION
WE CAN ASSIST AND THEY HAVE CORP
ARY FORMATION AND THIS HAPPENS
AS MUCH ACCELERATED BASIS.
WE HAVE FOUND THE SAME AND HAVE
INFLAMMATORY ROLES ARE PLAYING A
ROLE IN DRIVING THESE
CARDIOVASCULAR DISEASE AND WE'VE
FOUND HAVING THESE KNOW TREE
FILL SUBSET MAKE MORE NETS
ASSOCIATED WITH HAVING MORE
VASCULAR INFLAMMATION SO THIS
HAS IMPLICATION FORCE
COMPLICATIONS IN AUTOIMMUNE
DISEASES AND WE'RE UNDERSTANDING
HOW THESE SEX DIFFERENCES
BETWEEN MALES AND FEELS THAT WE
HAVE OBSERVED IN HEALTHY PEOPLE
AND WHEN WE COMPARE MALES AND
FEELS WITH AUTOIMMUNE DES CEASES
AND WHETHER THEY EXPLAIN SOME OF
THE DIFFERENCES IN
CARDIOVASCULAR RISK.
SO IN SUMMARY, I WOULD LIKE TO
EMPHASIZE THAT SEX DIFFERENCES
IN NEUTROPHIL BIOLOGY PLAYS A
ROLE IN THE IMMUNITY AND BETTER
UNDERSTANDING THEM AND HOW TO
HAVE THE ROLE THEY PLAY IN
DRIVING THIS REGULATED IMMUNITY
MAY BE KEY IN FINDING BETTER
THERAPY FOR AUTOIMMUNE
SUPPRESSIVE AND WE THINK THIS
NET DIFFER ESSENTIALLY MADE
BETWEEN MEN AND WOMEN ARE A
SOURCE OF AUTOIMMUNE THAT
PROMOTE OF FOR DISPOSED PEOPLE
AND THAT THESE SUBSTANCES MAKING
MORE NETS AND THE DIFFERENCES
BETWEEN MALES AND FEMALES MAY
HELP US FIND BETTER STRATEGIES
TO MITIGATE PREMATURE AND ALL
THE END ORGAN DAMAGE THAN OCCURS
IN LUPUS IN A VARIETY FOR
IMMUNITY AND EXPANDING IT TO
BETTER UNDERSTANDING FOR EXAMPLE
OF DEVELOPMENT OF CARDIOVASCULAR
DISEASE IN WOMEN THAT DON'T HAVE
AUTOIMMUNITY.
TO MITIGATE PREMATURE AND AL
>>WE'LL ASK EVERYONE TO TOLD
THEIR QUESTIONS UNTIL BOTH
SPEAKER PRESENT AND WE'LL HAVE A
MODERATED JOINT SESSION.
FOR THOSE WHO HAVE QUESTIONS,
PUT THEM IN THE CHAT OR RAISE
YOUR HAPPENED AS WE GET TO THE
END OF Dr. MAMMEN'S TALK.
>>GREAT.
IT LOOKS LIKE YOU GUYS HAVE MY
TALK UP THERE.
THANK YOU VERY MUCH.
CAN YOU SEE MY POINTER.
LET ME SEE IF I CAN GENERATE A
POINTER DO YOU SEE IT NOW?
>>NOPE.
>>OKAY.
SO I HAVE A PATENT FOR THIS
ANTI-AGING ANTIBODY TEST BUT I
DON'T RECEIVE COMPENSATION FOR
THAT AND SOMETIMES I DISCUSS OFF
TABLE TREATMENTS FOR AUTOIMMUNE
MUSCLE DISEASES BUT I WOULDN'T
DO THAT TODAY.
SO, IN TERMS OF OVER VIEW, I
WANTED TO TALK ABOUT FIRST I
WOULD LIKE TO THANK Dr. KAPLAN
FOR FIRE FIGH GIVING A GREAT OVF
SYSTEMIC AUTOIMMUNE.
EVERYTHING SHE SAID HOW THESE
DISEASES OVER TIME AND BREAKING
TOLERANCE AND SUCH IS RELEVANT
TO THE AUTOIMMUNE MUSCLE
DISEASES THAT I'M GOING TO TALK
ABOUT TODAY SO I WON'T REPEAT
THAT SAME STUFF.
I WILL TELL YOU ABOUT THE FOUR
MAJOR TYPES OF AUTOIMMUNE MUSCLE
DISEASE OUR GROUP STUDIES AND
TELL YOU ABOUT THE SEX
DIFFERENCES AMONG THOSE
DIFFERENT TYPES OF AUTOIMMUNE
MUSCLE DISEASES AND I'M GOING TO
DO A DEEPER DIVE INTO A STUDY
THAT WE DID IN ONE OF THOSE
TYPES WHERE WE CAN LOOKING AT
CLINICAL DIFFERENCES BETWEEN
MALES AND FEMALES WITH THE SAME
DISEASE SO NEXT SLIDE.
THIS ARE FOUR TYPES THAT WE
STUDIED.
I WOULD SAY, THIS IS REALLY A
HETERO GENIOUS FAMILY OF MUSCLE
DISEASES AND EACH ONE IS REALLY
DISTINCT SO BEFORE OUR THE NAME
I AM FLIES HAS BOTH SKIN AND
MUSCLE INVOLVEMENT, THERE'S
ANOTHER DISEASE CALLED THE ANTI
OFSYNTHETASE SYNDROME AND THE
AND I'LL TELL YOU A LITTLE BIT
ABOUT THOSE.
THERE ARE PATIENTS WHO HAVE
IMMUNE MEDIATED NEP ROW TIEING
MYOPATHY AND I'LL TALK ABOUT
INCLUSION BODY MYOSITIS WHERE WE
HAVE A DETAILED LOOK AT SEX
DIFFERENCES.
I SHOULD MENTION THESE ARE
REALLY PRETTY RARE DISEASES AND
WE THINK THAT OVER ALL
PREVALENCE OF THESE DISEASES IS
SOMEWHERE BETWEEN THROW AND 40
PER 100,000 IN THE POPULATION
AND REPHRASING I MENTIONED HERE
IS IN GENERAL, THEY WE CAN WOMEN
MORE THAN MEN AND WE'LL TALK
ABOUT THAT IN SOME DETAIL.
IS DERMATOMYOSITIS IS THE MOST
COMMON FORM OF AUTOIMMUNE MUSCLE
DISEASE IN THE PATIENT
POPULATION SO THOSE UNDER 50.
AND THESE PATIENTS WILL PRESENT
WITH EITHER MUSCLE WEAKNESS AOR
A RASH FIRST.
WHEN THEY PRESENT WITH MUSCLE
WEAKNESS, THE KIND OF WEAKNESS
IS THEY WILL COMPLAIN FIRST OF
THINGS LIKE DIFFICULTY GOING
UPSTAIRS AND THEN AS THE DISEASE
PROGRESSES, THEY MAY HAVE CULT
GETTING OUT A CHAIR WITHOUT
USING THEIR ARMS TO PUSH OFF AND
IF THEY GET REALLY WEAK THEY
MIGHT REQUIRE A WHEELCHAIR.
THERE ARE LEFT WITH THE RAISING
THINGS ABOVE THEIR HEAD.
THEY MAY DEVELOP DOING THINGS
LIKE SHAVING OR WASHING THEIR
HAIR BECAUSE OF MUSCLE.
WHAT THEY DON'T HAVE IS WEAKNESS
OF THE DISTAL MUSCLES LIKE THE
HANDS AND FEET.
SA SKIN RASHPROGRESSES QUICKLY R
MONTHS SO THEY MIGHT BE FINE IN
DECEMBER AND NOTICE A RASH IN
JANUARY AND BY MARCH THEY HAVE
RASH AND WEAKNESS.
I'LL SHOW YOU THE RASHES THESE
PATIENTS GET.
BECAUSE OF THE MUSCLE BREAKDOWN
OCCURS THE LEVEL OF MUSCLE
ENZYME LIKE CK LEVELS AND THEIR
SERUM IS USUALLY ELEVATED AND
JUST LIKE Dr. KAPLAN MENTIONED
FOR LUPUS AND OTHER TYPES OF
SYSTEMIC AUTOIMMUNE PATIENTS
PATIENTS GENERALLY DEVELOP AUTO
ANTIBODIES AND THEY CAN DEFINE
DIFFERENT TYPES AND I WON'T GET
TOO MUCH INTO THAT TODAY AND WE
DID ELECTRIC PHYSICAL STUDIES
THEY HAVE MIO PACT I CAN
FEATURES AS OPPOSED IT NEURO
AGAIN I CAN FEATURES AND WHEN WE
DO MUSCLE BUY ON SEES -- AND A H
OVER THE UPPER EYELIDS.
IT'S A PURPLE RASH.
IT'S JUST DIAGNOSED FOR
DERMATOMYOSITI IS S AND THESE
LESION ON THE EX TENSER SURFACE
OF THE HANDS AND AGAIN, THIS IS
A KIND OF RASH THAT WE ONLY SEE
IN DERMATOMYOSITIS PATIENTS.
WE HAVE LESIONS THAT CAN OCCUR.
YOU HAVE AN ULCER EIGHTING
LESION ON THE FINGER TIP AND ON
THE RIGHT, YOU SEE THAT ARE
ULCER EIGHTING AND SELLING ASK
CAUSE DOUBLE FOR TOUR PATIENTS.
AND IF YOU LOOK AT THE NAIL BED
OF THE MIDDLE FINGER YOU SEE
DILATED CAPILLARY.
SO THEY HAVE EFFECT CAPILLARY
AND YOU CAN SEE IT IN THE NAIL
BEDS AND ALSO CAPILLARY DROP
OUT.
THESE ARE TYPICAL FEATURES.
I'M GOING TO SHOW YOU IN THE
NEXT SLIDE SOME ABNORMAL MUSCLE
BIOPSY FROM PATIENTS.
WHAT I HAVE HERE IS A NORMAL
MUSCLE BIOPSY ON THE LEFT AND
THE RIGHT.
THE LEFT A LOW POWER.
ABOUT WHAT YOU CAN SEE THERE,
THIS IS A CROSS SECTION THROUGH
MUSCLE VIBERS AND EACH OF THOSE
RED CIRCLES IS AN INDIVIDUAL
MUSCLE FIBER.
YOU CAN SEE THEY'RE ORGANIZED IN
VLASICAL SO HAS ONE IN THE
CENTER WHERE YOU SEE A FULL MIO
FIBER AND YOU SEE THOSE WITH
THEIR DARK PURPLE NUKELY EYE
AROUND THE EDGES.
AND YOU DID SEE ARE DAMAGED MIO
FIBERS.
ON THE NEXT SLIDE, ARE EXAMPLES
OF MUSCLE BIOPSY WITH A PATIENT
WITH DERMATO.
THIS IS A CROSS THE SECTION AND
YOU CAN STILL SEE THE
ARCHITECTURE AROUND THE EDGES.
YOU SEE THE INDIVIDUAL MUSCLE
FIBERS ARE SMALL AND A TROPHIC
AND ATROPHY, ONE OF THE HALLMARK
FEATURES.
IN CONTRAST THE MIO FIBERS IN
THE CENTER ARE RELATIVELY NORMAL
AND OTHER THE RIGHT, YOU WITH
SEE IS EVIDENCE OF PERRY
VASCULAR INFLAMMATION.
SO THOSE DARK PURPLE DOTS ARE
WHERE IT'S A VERY HIGH LEVELS OF
TYPE ONE INTRA FUR OPPOSITE ANDY
CELLS WOULD BE PLASMA SIGH TIED
THAT ARE POTENCY COTTAGE
COUNTRIERS OF TYPE ONE PO -- THS
THE SECOND MAJOR TYPE OF
AUTOIMMUNE MUSCLE DISEASE WE SEE
AND IT IS DEFINED PARTNERSHIP BE
AUTOIMMUNE THAT RECOGNIZE ONE OF
THE TNRA SO THESE ARE THEN TIMES
THAT ATTACH THE APPROPRIATE
AMINO ACID SO THEY'RE IMPORTANT
FOR PROTEIN PRODUCTION AND FOR
REASONS WE DON'T UNDERSTAND,
THESE ENZYMES ARE TARGETS OF THE
IMMUNE RESPONSE AND SOME OF OUR
PATIENTS WITH AUTOIMMUNE MUSCLE
DISEASE AND THE MOST COMMON AUTO
ANTIBODY AND REALLY ONE OF THE
MOST AUTO ANTIBODIES IN PATIENTS
WITH MYOSITIS AND IT'S OTHERWISE
KNOWN AS JO1.
SEVERAL OF THE OTHER TRNA ARE
RECOGNIZED LESS COMMONLY THAN HI
IS STIDYL-TRNA.
THESE PATIENTS DON'T JUST HAVE
MYOSITIS.
THEY ALSO HAVE A SYNDROME THAT
CONCLUDES ARTHRITIS AND UP THERE
IN THE LEFT CORNER, YOU SEE A
PATIENT WHOSE HANDS IS SWOLLEN
WITH ARTHRITIS.
THEY GET FEATURES OTHER THAN THE
RASHES AND ONE OF THOSE
MECHANICS HANDS THERE'S A
PICTURE OF THAT IN THE UPPER
RIGHT CORNER IS THESE ARE TYPIER
LESIONS THAT OCCUR ON THE RAID
Y'ALL SURFARAID Y'ALLAND YOU SEG
WOMAN WITH THE SYNDROME AND
BOTTOM LOWER LEFT THERE, THAT IS
AN X-RAY OF A PATIENT WITH LUNG
DISEASE AND IT'S QUITE COMMON
AND PATIENTS WITH THE SYNDROME
AND EVEN MORE THAN THE RASH OR
THE MUSCLE INVOLVEMENT AND CAN
REALLY CAUSE LIFE-THREATENING
COMPLICATIONS FOR PATIENTS.
>>THE REASON IT'S CALLED NEP
ROW TIDES ASKING IN THE RIGHT
AND IT SHOWS A MUSCLE FROM
PATIENT WITH IMMUNE MEDIATED
NECROTIZING AND YOU SEE AGAIN
GENERATING MIO FIBERS AND
REGENERATING MYOFIBERS BUT YOU
DID SEE THIS ASTRO FEE OR
PERIVASCULAR INFORMATION AND YOU
DON'T SEE MUCH INFLAMMATION AT
ALL SO THIS IS A NECROTIZING
PROCESS.
THEY HAVE AN AUTO ANTIBODIES
THAT RECOGNIZES A SINGLE
RECOGNITION PARTICLE AND IT'S A
PROTEIN IMPORTANT FOR MOVING
NEWLY TRAPS KNEW TRANSLATED PROM
THEY HAVE ANTIBODIES THAT TARGET
AN ENZYME CALLED HMG-COA REDUCT
ACE AND IT'S THE BIO SYNTHETIC
PATHWAY AND STAFF MEDICATIONS
WHICH ARE PRESCRIBED IN THE
WORLD I BELIEVE, THEY LOWER
CHOLESTEROL LEVELS BY INHIBITING
HMG-COA AND LIMITING CHOLESTEROL
PRODUCTION AND ONE OF THE MAJOR
RISK FACTORS FOR DEVELOPING AN
ANTI HMG-CR IS EXPOSURE TO STAT.
IT PRE DISPOSES PATIENTS TO
DEVELOPING THAT DISEASE.
PATIENTS WITH THIS TYPE OF
MYOSTATI IS S HAS MUSCLE
WEAKNESS THAT TAKES THEM FROM
WALKING NORMALLY TO BEING IN A
WHEELCHAIR WITHIN A FEW SHORT
MONTHS.
THE WEAKNESS IS SEVERE.
UNLIKE PATIENTS WITH MYOSITIS
AND WHO HAVE EXTRA MUSCULAR
INVOLVEMENT LIKE SKIN, LUNG AND
JOINT, THE LAB IS A REALLY SEEMS
TO BE RESTRICTED TO DAMAGING
MUSCLE CELLS IN MOST PATIENCE
AND THIS IS ONE OF THE MORE
DIFFICULT TO TREAT TYPES OF MIO
SIGHT IS AND IN OUR YOUNG WOMEN.
THIS IS THE FOURTH TYPE OF
MYOSITIS, THE FOURTH OF FOUR
THAT I WILL TELL YOU ABOUT
TODAY.
I'LL TELL YOU MORE ABOUT THIS IN
DETAIL BUT INCLUSION BESIDE'
MYOSITIS IS THE MOST COMMON
ACQUIRED MUSCLE DISEASE THATS
PATIENTS OVER 50-YEARS-OLD.
THE IT'S THE MOST COMMON MUSCLE
DISEASE IN THAT PATIENT
POPULATION.
PATIENTS WHO DEVELOPED THE OTHER
TYPES OF MIO SIGHT US QUICKLY
OVER WEEKS OR MONTHS, INCLUSION
BY MYOSITIS HAS AN INSIDIOUS
ONSET TO PATIENTS MIGHT NOT EVEN
REALLY RECOGNIZE HOW WEAK THEY
ARE UNTIL THEY START FALLING AND
THAT IS OFTEN THE COMMON REASON
WHY THESE PATIENTS WILL SEE A
NEUROLOGIST BECAUSE THEY STARTED
FALLING.
IF YOU ASK THEM, THEY'LL REALIZE
YEARS AGO THEY DEVELOPEDEL
DIFFICULTY GOING UPSTAIRS OR
SOMETHING LIKE THAT SO WE THINK
THAT WITH THE DISEASE STARTS AND
TAKES YEAR BEFORE THE PATIENTS
ARE AWARE.
THEY HAVE A YOU NEXT PATTERN OF
WEAKNESS.
ALL THE TOO TYPES HAVE MUSCLE
WEAKNESS THAT WILL I DETAILED
FOR YOU WHEN I DESCRIBED IT IN
PATIENTS.
THESE PATIENTS IF CONTRAST, HAVE
SIGNIFICANT DISTAL WEAKNESS SO
ON THE TOP PICTURE THERE ON THE
RIGHT, YOU SEE A PATIENT WHO IS
TRYING TO FORM A STRONG GRIP
WITH THEIR HANDS.
TRYING TO BURY THE FINGERS BUT
ON THE LEFT THE PATIENT IS
UNABLE TO FLEX THE THINGERS
THERE AND THAT IS THE CLASSIC
PATTERN OF WEAKNESS.
THEIR HANDS MIGHT NOT WAKE AND
SIMILARLY IN THE LEGS, THEIR HIP
AND THE RIGHT AND THE LEFT OF
THE QUADRA.
WHEN YOUR KNEE STARTS BENDING
AND YOU CAN'T EXTEND IT YOU WILL
GO DOWN.
INSTEAD OF HAVING WEAKNESS ON
BOTH SIDES THERE'S AS I
SYMMETRY.
A THIRD OF THEE PATIENTS DEVELOP
SWALLOWING DIFFICULTIES AND SOME
OF THEM AS THE DISEASE
PROGRESSES, CAN REQUIRE FEEDING
TUBES.
I HAVEN TALKED A LOT ABOUT TREAT
BUT WE HAVE PRETTY GOOD
TREATMENTS FOR WITH TYPICAL
IMMUNOSUPPRESS LENT MEDICATIONS
IN CONTRAST, INCLUSION BODY
MYOSITIS BUT THERE ARE
TREATMENTS COMING ON-LINE THAT
ARE SPECIFICALLY TARGETED FOR IN
CONCLUSION BODY MYOSITIS SO
UNDERSTANDING THE NATURAL
HISTORY OF THE DISEASE IS
PARTICULARLY IMPORTANT.
AND THE NEXT SLIDE, WILL SHOW
YOU PATIENT WITH I AM CONCLUSION
BODY MYOSITIS AND THE POWER VIEW
OF A SINGLE MIO FIBER AND IT HAS
STRUCTURES THAT WE CALL RIMMED
VACUUMS AND THOSE ARE ABNORMAL
STRUCTURES WE ON THE SEE
INCLUSION PAYS SHE WAS AND
IT'S A TIME OF AGGRESSIVE CYTO
TOXIC T-CELL THAT IS RESI RESIS.
THAT'S ONE REASON WHY WE DON'T
HAVE BRAIN LUCK TREATING THESE
PATIENTS BUT ONE OF THE CRIMINAL
TRIALS GOING ON IS A ANTIBODY
TARGETING JUST EXACTLY THOSE CDA
POSITIVE AND CD57 POSITIVE T
CELLS.
ALL OF THE FIRST THREE ARE MORE
COMMON THAN MEN.
RAGING FROM 61% TO 70% IN IN
CONTRAST INCLUSION BODY IBM IS
MALE DOMIN APART DOMINANT AND TA
DISEASE THAT AFFECTS OLDER MEN
AND SO SOMETIMES WE THINK THAT
THE DIAGNOSIS MAY BE MISSED IN
WOMEN AND THE STUDY THAT I'M
GOING TO TELL YOU ABOUT ON THE
NEXT SLIDE, IS GOING TO HELP
ADDRESS THE SEX DIFFERENCES SO
AGAIN, I TOLD YOU MOST OF THESE
THINGS AND IT'S SLOWLY
PROGRESSIVE.
POOR RESPONSE TO
IMMUNOSUPPRESSIVE THERAPY
ALTHOUGH WE HOPED FOR SOME OF
THESE NEW TREATMENTS AND ONE
THING THAT IS IMPORTANT IS TO
RECOGNIZE THERE'S CLINICAL
HETEROGENEITY THAT INFLUENCES
TREATMENT RESPONSE IN THIS SO IF
MEN, FOR EXAMPLE, HAVE A
DIFFERENT COURSE OF PRE GRES
THAN WOMEN IT WILL BE REALLY
IMPORTANT TO UNDERSTAND FOR
CLINICAL TRIALS.
WE HAD VERY LIMITED DATA
REGARDING THE HETERO BEGIN A TEE
OF DISEASE AND MOST PATIENTS OF
INCLUSION, BODY MYOSITIS
INCLUDED 100 OR LESS PATIENTS EX
THAT MEANT THERE WERE FEW WOMEN
AND OTHER MINORITY POPULATIONS,
WOMEN AROUND MINORITY
POPULATIONS BUT THEY HAVE LARGE
NUMBERS OF MINORITY POPULATIONS
SO WE DID A BIGGER STUDY, NEXT
SLIDE, WHERE WE TOOK ALL OF THE
PATIENTS THAT WERE EVALUATED
BETWEEN 2003 AND 2018 AND I
MENTIONED THAT AT THE NIH NOW
BUT I STILL HAVE A STRONG
COLLABORATION AND I'M STILL PART
OF THAT MYOSITIS CENTER AT
HOPKINS AND THAT'S WHERE IT WAS
THE POPULATION THAT WE UTILIZED
FOR THIS AND WE IDENTIFIED
PROGNOSTIC FACTORS AND INTO
STUDY THE DISEASE OVER TIME SO
WE LOOKED AT THE EVOLUTION OF
MUSCLE ENZYME CLAIMS AND
STRENGTH USING LINEAR REGRESSION
MODELS AND WE ADJUSTED FOR
THINGS LIKE SEX, RACE, DISEASE
AND AGE ON ON IS S-SET.
SO WE WERE ABLE TO COLLECT 335
WITH THE NEXT BIGGEST STUDY AND
TWO-THIRDS OF THE PATIENTS WERE
MALE AND THE AVERAGE AGE OF
DISEASE WAS 60-YEARS-OLD AND YOU
KNOW I WOULD HIGHLIGHT THE
AVERAGE DIAGNOSIS WAS FIVE
YEARS.
IT TOOK FIVE YEARS OF THESE
PATIENTS SEEING DOCTORS WITH A
COMPLAINT OF WEAKNESS BEFORE
THEY WERE ABLE DIAGNOSED WITH
THE CORRECT DISEASE AND 50%
RECEIVED THE WRONG DYING K DIAGS
MANY PEOPLE HAVE THE WRONG
DIAGNOSIS FOR YEARS AND ONE
THING WE FOUND LOOKING AT THE
PATIENTS CLOSELY IS BLACK
PATIENT WERE SIGNIFICANTLY
WEAKER IN ARM ABDUCTORS AND HIP
FLEXORS AND KNEE EXTENDERS THAN
OUR NON BLACK NATION.
THAT WAS IMPORTANT THAT WE
LEARNED WHICH IS THE DISEASE IS
MORE SEVERE IN THE BLACK
POPULATION.
NEXT SLIDE, PLEASE.
WE LOOKED AT DIFFERENCES BETWEEN
MEN AND WOMEN SO WE WERE ABLE TO
DO THIS BECAUSE WE HAD OVER 100
WOMEN AND 200 MEN AND WE FOUND
THAT WOMEN HAD STRONGER QUADRA
AND THEY JUST IN STRONGER.
ON THE OTHER HAND, THEY WERE
MANY SIGNIFICANTLY MORE AT RISK
FOR DEVELOPING SWALLOWING
DIFFICULTIES.
TWICE AS LIKELY.
THE SLOPE WAS NOT AS STEEP IN
WOMEN.
WHEN WE LOOKED AT THESE
PATIENTS, WE FOUND THAT THE
WOMAN WERE MUCH MORE LIKELY TO
RECEIVE A WRONG DIAGNOSIS AND TO
BE MISTREATED OR MESS MANAGED
FOR YEARS AND WE THINK THAT IT
CAN BE BECAUSE THEY JUST
PRESENTED THE STRONGER AND THEY
HAVE MORE SWELLING AND ET CETED
IT TOOK LOOPER LONGER SO ON AVET
TOOK SIX YEARS FOR WOMEN TO
RECEIVE THE CORRECT DIAGNOSIS
AND COMPARED TO 4.7 YEARS FOR
MEN TO RECEIVE THE CORRECT
DIAGNOSIS.
ONE OF THE IMPLICATIONS OF THIS
STUDY.
THE FEMALE PATIENTS WITH
INCLUSION BODY MYOSITIS HAVE A
DISTINCT CLINICAL PHENOTYPE AND
A DIFFERENT DISEASE TRAJECTORY
AND THIS IS REALLY IMPORTANT TO
DEEP IN MIND FOR CLINICAL TRIALS
WHICH INCLUDE WOMEN AND MEN
BECAUSE OF THE WOMENNER GOING
TO, EVEN IN THE ABSENCE OF
TREATMENT, HAVE A SLOWER
PROGRESSION.
IT MAY MEAN THAT THE PATH OF
PHYSIOLOGY IS DIFFERENT AND
WE'RE INTERESTED IF STUDYING
THAT AND WHY DO WOMEN DO BETTER
THAN MEN.
THESE UNRECOGNIZED DIFFERENCES
MAY HAVE CONTRIBUTED TO THE
DELAY OF THE CORRECT DIAGNOSIS
IN WOMEN AND WE'RE TRYING TO GET
THE WORD OUT THERE THEY HAD NOT
LOOK OUT FOR WOMEN COMPARED TO
MEN AND WE THINK AT GOING TO
IMPLEMENT THE DESIGN OF FUTURE
CLINICAL TRIALS AND IT'S NOW
CAUSING US TO GO BACK AND LOOK
AT MUSCLE TISSUE TO SEE IF WE
CAN TROY TO BETTER UNDERSTAND
THE PHYSIOLOGY NOT BETWEEN MEN D
WOMEN IN THIS DISEASE.
THIS IS MY LAST SLIDE.
WE HAVE TO THINK ALONG WITH MARY
KAPLAN TO TAKE ANY QUESTIONS.
>>THANK YOU BOTH.
AT THIS TIME, WE WELCOME
QUESTIONS.
YOU CAN EITH EITHER RAISE YOUR
HAPPENED OR IF THERE'S
SOMETHING, I DON'T SEE ANYTHING
IN THE CHATBOX.
ARE THERE ANY INITIAL QUESTIONS
FOR OUR PRESENTERS?
FIRST QUESTION TO Dr. KAPLAN.
YOU COVERED LUPUS WHICH IS OF
COURSE A HUGE CONCERN BECAUSE OF
HEALTH DISPARITIES.
IS THERE INTERSECTIONALITY
BETWEEN FEMALE SEX AND MINORITY
WOMEN?
DO YOU CARE TO COMMENT, PLEASE?
>>WHETHER SOME OF THE
DIFFERENCES WE'VE SEEN MAY BE
OBSERVED WHEN YOU COMPARE
DIFFERENT ETHNIC GROUPS?
IS THAT YOUR QUESTION.
THAT'S A GREAT QUESTION.
THIS IS AN ONGOING STUDY AND
WE'RE LOOKING ACROSS THE AGE SO
WE HOPE TO HAVE MORE INFORMATION
ABOUT THAT.
I MEAN, THERE ARE SOME
INTERESTING OBSERVATIONS ABOUT
NEUTROPHIL NUMBERS THAT PEOPLE
OF AFRICAN DIS SEPTEMBER HAVE
LOWER NEUTROPHIL NUMBERS.
HOW THAT RELATES TO THE
OBSERVATIONS AND IT'S STILL
UNCLEAR.
IT MAY BE DIFFERENCES IN
NEUTROPHIL BIOLOGY THAT'S A
GREAT QUESTION.
THANK YOU.
>>I HAVE A QUESTION FOR Dr.
MAMMEN IN TERMS OF THE IBM IN
WOMEN, EVEN THOUGH THEY'RE A
LOWER PERCENTAGE, B WOULD WOULDE
MORE LIKELY TO PICK THIS UP IN
WOMEN?
YOU MENTIONED YOU ARE TRYING TO
GET THE WORD OUT?
>>YES, SO, USUALLY THEY WIND UP
IN THE OFFICE A NEUROLOGIST
WHERE IT'S MADE.
ONE OF THE THINGS THAT MAKES IT
DIFFICULT IS THIS MISS
UNDERSTANDING THAT IT'S NORMAL
FOR AN OLDER PERSON AND TO JUST
WRITE IT OFF WE MEET MORE
EXERCISE WHEN PATIENTS ARE
DEVELOPING YOU KNOW, A NEURO
MUSCULAR PROBLEM.
IT OFTEN TAKES PATIENTS STARTING
TO DO SOMETHING LIKE FALL OR
REALLY HAVE PROBLEMS WHERE THEIR
DOCTORS WILL REFER THEM TO SEE A
SPECIALIST WHO WILL BE BETTER
EQUIPPED TO MAKE THE DIAGNOSIS.
I THINK IT'S ASKING A LOT OF
INTERNISTS TOSH ABLE TO MAKE THE
DIAGNOSIS OF IBM EVEN IN
SPECIALIST EARLY ON IT CAN BE
DIFFICULT TO MAKE THE CORRECT
DIAGNOSIS.
SO, MOSTLY WE'RE TRYING TO
TARGET RHUMATOLOGIST AND
NEUROLOGISTS AND REALLY EXPLAIN
TO THEM YOU MAY NOT SEE THE SAME
TYPICAL PATTERN OF WEAKNESS
EARLY ON IN FEMALE PATIENTS WITH
INCLUSION BODY MYOSITIS SO IT
NEEDS TO BETTER CHANCE FOR
MAKING AN EASTERLY YEAR
INCORRECT DIAGNOSIS.
THANK YOU.
I SEE Dr. McGREGOR HAS HER
HAND UP, PLEASE.
JUST LAST COMMENT ADDRESSED WHAT
I WAS GOING TO SAY.
THIS REQUIRED A REFERRAL TO A
SPECIALIST SO TO ME IT'S REALLY
INTERESTING AND IT'S BACK TO MY
PRODUCTION AND WHICH IS IT'S
REALLY THAT MOMENT OF
INTERACTION WITH THE HEALTHCARE
PROVIDERS AND IT'S CRITICAL AND
SO I THINK THAT REALLY JUST AND
MAKING SURE THAT AWARE OF THESE
THINGS TO THEY KNOW WHEN THEY
FEE FER AND THEM THE OTHER POINT
IS WE GENDER DISEASE AND IT'S
MORE MALE AND IT'S LESS LIKELY
TO BE DIAGNOSED WITH WOMEN AND
WE CAN SEE IT WITH OSTEOPOROSIS
DYING KNOWED IN MEN KEEPING
THESE THINGS IN MINDS ARE
CRITICAL FOR BOTH MEN AND WOMEN
BASICALLY.
>>I HAVE A QUICK QUESTION.
>>CORRECT ME IF I'M WRONG, I'M
A NEUROLOGIST TO I'M IGNORANT
ABOUT MOST OTHER AUTOIMMUNE
DISEASES, ALTHOUGH LUPUS IS MUCH
LESS COMMON IN MEN, WHEN MEN GET
LUPUS IT'S MUCH MORE SEVERE AND
I WONDER WHAT YOUR THOUGHTS ARE.
DO YOU THINK IT'S THE SAME
DISEASE EVEN?
A DIFFERENT DISEASE?
WHAT ARE YOUR THOUGHTS ABOUT
THAT?
>>YEAH, THAT'S A REAL FIFTH
GREAT QUESTION AND I ALMOST
MENTIONED IT DURING THE TALK BUT
IT'S TRUE TYPICALLY WHEN WE SEE
LUPUS IN MEN IT'S VERY SEVERE
ORGAN DAMAGE.
MORE STUDIES ARE TOGETHER SO WE
DON'T HAVE A FULL EXPLANATION.
MANY GROUPS ARE DOING RESEARCH
IN MALE LUPUS AND WE'RE STARTING
BECAUSE WE'RE TRYING TO LOOK AT
THIS DIFFERENCES AND IF THERE
ARE DIFFERENT GENETICS THAT ARE
COMPACOMPARED TO RISK FOR DISEAD
THE PATHWAY IN THIS MALE LUPUS
IS CONTRARY TO WHAT WE SEE MALES
DIFFERENT, RIGHT AND THEY
RESPOND WHERE WHICH DON'T SEE IT
IN MALES.
>>I WILL HAND IT BACK TO Dr.
NOURSI TO CONTINUE WITH THE
AFTERNOON'S PROGRAM.
>>Samia Noursi: THANK YOU Dr.
BEGG AND Dr. KAPLAN AND Dr.
MAMME INTO JOIN US.
NOW WE'LL TURN TO A DIFFERENT
PART OF OUR MEETING AND PROVIDE
YOU WITH UPDATES ON THE PROCESS
OR THE DEVELOPMENT OF THE
2024-2028 NIH WIDE STRATEGIC
PLAN ON RESEARCH.
THIS IS JOINT PRESENTATION.
THE OTHER OVERARCHING STRATEGIC
PLAN TO PROVIDE A ROADMAP TO
GUIDE NIH WIDE RESEARCH ON THE
HEALTH OF WOMEN FOR THE NEXT
FIVE YEARS.
WE HAVE ENGAGE MULTIPLE PARTNERS
INCLUDING THE NIH INSTITUTE AND
CENTERS, AND OFFICES.
REPEATS WE CALWE CALLTHEM ICOs.
THEY DEVELOPED A PROCESS MODEL
THAT OUTLINES THE KEY STEPS FOR
THE DEVELOPMENT OF THE PLAN.
THE PROCESS BEGAN WITH ALL ORWH
COLLECTING AND ANALYZING DATA
FROM ACTIVITIES ALONGSIDE THIS
COMMITTEE, THIS ADVISORY
COMMITTEE AND THESE ACTIVITIES
INCLUDED RFI, BY ANNUAL REPORT
AND THE CONGRESSIONALLY MAP
DATED ORWH IC DIRECTOR'S
MEETINGS WHICH HAPPEN EVERY
YEAR.
THEY HAVE FIFTH PLAN WORKING
GROUP COMPRISED OF MEMBERS AND
REPRESENTATIVES FROM THE ICOs
AND FEDERAL PARTNERS.
WE HAVE INITIAL FINDINGS TO THE
STRATEGIC PLAN WORKING GROUP IN
A KICKOFF MEETING WE HELD IN
JUNE OF 2022.
FEEDBACK WAS OBTAINED FROM THE
EXTRA TOMMY I CASTRATEGIC GROUPE
MEETING AND FOLLOWING THE
MEETING.
THE STRATEGIC PLAN AREAS WITH
DEVELOPED USING INPUTS FROM THE
STRATEGIC PLAN WORKING GROUP,
THE RFI I MENTIONED THAT THE
DIRECTOR'S MEETINGS AND OR THE
ORWH.
THESE AREAS WERE APPROVED BY THE
WORKING GROUP AS WELL AS ACRWH
AT THAT OCTOBER 2020.
ORWH RECRUITED PARTICIPANTS FOR
FIVE THINK-TANK GROUPS, ONE FOR
EACH CONTENT AREA.
THE FIVE OF THINK TANKS WORK
TOGETHER WITH ORWH TO DEVELOP
THE STRATEGIC CALLS, OBJECTIVES,
AND PRELIMINARY METRICS FOR THE
RESPECTIVE CONTENT YEARS.
THEY HAVE A PLAN THAT WOULD BE
FOLLOWED BY IMPLEMENTATION AND
EVALUATION GUIDES AND THIS WILL
BE PUBLISHED SIX MONTHS LATER.
TODAY WE ARE HERE IN THE
PROCESS.
DRAFTING THE STRATEGIC PLAN WITH
THAT I'D LIKE TO INTERPRET IT TO
Dr. McGREGOR FOR THE NEXT
PORTION OF THIS PRESENTATION.
>>GREAT, THANK YOU SO MUCH FOR
INVOLVING ME IN THIS PROCESS.
WE WOULD LIKE TO ACKNOWLEDGE
THAT ACRWH WORKING GROUP CO
CHAIRED BY Dr. NOURSI AND
MYSELF THERE WERE GROUPS FOR THE
NEXT STRATEGIC PLAN AND APPROVE
THE CONTENT YEARS WHICH SERVED
TO INFORM THE STRATEGIC GOALS.
S.
>>BIOMEDICAL WORKFORCE AND
CAREER DEVELOP.
, BASIC SCIENCE AND
TRANSLATIONAL RESEARCH AS WELL
AS IMPLEMENTATION SCIENCE AND
COMMUNITY ENGAGEMENT.
I'LL TURN IT OVER TO Dr. KELLY
CHANDLER WHO WILL TALK ABOUT
WHERE WE ARE IN THIS PROCESS.
AS YOU CAN SEE IN THE PROCESS
MODEL, ORWH ESTABLISHED FIVE
THINK-TANK GROUPS THAT WERE
COMPRISED OF ORWH STAFF, ICO
SCIENTIFIC EXPERTS, APRWH
MEMBERS AND FEDERAL PARTNERS TO
ELABORATE ON THE INDIVIDUAL
CONCEPT AREAS AND DEVELOP A
STRATEGIC GOALS AND OBJECTIVES
FROM WITHIN.
THEY GO THROUGH EACH OF THE
DELIVERABLES AND THE THINK TANKS
PRODUCE.
THINK-TANK DEVELOP THE STRATEGIC
GOAL EXAMS, RESEARCH THAT EXAMS
THE MULTIPLE BIOLOGICAL AND
BEHAVIORAL AND SOCIAL STRUCTURAL
AND ENVIRONMENTAL FACTORS THAT
INFLUENCE THE HEALTH OF WOMEN
AND THE INTERSECTIONS OF THESE
FACTORS.
THEY HAD SIX OBJECTIVES TO SUB
STAN THEE EIGHT THESE GOALS AND
WE'LL TOUCH UPON THE HIGHLIGHTS
OF THESE OBJECTIVES.
ON DIFFERENCE ONE AND TWO AND
THE INTERSECTIONALITY OF SOCIAL
CULTURAL BEHAVIORAL AND
BIOLOGICAL FACTORS CONSIDERING
THE HISTORICAL CONTEXT HEALTH
DISPARITIES AND EQUITY AND
PAYING ATTENTION TO THE DIVERSE
AND MARGINALIZED POPULATION.
OBJECTIVE THREE ENCOURAGED
EXAMINING UP TREATMENT CAUSES OF
HEALTH DISPARITIES AND RACE AND
I WILL DETERMINANTS OF HEALTH
AND AND FOUR THROUGH SIX JUSTIFY
THE IMPORTANCE MULTI DIMENSIONAL
APPROACH AND IN ADDITION TO
INTERSECTIONALITY, WE ALSO NEED
TO INVESTIGATE A VARIOUS DOMAINS
OF GENDER AND FINALLY BECAUSE
AEROMEXICO AGE HEALTH CONDITIONS
AND AND WE SHOULD APPRAISE THE
WOMEN AND SHOULD BE WITHOUT THE
LIFE COURSE.
IT IMPROVES THE GOAL AND DATA
SCIENCE AND DATA MANAGEMENT
PROCESSES WITH INNOVATIVE
RESEARCH METHODS AND
MEASUREMENTS AND CUTTING EDGE
TECHNOLOGIES TO PREVENT AND
TREAT CONTINUES EFFECTING WOMEN.
ACCORDINGLY, THINK-TANK TWO
DEVELOPED FOUR OBJECTIVES.
THE FIRST FOCUSES ON DATA
SHARING.
WHICH WILL ENCOURAGE MORE
SCIENTIFIC INVESTIGATIONS AND
ENHANCE ANALYTICAL
REPRODUCIBILITY AND TRANSPARENCY
AND PROVIDE AN EVIDENCE-BASED TO
HELP US UNDERSTAND THE HEALTH OF
WOMEN.
OBJECTIVE TWO UNDERSCORES HOW
INNOVATIVE ANALYTICAL METHODS
SUCH AS DATA VISUALIZATION AND
A.I. AND ML AND SOPHISTICATED IS
SPECIFIC MODELING TECHS
TECHNIQUES ENABLE FOR COMPLEX
DATA STRUCTURES, EXAM NON LINEAR
TIME VARYING RELATIONSHIPS AND
HELP US GAIN FURTHER INSIGHTS
INTO THE HEALTH OF WOMEN.
AND TO EXAM AND PROGRESSION AND
THROUGH DIAGNOSIS AND
INTERVENTIONS AND INVESTIGATE
THE EFFECT OF LIFE TRANSITIONS
HERE AND FINALLY AND SUPPORT THE
DEVELOPMENT AND CUTTING EDGE
COMPUTATIONAL AND FACILITATE
SCREEN ASKING DIAGNOSIS AND
TREATMENT AND THE STRATEGIC GOAL
IS TO PROMOTE FOR NOT TRAINING
AND EDUCATION THAT ADVANCES FOR
HEALTH IN WOMEN AND THE SCIENCE
OF SEX AND GENDER INFLUENCES AND
TO FOSTER WOMEN'S SCIENCES
CAREER DEVELOPMENT.
THERE ARE FIVE OBJECTIVES TO
THIS.
OBJECTIVE ONE AND TWO ADDRESS
HOW TO TRAIN OR SCIENTIFIC
WORKFORCE AND IN PARTICULAR
OBJECTIVE ONE EMPHASIZES
INTEGRATING KNOWLEDGE OF SEX AND
GENDER INFLUENCES AT ALL LEVELS
AND TO ACCELERATE THE
TRANSLATION OF KNOWLEDGE AND
PRACTICE.
OBJECTIVE TWO ENCOURAGES THE
METHODS WITH NEXT GENERATION
RESEARCH AND THE NEXT OBJECTIVE,
ENCOURAGES IC OLYMPICS TO PART
PROGRAMS TO RECRUIT AND RETAIN
AND FACILITATE REENTRY AND
ADVANCEMENT OF ALL STAGES OF
THIS CAREER.
AND POLICIES AND MEASURING AND
COLLABORATIVE NETWORKS AND
ADVANCE WOMEN SCIENCES CAREERS
AND SPECIAL ATTENTION TO UNDER
REPRESENTED POPULATIONS AND
DISABILITY AND AIMS TO TACKLE A
BARRIER THAT HINDER WOMEN
SCIENCES CAREER DEVELOPMENT AND
THROUGH PROPER INNER VISIONS WE
HOPE TO INCREASE WOMEN'S
RECRUITMENT, RETENTION AND
REENTRY THINK THINK FOUR
DEVELOPED THE GOALS AND BASIC
AND TRANSLATIONAL STUDY UNDER
THE BIOLOGY AND INFLUENCEs AND
INTERSECTION IS A DID I SEES AND
HEALTH PRESSURE OVATION ACROSS
THE LIFE COURSE AND THE GROUP
PROPOSED FOUR DIVORCE PONDING
AND THE FIRST RESEARCHES TO
ADVANCE MECHANISTIC BASIC AND
TRANSLATIONAL RESEARCH INTO THE
EFFECT OF SEX AND GENDER OF
BIOLOGY DISEASES AND HEALTH
OUTCOMES ASSESSMENTS.
OBJECTIVES TO IS ENHANCING THE
YEARS OF INVETO IN VIVO AND EX
IN VIVO AND BIO MEDICINE.
OBJECTIVES THREE SUGGESTS THE
RESEARCH ON THE ROLE OF SEX AND
GENDER ON THE INTRINSIC
PROCESSES FOR EXAMPLE SLEEP AND
PAIN AND IN RESPONSE TO STRESS
FACTORS SUCH AS MICROBIOME,
NUTRITION AND TOX OWNS ACROSS
THE LIFE COURS COURSE.
STIMULATE INTRA DISCIPLINARY
SYSTEM APPROACHES WITH
BIOMEDICAL DEMAND SUCH AS
MOLECULAR AND CELLULAR BIOLOGY
TO IMMUNOLOGY.
OUR LAST GROUP THINK-TANK FIVE
PROPOSED THE GOAL ADVANCED
COMMUNITY ENGAGE SCIENCE ACROSS
THE RESEARCH PRACTICE CONTINUUM
AND IMPLEMENTATION OF EVIDENCE
BASED SOLUTIONS O IMPROVE THE
HEALTH.
THERE ARE FIVE OBJECTIVES WITH
THIS GOAL.
ONE AND TWO FOR COMMUNITY
ENGAGEMENT AND TRAINING AND
RESEARCHERS AND PUBLIC-HEALTH
PRACTITIONERS ON IMPLEMENTATIONS
SCIENCE AND METHODS AND
BIDIRECTIONAL LISTENING AND
CULTURALLY AND COMMUNICATIONS
AND AND ENGAGEMENT AND RELATED
TO IMPLEMENTATIONS, BEHAVIORS
AND HEALTH OUTCOMES RELEVANT TO
IMPROVING THE HEALTH OF WOMEN.
AND OBJECTIVES FOUR AND FIVE
SUPPORT EXPANDING
IMPLEMENTATIONS SCIENCE,
TAILORING DELIVERING TO THE
NEEDS OF WOMEN AND INVESTIGATING
AND INTERVENING ON THE MULTI
DIMENSIONAL FACTORS THAT
INFLUENCE SEX AND GENDER
DISPARITIES AND THE HEALTH OF
WOMEN.
WE REALLY APPRECIATE YOUR
ENGAGEMENT AND WOULD NOT BE HERE
WITHOUT YOU HAVING THE DIVERSE
PERSPECTIVE AND CRITICAL SUCCESS
OF THIS AND PORTION PLAN AND EYE
TAL SIZED THE THE TOP OF EACH
LIST FOR EACH THINK-TANK AND WE
HAVE WONDERFUL BROAD
REPRESENTATION ACROSS THE NIH
AND FROM OUR ADVISORY COMMITTEES
AND OTHER FEDERAL PARTNERS.
SO AS WE LOOK AHEAD TO THE 2024,
2028-INCH WIDE STRATEGIC PLAN ON
RESEARCH ON THE HEALTH OF WOMEN
WE'RE INFORMED BY THE CURRENT
STRATEGIC PLAN AND FRAMEWORK
THAT WAS DEVELOPED BY DOCTORS
SHEA AND WE WOULD LIKE TO SHARE
WITH YOU AND MODEL STRATEGIC
PLAN AND IN RESPONSE TOP SHIFTS
IN THE SCIENTIFIC LANDSCAPE AND
UPDATE THE MULTI DIMENSIONAL
FRAMEWORK TO ADDRESS SOCIAL
DETERMINANTS OF HEALTH AND IN
SOCIAL SERIES OF HEALTH AND
HEALTH DISPARITIES AND
BEHAVIORAL AND ENVIRONMENTAL
DRIVERS OF HEALTH.
WE WE WITH LIKE YOUR INPUT AS WE
MAKE ADJUSTMENTS TO THIS MODEL.
TO MAINTAIN A LIFE COURSE
PERSPECTIVE CONSIDERING THE
HEALTH OF WOMEN FROM
PRECONCEPTION TO CAPTURE
GENERATIONAL TRANSMISSION AND
CONTRIBUTIONS, ALL THE WAY
THROUGH AGING.
EXAMPLES OF THE BIOLOGICAL
FACTORS AND SOCIAL AND
ENVIRONMENTAL EXPOSURES ARE
SHOWN HERE.
THESE INCLUDE HEALTHCARE ACCESS
AND EQUALITY, DIFFICULT EXPOSURE
SUCHS RISING TEMPERATURES DUE TO
CLIMATE CHANGE OR CHEMICALS
FOUND IN DRINKING WATER WHERE
YOU LIVE.
MENTAL HEALTH OR THE INTERNAL
DIALOGUE THAT EXPERIENCES HOW WE
GO THROUGH THE WORLD.
LIFE CONTEXT INCLUDING BEHAVIOR
SUCH AS EXERCISE AND NUTRITION
OR NIGHT SHIFT WORK.
SOCIAL AND COMMUNITY CONTEXT AS
WELL AS EDUCATION ACCESS AND
INEQUALITY.
BIOLOGICAL FACTORS SUCH AS A MAA
NATALIE AND PHYSIOLOGY AND
HORMONES AND GENOMIC SOCIAL AND
ENVIRONMENTAL EXPOSURE TO SHAPE
HEALTH As COULD THE LIFE
COURSE OF A WOMAN.
A COMPLEX INTERSECTION OF
MULTIPLE FACTORS AND EXPOSURES
EFFECT THE HEALTH STATUS,
DISEASE PRESENTATIONS, TREATMENT
RESPONSE, AND QUALITIES OF LIFE
FOR WOMEN.
THESE LIFE COURSE INTERACTIONS
OCCUR UNDER THE INFLUENCE OF
INTER GENERATIONAL FACTORS SUCH
AS EXPOSURE TO VIOLENCE, WEALTH
OR ENDOCRINE EXPOSURE CHEMICALS
EX CONSIDERATIONS OF A
THEORETICAL MODEL WILL IMPROVE
THE QUALITY OF WOMEN'S LIVES,
REDUCE THEIR DISEASES BURDEN
ACROSS THE LIFE COURSE AND
ADDRESS HEALTH DISPARITY FROM
POPULATIONS OF WOMEN AT GREATEST
RISKS FOR DISEASE.
I'LL TURN IT OVER TO Dr.
NOURSI TO FINISH US OUT.
>>
>>Samia Noursi: THANK YOU Dr.
CHANDLER AND Dr. McGREGOR.
IN THE NEXT STEPS OF DEVELOPMENT
OF STRATEGIC PLAN WE WILL
EVALUATE THE STRATEGIC PLAN AND
WE WILL DO THAT IN COLLABORATION
WITH VARIOUS ICOs AT NIH AND
WE EXPECT TO RELEASE STRATEGIC
PLAN IN JANUARY OF 2024 AND THE
GUIDE AS I MENTIONED EARLIER,
ABOUT SIX MONTHS LATER.
I'D LIKE TO THANK ALL OF THE
MEMBERS OF OUR ADVISORY
COMMITTEE AND EVERYONE WHO
PARTICIPATED IN THIS PROCESS
FROM NIH AND THE FEDERAL
GOVERNMENT AND WE WILL OPEN THE
FLOOR RIGHT NOW FOR QUESTIONS OR
COMMENTS.
FELL FREE TO USE THE CHAT AND
CAN YOU BRING EVERYONE HOME,
THANK YOU.
WE'D LIKE TO HEAR YOUR COMMENTS
AND YOUR SUGGESTION TO THE
THEORETICAL COMMENTS.
Dr. SIMON WE'LL START WITH
YOU.
>>HI, EVERYONE, THIS IS REALLY
GREAT AND AGAIN, I WANT TO BRING
UP SEX IS A BIOLOGICAL VARIABLE
BECAUSE I REALLY THINK THIS IS
AN IMPORTANT SHOE AND THE TIME
IS RIGHT AND WOMEN'S HEALTH ARE
BEAK A TAGGED WITH AN FDA
UNPRECEDENTED RULING FROM A
JUDGE AND SO I THINK RIGHT NOW
WE HAVE TO PUSH WITH HOW YOU
ADVANCE THE SCIENCE THAT MEANS
THAT CLINICAL HEALTHCARE NEEDS
OF WOMEN IN THIS COUNTRY AND SO,
I WOULD REALLY LIKE, I THINK,
THE STRATEGIC PLAN, THIS IDEA OF
REVISITING THE SABB POLICY FOR
CLINICAL RESEARCH AND BE A PART
OF THE STRATEGIC PLAN AND REALLY
CONSIDERING WHAT I TALKED ABOUT
EARLIER, IN TERMS OF INTER
SEXUALITIES INCLUDING GENDER,
AND SEX AND PERHAPS OTHER
IDENTITIES BECAUSE WE ALL KNOW
THAT RACIAL ETHNIC MINORTIZIED
PERSONS, WOMEN VERSUS MEN, GET
TREATED DIFFERENTLY AND THEY GET
TREATED DIFFERENTLY THAN WHITE
WOMEN VERSUS MEN AND AGAIN
ACROSS THE LIFESPAN, ADOLESCENCE
GET TREATED DIFFERENTLY THAN
PEOPLE IN MIDDLE AGE AND TREAT
VOWED DIFFETREATEDDIFFERENTLY TR
AGE.
THERE'S SEX ADDRESSING, I DON'T
KNOW HOW TO WORD IT WELL AND I'M
HOPING MEMBERS OF THE COMMITTEE
CAN HELP ME TWEAK IT.
IN HIGHWAY BRINGING UP TO THE
STRATEGIC PLAN ADDRESSING SEX IS
A BIOLOGICAL VARIABLE.
>>Samia Noursi: THANK YOU SO
MUCH FOR THAT COMMENT AND
SUGGESTION Dr. SIMON.
WE REALLY VALUE THAT AND AS WE
MOVE FORWARD FROM THE STRATEGIC
PLAN WE'LL BE INCORPORATING
THOSE TYPES OF EFFECT.
ONE THING I WANTED TO POINT OUT
IS THAT WE DIDN'T MENTION IN THE
PRESENTATION IS THAT PART OF THE
STRATEGIC PLAN WILL HAVE MORE OF
A DESCRIPTION OF SOME OF THESE
CROSS-CUTTING AND OVERARCHING
THEMES THAT WE ACCEPTED AS PART
OF RESEARCH ON THE HEALTH OF
WOMEN AND THERE WILL BE A
SECTION ON SEX AND GENDER,
REPRODUCIBILITY AND THINGS LIKE
THAT SO PERHAPS WE'LL BE ABLE TO
ADDRESS YOUR FEEDBACK IN THAT
WAY.
>>Samia Noursi: THANK YOU,
Dr. SIMON.
Dr. ROBINSON.
>>MY QUESTION IS ABOUT THE
CONVERGENCE BETWEEN THINK-TANK 2
AND THINK-TANK 3.
2 WAS REIS SEARCH REGARDING DATA
SCIENCE AND DATA MANAGEMENT AND
THEN THINK-TANK 3 WAS THE
WORKFORCE TRAINING AND EDUCATION
SO I WAS WONDERING IF THERE ARE
SPECIFIC TARGETED EFFORTS TO
MAKE SURE THAT WOMEN ARE
DIRECTED TOWARDS RESEARCH
INVOLVING DATA SCIENCE AND DATA
MODELING, A.I., AND THAT'S NOT
AN AREA WHERE WE ACTUALLY SEE A
LOT OF WOMEN.
IN ADDITION TO MAKING SURE THAT
WOMEN ARE INCLUDED IN THE
RESEARCH, AS SUBJECTS, MAKING
SURE THAT WOMEN ARE ALSO PART OF
THE TRAINING AND THAT THERE'S
SPECIFIC EFFORTS TO PUSH WOMEN
IN THAT DIRECTION.
>>Samia Noursi: YES, YES.
THE ANSWER IS YES.
DEFINITELY.
THIS IS PART OF THE DISCUSSION
THAT PARTICULARLY THE GROUP THAT
WAS FOCUSING ON CARRIER BROUGHT
UP SO THERE WILL BE MORE
DETAILED OF INVOLVED IN THAT THE
DESCRIPTION OF ABOUT WHAT THE
GOAL OR THE OBJECT OF THE THIS
GROUP ARE.
THANK YOU FOR POINTING THAT OUT.
>>THANK YOU.
>>WHAT IS THE STRATEGY FOR
REDUNDANCY OR OVERLAP BETWEEN
THE AREAS BECAUSE I KNOW A LOT
OF REPORTING FOR EXAMPLE WE HAD
SOME CHALLENGES WITH MAKING SURE
THAT THE OBJECTIVES IT'S NOT
REITERATING.
>>SO THAT WAS ONE OF THE TOPICS
WE DISCUSSED WHEN WE MET AS
CHAIRS AND THE CO-CHAIRS MET
TOGETHER IN THE MEETING IF
FEBRUARY AND WE DISCUSSED THAT
BUT WE'LL DEFINITELY AND AS WE
REFINE THE REPORT WE'LL DISCUSS
IT AND MAKE SURE THERE ARE NO
REDUNDANCY ACROSS THE OBJECTIVES
ASSOCIATED WITH EACH ONE OF THE
GOALS AND WE'RE ALSO THE NEXT
STEP WE'RE DOING IS THE PLAN IS
TO ALLOW THE CO-CHAIR TO TO
REVIEW THE SECTION THAT ARE
COMING THAT THE GOALS AND
OBJECTIVE OF EACH GROUP SO THEY
CAN HAVE ANOTHER REVIEW OF THE
REPORT BEFORE IT'S FINALIZED.
>>YES.
>>YOUR WELCOME.
>>Dr. SIMON IS THIS PLEASE.
>>A QUICK ONE.
WHY IS FETUS.
I UNDERSTAND IN THE SENSE OF
IMPACT PREGNANCY AND WHAT FETAL
PROGRAM AND I'M NOT SURE THE O
STRATEGIC PLAN BECAUSE I'M
WORRIED IN SOME SENSE FETUS IS
TAKEN OUT OF CONTEXT FOR THE
POLITICIZATION OF WOMEN'S HEALTH
AND SO I WORRY ABOUT FETUS.
I'M FAMILY PLANNING TRAIN.
>>Samia Noursi: I KNEW THIS
WOULD COME Dr. SIMON SO GOING
TO HAND YOU TO Dr. CLAYTON AND
I THINK WE'LL DISCUSS IT IN THE
PAST.
Dr. CLAYTON WOULD YOU LIKE TO
RESPONDED TO THAT?
>>YOU ARE TALKING ABOUT THE
MULTI DIMENSIONAL FRAMEWORK
UPDATE, IS THAT WHAT YOU ARE
TALKING ABOUT.
>>BECAUSE THE WORK AND IN UTE
UTERO.
>>O, THAT'S WHAT I WORRY ABOUT.
I JUST WORRY ABOUT WHEN WE USE
THE WORD FETUS -- I'M NOT SURE
IF IT'S GOING TOKING WRITTEN
DOWN BUT I WORRY ABOUT POLITICS
ENTERING THE RA EVE THE ARENA.
>>THE MULTI DIMENSIONAL
FRAMEWORK THE ACTUAL LIFE COURSE
LABELS HERE ARE SIMILAR TO THE
PREVIOUS VERSION IF I'M NOT
MISTAKEN SO THE THINKING THERE
IS IT'S IMPORTANT WHEN YOU THINK
ABOUT THE HEALTH OF WOMEN YOU
NEED TO THINK ABOUT EACH OF
THESE STAGES OF THE LIFE COURSE
AS CONTRIBUTING AND AS IT US AND
CONNECTED TO DO YOU HAVE
CONCERNS ABOUT THE FRAMEWORK OR
ARE YOU ENCOURAGING US TO LOOK
AT DOCUMENT THAT THE OBJECTIVES
OR ANOTHER PIECE OF THE
DOCUMENT, MELISSA.
>>I JUST WANT TO MAKE SURE THAT
WHEN WE TALK ABOUT LIFE COURSE
AND IN UTERO AND THING LIKE THAT
THAT WE JUST ARE MINDFUL WE ARE
ABOUT FETUS AND WE NEED TO BE
MIND MANY OF ABOUT HOW WE PUT
OURSELVES IN A POSITION OF
VULNERABILITY WHEN IT COMES
TO -- I WANT FEEDBACK AND I WANT
TO BUCKLE IT UP.
>>Samia Noursi: I WANT TO
RESPOND TO THAT AND MAYBE SOME
KIND OF COLLEAGUES HERE ON THAT
ADVISORY COMMITTEE.
WE STRUGGLED WITH THIS.
WE STRUGGLED OF HOW TO DEPICT,
YOU KNOW, WE CAN'T START AT
BIRTH, RIGHT.
WE CAN'T START AND AT BIRTH.
WE BRING WITH US MANY OF THE
FACTORS THAT HELP TO WHO WE ARE.
IF OUR MOTHER WAS DRINKING, IF
OUR MOTHER WAS USING ANYTHING,
WE BRING OUR GENETICS WITH US SO
WE STRUGGLE WITH HOW DO WE START
AND WE CAN'T START IT AT BIRTH.
SO, WE'RE HAPPY TO HAVE ANY
SUGGESTION THAT YOU MAY TO
ENSURE THAT WE ARE PRESENTING
THE HISTORY OF (INAUDIBLE) US.
>>THIS IS EXACTLY WHY SEX IS A
BIOLOGICAL VARIABLE POLICY NEEDS
TO BE ADDRESSED IN TERMS OF HOW
GENDER, HOW YOU SHOW UP IN THE
WORLD.
AT BIRTH, WHEN YOU ARE
IDENTIFIED OF OR ASSIGNED FEMALE
AT BIRTH YOU ARE -- THAT'S WHEN
YOU START YOUR WOMANHOOD SO TO
SPEAK YOU TEEN TYPICALLY SHOW UP
AT A WOMAN IN THE WORLD AND
THAT'S WHEN THE DISCRIMINATION
AND THE DIFFERENCES I WOULD
ARGUE START.
NOW, NOT THE BIOLOGICAL ALTHOUGH
I WOULD SAY THAT SOME SOCIAL,
THE WAY I SHOW UP SOCIALLY AND
THAT EXPERIENCE OF
DISCRIMINATION OVER TIME WHETHER
IT'S MASSAGE MASS -- THIS IS TD
STUFF.
THIS IS WHAT THIS COMMITTEE AND
THIS OFFICE IS MEANT TO DO TO
ADVANCE THE SCIENCE.
SO THE MINUTE, AT BIRTH, IS WHEN
YOU ARE A WATCH INSIDE THE
UTERUS, YOU ARE A FETUS, YOU ARE
NOT GENDERED.
YOU HAVE OF A SEX, YES, I AGREE
BIOLOGICALLY, BUT WHEN YOU COME
OUT, INTO THE WORLD, AND THEY
SEE YOUR PARTS, YOU ALREADY PUT
A PINK HAT ON.
ON OUR LABOR FLOOR YOU ARE STILL
GIVEN PINK OR BLUE.
YOU ARE ALREADY THEN WITHIN THAT
FIRST MINUTE OF LIFE, YOU GET A
HAT AND YOU HAVE AN IDENTITY AND
YOU ARE SOCIALIZED TO BE A WOMEN
VERSUS MALE.
>>THANK YOU.
WE HAVE FIVE MORE MINUTES AND
I'D LIKE TO GIVE AN OPPORTUNITY
TO Dr. RAG NOTSTEINER AND
OTHERS BUT THIS IS ALL GREAT
CONVERSATION AND WE'LL
INCORPORATE AS WE LOOK AT THIS
AND MAKE ADJUSTMENTS AND WE'LL
START WITH Dr. RAG ANSTEINER.
>>I DON'T KNOW WHERE THE
THINKING COMES IN THIS BUT THE
FETAL ORIGINS OF ADULT DISEASE
WE HAVE TO STUDY THE FEE AT
ORIGINS OF THE ADULT DISEASE AND
THAT HAS AFFECT SEX DIFFERENCES
MAKE A BIG DIFFERENCE IN THAT
ROLE.
I AGREE WITH THIS CHART AS
WRITTEN, EVEN WHEN PEOPLE ARE IN
UTERO.
I THINK THAT'S REALLY AN
IMPORTANT AREA OF STUDY.
I THINK IT'S PART OF THE
EXPERIENCE AND THE WHOLE AREA OF
EPIGENETICS SHOULD BE CONSIDERED
AS WELL.
>>THANK YOU, DOCTOR.
>>I'M CHANGING THE DIRECTION
HERE SO I DON'T KNOW IF Dr.
SUDOSKI WANTS TO GO BEFORE ME.
>>SURE.
>>YEAH, I'M NOT CHANGING THE
DIRECTION I'M STAYING ON IT IT.
I THINK THAT, I MEAN I
UNDERSTAND THE SENSITIVITIES BUT
I DO THINK THAT BIOLOGICAL SEX
IS A DETERMINANT OF GENDER AND
OF COURSE GENDER HAS MANY OTHER
COMPONENTS BUT FETAL SEX
BIOLOGICAL SEX INFLUENCES I ALSO
WANT TO SAY MANY PARTS OF THE
WORLD WOMEN MAY TREAT THEIR
PREGNANCY DIFFERENTLY IF IT'S A
MALE OR A FEMALE.
ESPECIALLY IF THEY WANTED THE
OPPOSITE SEX IS VERY SAD BUT
IT'S A REALITY SO I THINK THAT
MANY COMPONENTS OF FETAL SEX
PRIOR TO GENDER DETERMINATION
AND BIRTH ARE CRITICAL AND ONE
MORE THING IS THAT FETAL SEX
DOES EFFECT MATERNAL HEALTH
DURING PREGNANCY AND MATERNAL
HEALTH IS A KEY PART OF WHAT
WE'RE TALKING ABOUT.
>>Samia Noursi: THANK YOU.
>>I WAS HEADING TO THE OTHER
END OF THE SPECTRUM ON AGING AND
THESE STAND ORDER CATEGORIES
THAT YOU CHOSE HERE BUT WONDERED
STOOD OF ADULTHOOD AND AGING
COULD IT BE EARLY, MID, LATE
ADULTHOOD IN WOULD BE MORE A
CONTINUUM THAN THE WAY IT IS IF
IF THE WAY IT IS SET UP RIGHT
NOW AND THEN JUST A QUICK SIDE
WITH THINK-TANK FIVE, OBJECTIVE
TALKING ABOUT TAILORING NEEDS OF
WOMEN, A GROUP REALLY CAME TO
MIND THAT IS THE MAJORITY ARE
WOMEN OR INFORMAL CARE CURVES SO
I WANTED TO THROW THAT AS A
GROUP THAT HAS A LOT OF CHRONIC
DISEASE AND IT'S IMPORTANT GROUP
AS WE'RE MOVING FORWARD WITH
AGING AND TAKING CARE OF THOSE
WITH DEMENTIA.
SO, I'D LIKE TO THANK EVERYONE
AND THIS WAS GREAT.
IS AREA HAND STILL UP?
YOU ARE DONE.
I'D LIKE TO THANK Dr.
McGREGOR AND THANK Dr.
CHANDLER FOR THEIR EFFORTS
WORKING WITH ME AND LEADING THIS
AND THANK YOU ALL FOR YOUR
CONTRIBUTIONS, WE APPRECIATE ALL
YOUR COMMITMENT TO ENSURING THAT
WE ARE IN THE RIGHT DIRECTION
WITH REGARDS TO THE STRATEGIC
PLAN.
BUT IF YOU DO HAVE ADDITIONAL
COMMENTS THAT YOU DIDN'T HAVE A
CHANCE TO SHARE HERE, PLEASE
REACH OUT TO US, SARAH OR MYSELF
ARE ALWAYS HAPPY TO RESPOND TO
YOUR E-MAILS SO THANK YOU AGAIN.
WE'RE GOING TO MOVE TO HAVE THE
NEXT PART OF OUR MEETING RIGHT
NOW AND LET ME JUST LOOK HERE AT
THE NEXT PART AND THAT IS WHERE
I WELCOME Dr. XENIA TIGNO WHO
IS ASSOCIATE DIRECTOR FOR CAREER
AT ORWH AND SHE WILL BE OUR NEXT
SPEAKER.
PRIOR TO THIS CURRENT POSITION
Dr. TIGNO WAS PROGRAM AT THING
HEART AND LUNG BLOOD INSTITUTE
AND THE NATIONAL INSTITUTE FOR
NURSING RESEARCH AT THE NIH.
SHE HAS PUBLISHED IN THE YEARS
OF BIOPHYSICS OF THE MICRO
CIRCULATION, OWE BEE TEES,
DIABETES, AGING, COMMUNITY BASED
EPIDEMIOLOGY AND PURPLE MEDICINE
AND WOMAN'S HEALTH.
Dr. TIGNO'S CURRENT EFFORTS
ARE DIRECTED TOWARDS SUPPORTING
ADVANCEMENT OF WOMEN IN
BIOMEDICAL CAREERS AND PROMOTING
DIVERSITY OF INCLUSION IN
ACADEMIA.
WELCOME Dr. TIGNO.
>>THANK YOU VERY MUCH Dr.
NOURSI.
GOOD AFTERNOON, LADIES AND
GENTLEMEN.
IT IS MY PLEASURE TO GIVE YOU AN
UPDATE ON THE OLDEST FUNDING
OPPORTUNITY EVER ISSUED BY THE
OFFICE OF RESEARCH ON WOMEN'S
HEALTH.
AND AT THE SAME TIME, ALSO SEEK
YOUR APPROVAL FOR THE NEXT
REISSUANCE OF THIS FUNDING
MECHANISM.
SO THIS REFERS TO ISSUES WAY
BACK IN FIRST-DEGREE 92.
1992 TO ALLOWFULSCIENTISTS, WOMR
THE SCIENTIFIC WORKFORCE AFTER
HAVING HAD AN INTERRUPTION OF
THEIR CAREERS DUE TO RESPONSE
ABILITIES.
SINCE THOSE THAT DROPPED OUT OF
THE WORKFORCE BECAUSE OF FAMILY
CONCERNS, MOSTLY WOMEN, THE
REENTERED PROGRAM WHILE NOT
DISQUALIFYING MEN, WAS MORE
LIKELY TO BE BY WOMEN.
CANDIDATES WHO WISHED TO APPLY
FOR THESE ADMINISTRATIVE
SUPPLEMENTS WERE ASKED TO
IDENTIFY A MENTOR WITH AN NIH
FUNDED RESEARCH PROJECT GRANT
WHO WOULD BE WILLING TO
INTEGRATE THIS CALLER INTO THE
RESEARCH PROJECT AND PROVIDE
RESEARCH TRAINING FOR THE
DURATION OF THE SUPPLEMENT
AWARD.
AS CAN BE SEEN FROM THE SLIDE,
THIS FUNDING OPPORTUNITY HAS
BEEN CONTINUOUSLY REISSUED
THROUGHOUT THE YEARS AND THE
LATEST ONE BEING IN 2021 AND
IT'S PRIOR IN OCTOBER OF THIS
YEAR.
THE REST OF THE PRESENTATION
WILL TOUCH UPON THE ASSESSMENT
WE HAVE PERFORMED PRESENTING
DATA FROM PREVIOUS ISSUANCES AND
SUGGEST MODIFICATIONS TO MAKE
THIS MECHANISM MORE RESPONSE
ITCH AND THE CHANGING CHALLENGES
THAT WOMEN SCIENTISTS FACE.
NEXT LINE, PLEASE.
SO, SINCE THE DATA AND THE NIH
QVR DATABASE DID NOT GO BACK TO
THE 1990s WE MADE FROM 2012 TO
22021.
20 YEARS TO THE PENULTIMATE
ISSUANCE OF 2018 AS PA-18-592.
THE PERSON OF THE FOA IS STATED
HERE.
SOME OF THE INTERRUPTIONS THAT
WERE CONSIDERED AS APPROPRIATE
FOR THIS ADMINISTRATIVE
SUPPLEMENTS, WERE A COMPLETE OR
PARTIAL RESEARCH TECHNIQUES IT
TO THE CHILD BEARING AND CHILD
REARING AND ILLNESS OR INJURY OF
THE CANDIDATE, HIS OR HER
SPOUSE, PARTNER OR A MEMBER OF
THE IMMEDIATE FAMILY.
RELOCATION OF DOCTORAL SCIENTIST
TO ACCOMMODATE A SPOUSE, PARTNER
OR OTHER CLOSE FAMILY MEMBER.
JOB OFFERS THAT WERE RESCINDED
DUE TO NATURAL DISASTERS OR
PUBLIC-HEALTH EMERGENCIES SUCH
AS THE COVID PANDEMIC.
OR EVEN PURSUIT OF NON RESEARCH
ENDEAVORS TO PERMIT EARLIER
REPAYMENT OF DEBT INCURRED IN
OBTAINING THE DOCTORAL DEGREE.
A HIATUS DUE TO MILITARY SERVICE
IS ELIGIBLE.
CANDIDATES WHO ARE IN NON
RESEARCH CAREER AND HAVE HAD NO
PREVIOUS RESEARCH TRAINING ARE
NOT ELIGIBLE TO APPLY.
THESE ADMINISTRATIVE SUPPLEMENTS
PROVIDED PART-TIME OR FULL TIME
SUPPORT TO THE CANDIDATES AS HE
OR SHE UPDATES AND ENHANCES HER
RESEARCH SKILLS WITH THE
EXPECTATION THAT AT THE END OF
THE SUPPLEMENT PERIOD, HE OR SHE
WILL BE COMPETITIVE ENOUGH TO
APPLY FOR INDIVIDUAL K OR RO1
AWARDS.
SHOWN HERE IS THE USAGE OF THIS
SUPPLEMENT AS MENTIONED AND THE
RELATIVE SUCCESS RATE OF
OBTAINING AN AWARD.
THE TOTAL NUMBER OF APPLICATIONS
ARE SHOWN IN BLUE AND THE NUMBER
OF A WARPEDDED APPLICATIONS IN
VIOLET.
ALL AND ALL THERE WERE ONLY 144
APPLICATIONS AND 88 AWARDS FOR A
SUCCESS RATE OF 61%.
BECAUSE THERE WAS NO SEX OR
TENURE DATA IT COULD BE THE QVR
DATABASE FROM THE TRAINEES WE
USED THE SUPPORTING DOCUMENTS TO
DETERMINE THE GENDER OF THE
APPLICANTS AND AWARDEES AND ASK
AND BE SEEN THE MAJORITY THAT IS
80ER OF THOSE APPLIED WERE
IDENTIFIED AS SHEs.
ALSO THE MAJORITY OR 76% WHY
ALSO IDENTIFIED AS SHE.
NEXT SLIDE, PLEASE.
THE DATA FROM 2012 TO 2021
REVEALS THAT 62% OF WOMEN
APPLICANTS CITED CHILD BEARING
AND 27.6% OF CITED THE.
AS FOR CAREGIVING FOR FAMILY
MEMBERS WITH ILLNESS, THIS WAS
MENTIONED 51% OF THE TIME BY THE
HE AND 22% OF THE TIME BY THE
SHE.
PLEASE NOTE HOWEVER IN THIS
CATEGORIES ARE NOT MUTUALLY
EXCLUSIVE.
NEEDING TO SAY YOU CAN CHOSE
MORE THAN ONE AT ANY GIVEN TIME
DURING THE APPLICATION.
APART FROM THE ORWH, 23 OTHER
INSTITUTES CENTERS OR OFFICES
PARTICIPATED IN THE REENTER TREE
SUPPLEMENT PROGRAM AND THEY CAN
BE SEEN FROM THESE SLIDES.
SO MAJORITY OF ALL OF THE
ICOs, THEY HAD SUITABLE
PROJECTS GRANTS THAT COULD APPLY
FOR SUPPLEMENTS WERE INCLUDED.
THE NATIONAL INSTITUTE OF
GENERAL MEDICAL SCIENTISTS OR
NIGMS SHOWED IN GRAY WAS THE IC
WHICH HAD GIVEN THE MOST NUMBER
OF AWARDS.
THIS WAS FOLLOWED BY THE
NATIONAL CANCER INSTITUTE
DEPICTED IN BLUE.
AND MOST SUPPLEMENTS WERE
ATTACHED TO OUR O1 AWARDS SHOWN
IN GREEN FOLLOWED BY SPECIALIZED
CENTER OF GRANTS AND ALSO
R35s.
AS CAN BE SEEN, THERE ARE MANY
THAT ARE ELIGIBLE FOR HAVING
SUPPLEMENTS.
IN 2021, WE MADE SOME CHANGES TO
THE REENTRY SUPPLEMENTS TO
ENABLE ORWH TO ADDRESS OTHER
CONTEMPORARY CHALLENGES FACED BY
WOMEN IN STEM.
AND THAT NOSI WAS PROVED BY THE
ACRWH.
SO THE ISSUANCE OF THE REENTRY
SUPPLEMENT THIS IS 2021 ADDED A
NEW PROGRAM TO ADDRESS THE ISSUE
OF SEXUAL HARASSMENT AND ISSUE
THAT WOMEN SIGNED TO FACE AND
EXTENSIVELY DISCUSSED IN A
REPORT PUBLISHED IN 2020.
IN RESPONSE, ORWH CREATED THE
REINCOMPETENT INAUGURATION
REINTEGRATE AND CHARGE THE ISSUE
BROUGHT ABOUT BY THE REPORT AND
FULFILL THE CHARGE OF THE NIH
ACT WORKING GROUP TO PROMOTE A
SAFE AND INCLUSIVE CULTURE AND
INDIVIDUALS IN TRAINING WHO ARE
EXPERIENCING VARIOUS FORMS OF
DEPRESSION SUCH AS SEXUAL,
RACIAL, GENDER BASED, DISABILITY
BASED, RELIGIOUS BASED AND OTHER
FORMS OF HARASSMENT, WERE
PROVIDED AN EXIT TO RAPIDLY
TRANSITION FROM THEIR
ENVIRONMENT INTO A NEW AND SAFER
ONE THAT WOULD SUPPORT AND
ENABLE THEM TO PURSUE AND
CONTINUE THEIR SCIENTIFIC
PREMIERES.
AND IMPORTANTLY, IN CONTRAST TO
THE REENTRY SUPPLEMENTS,
CANDIDATES FOR THE REINTEGRATION
PROGRAM DID NOT NEED TO BE IN
THE POSTDOCTORAL STAGE.
THEY COULD BE GRANT STUDENTS.
SINCE THE NOTICE IN 2021, TWO
YEARS AGO, WE'VE RECEIVED 22 NEW
APPLICATIONS.
TWO OF WHICH WERE FOR THE
REINTEGRATIONS ON THE LIST.
BOTH OF THESE WERE INTEGRATION
SUPPLEMENT APPLICATIONS WERE
FUNDED.
WHEREAS THE FUNDING RATE FOR THE
PURE REENTRY WAS 13/20 OR 65%.
SOME OF THE REASONS GIVEN FORAY
FLYING FOR THE REENTRY
SUPPLEMENTS ARE SHOWN HERE.
THEY INCLUDE CHILDBIRTH, SPOUSAL
ACCOMMODATION, CAREGIVERS AND
SELF-ILLNESS.
OF NOTE, COVID WAS MENTIONED IN
FIVE OF THE REENTRY SUPPLEMENTS
REQUESTS.
WE ASKED FOR YOUR APPROVAL FOR A
DIDDATIONAL COM POPE ANT TO THE
PREVIOUS VERSION THE MAJOR
CHANGE WILL BE TO OFFER AN
OPPORTUNITY FOR INDIVIDUALS
POSTDOCTORAL EXPERIENCE TO
EXPAND THEIR SKILLS SET SO THAT
UNDER REPRESENTED GROUP,
ESPECIALLY WOMEN IN MID CAREER
STAGES, WILL BE ABLE TO ADVANCE
IN THEIR CAREERS.
ASK AND BE SEEN FROM THE SLIDES,
THE RETRAINING AND RETOOLING
PROGRAM PROVIDES SUPPORT FOR AN
INTENSIVE SUPERVISED IMMERSIVE
EXPERIENCE IN A LABORATORY AND
INSTITUTION, GOVERNMENT
ORGANIZATIONS, NON-PROFIT OR
CHARITABLE ORGANIZATIONS, AND
PUBLISHING HOUSING AND OTHER
FORMS OF SCIENCE RELATED
INDUSTRY AND THE INTENT OF THE
PROGRAM AND TO FACILITATE INTER
DISCIPLINARY PARTNERSHIPS AND
CROSS SECTOR AND COLLABORATIONS
THAT WOULD ENABLE THE CALLER TO
ACQUIRE SPECIALIZED SKILLS AND
NOVEL PERSPECTIVES THAT COULD
PROVIDE MOMENTUM TO THEIR
CAREERS AND NEXT SLIDE.
SO WHY ARE WE DOING THIS?
WHY IS THERE A SNEED OF THIS
COMPONENT AND SCIENCES IN 2020
IN THEIR REPORT PROMISING
PRACTICES FOR ADDRESSING UNDER
REPRESENTED VERY WOMEN AND IN
SCIENCE AND ENGINEERING OPENING
DOORS AND AND RELATIVE TO BE
LOWER AT HIGHER AK RAIZATION AND
DOCTOR BLOOD SCIENCES AND THEY
ARE UNDER REPRESENTED AND THE
ASSOCIATE RANKS BY MORE THAN 40%
AND TRUE AND IT'S ALSO REPORTED
MANY MID CAREER WOMEN TO NOT
ADVANCE IN THEIR CAREER OR DROP
OUT OF THE BIOMEDICAL RESEARCH
AND IN THE TECHNOLOGY AND
ARTICLE ESTIMATES WHILE WOMEN
MAKE UP 57% OF THE OVER ALL
WORKFORCE THEY ONLY MAKE UP 27%
OF THE TECHNOLOGY INDUSTRY.
AND THAT WOMEN REPRESENT AND
QUARTER OF COMPUTER WORKERS AND
50% OF THOSE ENGINEERING
OCCUPATIONS.
IN MORE RESEARCH REPORT ON THE
IMPACT OF COVID-19 AND ON THE
CAREER OR WOMEN AND ACADEMIC
SCIENCE AND ENGINEERING AND ALSO
ARGUED THAT THE THEY HAVE
REDUCED MORE GENDER IN EQUITABLE
AND AND LEADING TO FURTHER
ISOLATION THE WOMEN WITHIN THEIR
FIELDS NETWORKS AND COMMUNITIES
FURTHERMORE, THE ORWH SPONSORING
PARTNERSHIP SUMMIT REIMAGINING
WOMEN IN THE BIO ENGINEERING
TECHNOLOGY AND DATA SCIENCE AND
THE SYSTEM WHICH WAS HELD LAST
YEAR IN MAY AND HIGHLIGHTED THE
CAREER PATHS AND INSTEAD AND
RIVERS INSTEAD OF A STRENGTH
PIPELINE AND THAT CROSS SECTOR
CAN CREATE ECOSYSTEMS IN WHICH
ALL SCIENTISTS ENGINEER AND
INNOVATORS, PROBLEM SOLVERS AND
LEADERS AND THE SUMMIT IT WAS
NOTED AND CROSS SECTOR
OPPORTUNITIES I NEEDED TO FOSTER
DIVERSITY AND EMPLOYMENT AND
HELPS ROW GAIN SCIENTISTS
PARTICULARLY WOMEN, IN RESEARCH.
THE RETOOLING PROGRAM IS HELP
MITIGATE THE RISK OF WOMEN
LEAVING STEM PROVIDING A SAFE
AND COLLABORATIVE SPACE BY WHICH
TO RETAIN WITHOUT FEAR OF LOSING
THE SOURCE OF EMPLOYMENT IT MAY
BE THREE MONTHS TO A NEARBY NIH
WILL PROVIDE A STIPEND
CORRESPONDING TO THE NUMBER OF
MONTHS SPENT IN TRAINING THE
BUDGET LIMITS ARE 90,000 A YEAR
AND AN ADDITIONAL 50,000 PROGRAM
RELATED EXPENSES.
IN ALL CASES, THE TRAIN
EXPERIENCE MUST HAVE THE
POTENTIAL TO CONTRIBUTE
SIGNIFICANTLY TO THE RESEARCH
CAREER DEVELOPMENT OF THE
CANDIDATE AND EXPAND HIS OR HER
NETWORK AND FOSTER INNOVATIVE
THINKING.
IT'S A FULL PARTICIPANT IN THE
RESEARCH PROJECTS AND GIVEN AN
OPPORTUNITY TO UM DATE AND
ENHANCE AND ALLOWING THEM AND
RESURRECTING THE CAREER
PRODUCTIVE COMPETITIVE
INVESTIGATOR AND IT WILL HAVE A
CHANCE TO EXPERIENCE A VARIETY
OF SCIENTIFIC CAREER OPTIONS
INCLUDING RESEARCH, INDUSTRY,
SCIENCE POLICY AND
ENTREPRENEURSHIP, SCIENCE
COMMUNICATION, REGULATORY
AFFAIRS, CONSULTING, DRUG
DISCOVERY, PATTERNS, REOPEN
ADMINISTRATION AND GOVERNMENT AS
WELL AS IN OTHER FUNDING
AGENCIES.
TO ENABLE THIS FOR THIS FUNDING
MECHANISM HAS BEEN EXPANDED TO
INCLUDE THOSE WHICH SUPPORT
TECHNOLOGY DEVELOPMENT AND AS
ALWAYS, TRAINING FOR ARE
ENCOURAGED ARE ENCOURAGED TO
APPLY.
AND THE RETAINING AND RETOOLING
ARTIST AND FROM THE OTHER TO
COMPONENTS 69 SUPPLEMENTS IN
THAT THE SUPPLEMENTS CALLER WILL
BE ENGAGE IN THE LAB OR
ENVIRONMENT DISTINCT FROM THEIR
CURRENT PLACE OF WORK.
THE IDEA IS WHERE THE TRAINING
CAN CROSS CENTER AND RETAINING
THE CURRENT POSITION.
FOR EXAMPLE, AN ASSOCIATE
PROFESSOR WHO IS A NIH FUNDED
MAY OFF TO IMMERSE OURSELF IN A
DRUG COMPANY EXPERIENCE FOR
THREE MONTHS AND DURING WIND
CHILL FOR THE THREE MONTH SALARY
AND PLUS, PROVIDES RESEARCH
FUNDS OF AROUND $50,000 AND FOR
HER INITIAL START UP OF EYE NEW
PROJECT.
WE DECIDE TO RETURN TO HER
UNIVERSITY WITH ADDED SKILLS AND
POTENTIAL NEW PROJECT THAT WILL
ENABLE HER TO OBTAIN A
SUBSEQUENT RO1 AND BE PROMOTED
AT HER CURRENT UNIVERSITY.
SIMILAR LEANNE INDUSTRY BASED
SCIENTIST MAY OPT TO JOIN AN NIH
FUNDED INVESTIGATORS LAB FOR A
PERIOD OF TIME TO LEARN MU
TECHNIQUES WHICH COULD BRING
BACK HER JOB AND IMPROVE HER
CHANCES OF CAREER ADVANCEMENT.
IT WILL ALSO ASSIST AND THE
MENTOR TO GAIN NEW PERSPECTIVES
FROM INDUSTRY AND THE
ESTABLISHED NEW CONNECTIONS AND
FORGE NEW PARTNERSHIPS.
THIS CROSS SEC ACTUAL
COLLABORATION CAN HELP BRIDGE
SILOS, CROSS POLLENATE
SCIENTIFIC IDEAS, GENERATE NEW
ONES AS WELL AS FROM DIVERSITY
AND EQUITY IN THE WORKFORCE.
NEXT SLIDE, PLEASE.
THE THREE DIFFERENT SUPPLEMENT
ARMS HAVE ELIGIBILITY CRITERIA
AND THEY MENTIONED ARE PRIMARILY
INTENDED FOR EARLY SCIENTISTS IN
THE POSTDOCTORAL FACE.
THE REINTEGRATION SUPPLEMENTS
AND STUDENTS WHEREAS THE NEW
RETRAINING SUPPLEMENTS ARE EARLY
AS WELL AS MID CAREER SIGNISTS
ESPECIALLY THOSE WHO HAVE NEVER
RECEIVED OR ARE CURRENTLY NOT
RECEIVING ANY PROJECT WORK.
THEY'RE OPEN TO SCIENTISTS OR
NOT IN THE FIRST OF ALL THEY
HAVE HAD REACH SEARCH EXPERIENCE
WITH TWO YEARS OF THE
POSTDOCTORAL TRAINING.
WE ARE ASKING YOUR APPROVAL FOR
THE RENEWAL OF THE INCOMPETENT
INAUGURATION SYSTEM PROGRAM
TOGETHER WITH A NEWLY ADDED
RETRAINING SUPPLEMENTS PROGRAM.
WE ALSO ASKED YOUR HELP IN
ADVERTISING THE OPPORTUNITIES TO
YOUR NETWORK AND YOUR RESEARCH
COMMUNITY.
YOU ARE PROBABLY IN THE BEST
POSITION VICTIMS WHO MAY BENEFIT
FROM THESE PROGRAMS WHICH ARE
INTENDED TO FOSTER THE REENTRY
AND RETENTION AND AND A
TRANSFORMATION AND
INFIGURIZATION OF THEIR CAREER.
THANK YOU, VERY MUCH.
I'M HAPPY TO ANSWER THE
QUESTIONS.
>>THANK YOU DOCTOR.
WE HAVE TIME FOR QUESTIONS HERE
BEFORE WE TAKE A VOTE.
PLEASE UTILIZE THE CHAT IF IT'S
MORE COMFORTABLE AND I'M SURE
THE DOCTOR MAY ANSWER THE
QUESTIONS THAT YOU MAY HAVE.
Dr. ANDERSON.
>>YOU ARE ON MUTE, Dr.
HANDSER SON.
>>THANK YOU.
YOU THINK I WOULD KNOW AFTER
THIS MANY YEARS.
THIS A GREAT PROGRAM I WASN'T
AWARE OF IT BEFORE AND IT'S
FANTASTIC AND I WOULD LOVE TO
OFFER IT TO SOME OF OUR FACULTY
WHEN THEY'RE ELIGIBLE.
CAN YOU TELL ME A FOLLOW-UP ON
THE ORIGINAL RECIPIENT OF IT
GRANT AND HOW WELL THEY HAVE
REENTERED THE WORKFORCE AND
THEIR SUCCESS THERE.
>>YES, SO WE'RE IN THE PROCESS
OF EVALUATING, AS WE MENTIONED,
WE CON OBTAIN ALL OF THE DATA
FROM WAY BACK IN THE 1990s SO
WE JUST OPTED FOR THOSE 10 YEARS
FROM 201 TO 2018 GRANTEES WHICH
INCLUDED UP TO 2021 AND IT'S
REALLY VERY DIFFICULT TO TRACE A
TRAINEE BECAUSE THEY ARE NOT
INCLUDED IN THE QER AS
INDIVIDUALS.
THEY ARE UNDERNEATH THEIR
MENTORS AND SO EVEN UPON
REQUEST, FROM THE DATA WORKING
GROUP AND OER, WE GET THE DATA
ABOUT THE MENTOR BUT NOT THE
TRAINEES AND BECAUSE THE
TRAINEES HAVE NAMES WHICH MAY BE
SIMILAR, TRACING THEM IS REALLY
BEEN VERY DIFFICULT TASK FOR OUR
COLLEAGUES HERE AT THE CAREER
CENTER WHERE WE HAVE TO GO TO
GOOGLE AND LinkedIn AND SEE
WHERE WHEN LOOK AGAIN BUT IT'S
VERY DIFFICULT TO HAVE A WAY
ESPECIALLY IF YOU HAVE THE SAME
NAMES.
SO I THINK NIH IS TRYING ITS
BEST NOW TO BE ABLE TO FOLLOW
THEIR TRAINEES BY HAVING THEM
HAVE AN ORCHID OR THIS I.D. BUT
IT'S NEW TO THE SYSTEM SO WE
HAVE NOT BEEN ABLE TO AVAIL THAT
FOR THESE PAST TRAININGS.
BUT WE DID GET A GOOD LETTER
RECENTLY IN FACT FROM ONE OF THE
NIDDK AWARDING SAY HOW HAPPY SHE
WAS THAT SHE OBTAINED THE
SUPPLEMENT AND IT HAD ACTUALLY
REVIVED HER CAREER AND WE THOUGH
SHARE THAT IN THE FUTURE INFO OF
THIS ISSUE.
THANK YOU.
>>Samia Noursi: Dr.
McGREGOR AND WE HAVE ANOTHER
QUESTION IN THE CHAT SO WE'LL GO
WITH Dr. McGREGOR.
>>ACTUALLY TEMPLETON TYPED MY
EXPECT QUESTION.
SO SOMEONE IS AVAILABLE TO
QUESTION SCIENTISTS AS WELL OR
JUST POSTDOCS.
>>CLINICIAN SCIENTISTS ARE
POSTDOCS AND WHO SO THEY ARE
ELIGIBLE.
SPECIFICALLY FOR REENTER
FORECAST THEY LET THE CLINICAL
SPACE FOR A BED?
>>SURE FOR AS LONG AS THEY HAVE
A DOCTORAL DEGREE EX THEY'RE
CURRENTLY NOT EMPLOYED IN
RESEARCH AND THEY COULD BE
EMPLOYED IN SOME OTHER
PROFESSION IT'S NOT A RESEARCH
CAREER.
MAYBE THEY HAVE ADDITIONAL.
>>NO, I APPRECIATE ABOUT THAT
AND SO WHAT I IT HAD TYPED IN
THE COMMENTS IT'S CLINICIAN
SCIENTISTS WHICH WE KNOW ARE
RARE BREEDS AND WE NEED MORE OF
THEM IN MY PERSONAL OPINION,
IT'S NOT JUST FUNDING TO GET
THEM BACK AND GET THEM RESTARTED
ON THE RESEARCH ASPECT OF THEIR
CAREER BUT IT'S REENTRY OF THE
CLINICAL SIDE OF THEIR CAREER
AND IT IT HAS ITS OWN SET OF
CHALLENGE AND CAN BE INCREDIBLY
EXPENSIVE AND THERE ARE PROGRAMS
FOR PHYSICIANS WHICH ONE ABOUT
$20,000 IF YOU WANT IT ON
AVERAGE IF IF YOU WANT TO GET
BACK TO CLINICAL WORK SO, CAN
ANY OF THIS FUNDING BE USED FOR
THE CLINICAL SIDE OF THEIR WORK
AND IF NOT ARE THERE WAYS IN
WHICH WE CAN START LOOKING AT
THAT?
BECAUSE YES, WE NEED TO SUPPORT
THE RESEARCH SIDE BUT IF THE
CLINICAL SIDE ISN'T SUPPORTED IT
WILL BE HARD TO BRING BACK
CLINICIAN SCIENTISTS BACK IN THE
WORKFORCE.
>>THANK YOU FOR BRINGING THAT
UP.
THAT WAS NOT IN OUR RADAR SO TO
SPEAK.
IT'S WORTH THINKING ABOUT.
THIS IS FOR RESEARCH RATHER THAN
SUPPORT.
THERE'S ANOTHER COMMENT AND IT'S
CHALLENGING TO FIND INDIVIDUALS
WITH COMMON NAMES O SHE'S GLAD
THAT THE ORCHID I.D. IS MOVING
FORWARD.
>>YEAH.
>>THANK YOU.
>>DO YOU HAVE ANY QUESTIONS?
OKAY WITH THAT I WOULD LIKE TO
TAKE TIME TO VOTE TO APPROVE THE
REENTRY AND REINTEGRATION AND
RETRAINING SUPPLEMENTS CLEARANCE
IS THERE A MOTION ON THE TABLE
TO APPROVE THE REENTRY AND
REINTEGRATION AND RETRAINING
SUPPLEMENTS CONCEPT CLEARANCE?
>>I MAKE A MOTION.
>>Samia Noursi: WHO WAS THAT?
>>Dr. REGULARRENSTEINER.
>>DO I HAVE A SECOND.
>>I'LL SECOND.
>>Dr. SIMON SECONDED THE
MOTION.
THE POM IS OPEN TO RESTART IF
APPROXIMATE YOU ARE IN FAVOR
OPPOSED OR OBTAINED AND PLEASE
AND YOU HAVE 0 SECONDS.
TO RESPOND.
>>THANK YOU.
SARAH DO WE HAVE THE VOTES?
>>YES, WITH 14 IN FAVOR.
>>THANK YOU.
THE REENTRY REINCOMPETENT
INAUGURATION AND RETRAINING
CLEARANCE HAS BEEN ACCEPTED WITH
14 IN FAVOR.
THANK YOU EVERYONE FOR THE
DISCUSSION FEEDBACK AND VOTING.
I WOULD LIKE TO WELCOME BACK
LISA BEGG FOR OUR NEXT
PRESENTATION.
OVER HER CAREER, HE HAS WORKED A
SO I SENIOR SCIENTIST AND
EDUCATOR WITHIN THE FEDERAL
GOVERNMENT AND RESEARCH SETTINGS
AND SINCE JOINING THE NIH, HE
HAD DEVELOPED IMPLEMENTED AND
MANAGED SEVERAL LARGE EXTRAMURAL
RESEARCH AND ORWH AND Dr. BEGG
WORKS ACROSS ICOs TO DEVELOP
AND ENHANCE A VARIETY OF
INITIATIVES AND WOMAN'S HEALTH
AND SEX GENDER DIFFERENCES
RESEARCH AND INCLUDING FEDERAL
WIDE RESEARCH AND INITIATIVES
AND Dr. BEGG OVERSEES THE PIR
MUCH PROGRAM IT WAS CREATE AID
GRANT PROGRAM AND WELCOME LISA
BEGG.
>>THANK YOU SO MUCH AND GOOD
AFTERNOON TO EVERYONE AGAIN AND
IT'S MY PLEASURE TO COME BEFORE
YOU TO PRESENT A FEW SLIDES
APPROXIMATE TO GIVE YOU
BACKGROUND AND REQUEST YOUR
APPROVAL FOR THE CONCEPT
CLEARANCE FOR ITS BEING TITLED
THE FY21 BIRCH PROGRAM
ADMINISTRATIVE SUPPLEMENTS AND I
CAN HELP THE NEXT SLIDE, PLEASE.
TO GIVE FOLKS A LITTLE
BACKGROUND BECAUSE SOME PEOPLE
ARE MORE AWARE OF THE PROBLEM
THAN OTHERS, I INVITE YOU TO GO
TO OUR WEBSITE THE ORWH HOME
PAGE AND THIS IS SCREEN CAPTURE
OF IT AND YOU CAN SEE THAT
THERE'S A BACKGROUND AND THE
PROGRAM WAS CREATED BY CONGRESS
IN 2000 SO IT'S 23 YEARS AND
THRIVING SO TO SPEAK TO WE'RE
VERY PLEASED IT AND THERE'S A
LOT OF INFORMATION AND WE HAVE
19 ACTIVE PROGRAMS EACH OF THEM
HAVE THEIR OWN WEB SITES AND
THEY CAN GO ON THEM SPECIFICALLY
AND WE HAVE ARCHIVED THE VARIOUS
ANNUAL MEETINGS THAT ARE HELD IN
LATE FALL EACH YEAR AND ARE
INTENTED TO HELP PROMOTE
MENTORING AND COLLABORATION
ACROSS THE 19 PROGRAMS OF THE
PIs AS WELL AS THE SCHOLARS
AND NIH STAFF SO IF I COULD HAVE
THE NEXT SLIDE.
SO TO GIVE A IS SUMMARY AND THE
ADMINISTRATIVE SUPPLEMENT CAME
FROM AND ORWH IS UP TO
$15 MILLION A YEAR AND OUR
DIRECTOR Dr. CLAYTON MENTIONED
WE'RE GETTING IN FY22 AND FY23
ADDITIONAL FUNDING FOR THE BIRCH
PROGRAM AND IT'S BECAUSE IT'S
ACTUALLY BEEN HIGHLY EFFECTIVE
SO IT'S NOW $15 MILLION A YEAR
AND I LISTED THE NINENS TO USE
THE AND CENTERS AND THAT HAVE
BEEN CO PARTNERS WITH US AND THE
23 YEARS AND SOME CONTINUES FOR
ALL 23 YEARS AND OTHERS HAVE IN
AND OUT DEPENDING ON THEIR
MISSION AND OR PRIORITY SETTING
AND NEXT SLIDE, PLEASE.
HERE IS A MAP AND WE'RE QUITE
PLEASED WITH THIS BECAUSE IT'S
WELL AND DISTRIBUTED ACROSS THE
COUNTRY AND WE HAVE 19 ACTIVE
PROGRAMS IN THE DARK TOOL WOULD
BE DESCRIPTION OF THE COLOR AND
MINNESOTA HAS TWO BIRCH PROGRAMS
AND UNIVERSITY OF MINNESOTA AND
MAYO CLINIC AND CALIFORNIA HAS
TWO PROGRAMS AND UCSF AND UC
DAVIS AND THEY HAVE TWO
PROGRAMS, HARVARD AS WELL AS
TUFTS AND THEN THERE'S WITHIN
PROGRAM IN EACH OF THE OTHER
STATES.
THEY ARE SO VERY PLEASED WITH
THAT AND THE MECHANISM IS A K-12
SO IT'S AN INSTITUTIONAL CAREER
DEVELOPMENT AWARD.
THE PROGRAM IS A ORIGINALLY
FUNDED IN 2000 WITH AN RFA AND
THERE WAS THE SECOND RFA IN 2002
AND EACH FOR FIVE YEARS AND EACH
ONE OF THOSE RF ANTI-SEMITISM
HAVE BEEN REISSUED AND SO IT'S
BEEN CONTINUOUSLY FUNDED OVER
THE 23 YEARS AND 19 ACTIVE
AWARDS AND THERE'S BEEN ACTUALLY
A TOTAL OF ABOUT 42 INSTITUTIONS
WHO HAVE RECEIVED GRANTS OVER
THE YEARS AND THESE ARE HIGHLY
COMPETITIVE AND RENEWAL SO IT'S
DIFFICULT FOR PROGRAMS TO
MAINTAIN BUT THE CURRENT BLOCK
WE HAVE NOW IS HIGHLY SUCCESSFUL
AND FOR THE CURRENT RFAs WE
HAVE CO PARTNERS FROM NIAAD AND
NIAAA AND NICHD AND NCI AND
NAIDA AND WE HAVE 12 OF THE
MULTI PEIs WORE SEEING IT NOW
IN ELSE IT OF THE SCIENTIFIC
TEAMWORK AND 14 OF THE 19
PHYSICIAN-SCIENTISTS AS PIs
SOL OR OR WITHIN THE MULTI PI
AND WE HAVE LAST COUNT 750
SCHOLARS SINCE 2000 AND 88% HAVE
STAYED IN RESEARCH AND 42% ARE
PHYSICIANS SCIENTISTS.
AND 80% OF THE SCHOLARS ARE
WOMEN AND 20% OF MEN AND THAT
HAS BEEN PRETTY STABLE OVER THE
FULL 23 YEARS AND NEXT SLIDE,
PLEASE.
IN TERMS OF THE ACTUAL NOSI
WE'RE ASKING FOR APPROVAL FOR
THE CONCEPT CLEARANCE THIS IS
CONSIDERED AN ADMINISTRATIVE
SUPPLEMENT TO THE PARENT K-1s
WE DID THIS YACHT L'ISLE-VERTE
WITH THE CONGRESSIONAL FUNDING
AS WELL AND WE DIDN'T HAVE TO EX
TO YOU LAST YEAR BECAUSE IT WAS
AN RFA ROUND SO THE APPROVAL WAS
GRANTED AS PART OF THE RFA PLAN
AND APPROVAL OF THOSE
APPLICATIONS.
THE BUDGET LIP ITS THIS YEAR ARE
SLIGHTLY DIFFERENT THAN PREVIOUS
DREAD COST OF $90,000 A YEAR
FROM NIH FUNDS FOR EACH GRANTEE
AND SO WE HAVE ENOUGH SUFFICIENT
MONEY FOR EACH OF THE 19
PROGRAMS THAT HAVE ONE OF THESE
TRAINEE AND THAT INCLUDES A
MAXIMUM OF NIH FUNDS OF 65,000
AND CAN BE AUGMENTED BY THE
INSTITUTES IN CASE IT THIS WOULD
MAKE THEM MORE COMPETITIVE IN
TERMS OF RECRUITING AN
APPROPRIATE TRAINING AND SAME
WITH THE 25,000 SO WE'RE
ALLOWING 90,000 DIVIDED 65 AND
25 BUT IT CAN'T BE AUGMENTED AND
PER NIH POLICIES THESE ARE 8% IN
DIRECTION COST FOR EACH AWARDS
AND IT'S ONLY OPEN TO THE 19
ACTIVE BIRCH PROGRAMS AND AGAIN
BECAUSE THIS IS ADMINISTRATIVE
SUPPLEMENT TO THEM AND THERE'S A
TRAINEE ELIGIBILITY IN TERMS OF
BEING A U.S. CITIZEN OR A NON
CITIZEN NATIONAL AND IN THE
UNITED STATES YOU CAN SEE WE
ALSO REQUIRED TO ENCOURAGE AND
WORE PLEASED WITH THE TYPE OF
RECRUITMENT THAT IS HAPPENING IN
TERMS OF RECRUITING CANDIDATES
WHO ARE REPRESENTING POPULATIONS
AND FOR THOSE WHO MEET THE
DEFINITION AND DISADVANTAGED SO
THAT IS THERE BUT NOT A
REQUIREMENT.
NEXT SLIDE, PLEASE.
THE REASON WE'RE COMING TO YOU
NOW IS FUNDING CAME OUT OF THE
OMNIBUS BILL SIGNED BY PRESIDENT
BIDEN BEFORE CHRISTMAS AND THESE
FUNDS HAD TO BE COMMITTED IN
ORDER IN FY23 AND CAN BE DONE
OVER WITH YOUR APPROVAL TODAY
AND NUMBER OF TRAINEES AS WE
SAID 19 TRAININGS AND TOTAL ONE
PER PROGRAM IF THE REMEMBER LAGS
TO APPLY AND THAT'S GIVEN AND WE
ARE GIVEN EVERYONE THE
OPPORTUNITY AND LAST YEAR ALL 19
PROGRAMS DID ADD A NEW LAST YEAR
CASE OF SCHOLARS.
WHEN THE APPROVAL OBTAINED AND
PUT THE NOTICE OF SPECIAL
INTEREST IN THE NIH GUIDE SO
THAT IT WILL HOPEFULLY COME OUT
IN THE NEXCOM OF WEEKS AND WE'RE
REQUIRED TO ALLOW 30 DAYS FOR
APPLICATIONS TO COME IN AND
THESE ARE CONSIDERED NOT
COMPETITIVE AND ADMINISTRATIVE
SUPPLEMENTS AND THERE IS AN
INTERNAL NIH REVIEW TO WORKING
DILIGENCE EX MAKE EVERYTHING IS
IN ORDER AND FOR THE K12 AND THE
NEXT SLIDE IS THE CLOSING ONE.
I WOULD BE HAPPY TO TAKE ANY
QUESTIONS OR COMMENTS AND THEN
HOPEFULLY AT END THE GUIDANCE
AND SHE WILL TAKE A VOTE AND I'M
OPEN FOR QUESTIONS OR COMMENTS.
>>Samia Noursi: THERE'S A
COMMENT IN THE CHAT.
FROM Dr. SIMON.
>>OKAY.
>>Samia Noursi: WOULD YOU LIKE
US TO READ IT?
>>I'M JUST WONDERING IF ANY
PROGRAMS ARE HBCUs OR
FEDERALLY DESIGNATED MINORITY
SERVING INSTITUTIONS.
>>THANK YOU FOR THAT QUESTION.
OF THE 19, I BELIEVE THERE'S
EIGHT PROGRAMS THAT HAS
COLLABORATION WITH AN HBCU OR
MINORITY SERVING INSTITUTION OR
TRIBAL HEALTH SO WE HAVE OVER
THE YEARS REQUIRING IT AND WE
HAVE ENCOURAGED AND HELPED
FACILITATE RECRUITMENT OF
CANDIDATES AND SCHOLARS SO WHOA
THINK ANY OF THE 19 IS A PRETTY
DECENT AMOUNT AND I WOULD BE
HAPPY TO TALK WITH YOU OFF LINE
IF YOU HAVE ANY QUESTIONS AND WE
DO CONSIDER THAT VITALLY
IMPORTANT.
ABSOLUTELY.
>>CAN THIS BE A POSTDOC, NOT
ONLY FACULTY.
>>YES, THE WAY IT'S CLIN ON
YOUR POSTDOCTORAL TRAINING WE
TRIED TO KEEP IT SOMEWHAT
GENERAL BECAUSE AGAIN WE KNOW
THAT THIS IS SHORT TIME TO FIND
PEOPLE AND SO FOURTH AND SO,
YES, IN TERMS OF POSTDOC, WE'RE
HOPEFULLY AN INSTRUCTOR LEVEL
BUT YES, THE WAY IT'S WORDED,
HOPEFULLY IT WILL BE REASONABLE
FOR THE PIs TO WORK WITH.
>>ANY COMMENTS OR QUESTIONS?
WE HAVE TIME FOR MORE QUESTIONS
IF THERE ARE ANY.
>>I HAVE A QUESTION.
>>YES, PLEASE.
>>SO, WE WOULD LOOK, AS A BIRCH
PI WOULD LOOK FOR THE SECOND
YEAR OF THEIR POSTDOCTORAL
TRAINING AND WITH THAT
TRANSITION ONTO THE FACULTY AND
SO THE WAY THAT WE'RE TRYING TO
BE CAREFUL WITH THE WORDINGS
BECAUSE LAST YEAR AND IT WAS A
STRAIGHT FORWARD AND A FOURTH
SCHOLAR SO ALL THE DEFINITIONS
AND THE RFA AND THIS YEAR
BECAUSE OF A REDUCED LEVEL OF
FUNDING AVAILABLE AND BY THE WAY
THIS IS ONLY ONE YEAR AND WE'RE
TRYING TO BE RESPONSIVE TO THE
CONGRESSIONAL INTENT AND NEW
CANDIDATES BUT, I THINK PROBABLY
THE WAY TO DESCRIBE IT WOULD BE
SOMEONE WHO WOULD COME ON THIS
YEAR AND BE ELIGIBLE OR
COMPETITIVE FOR CONSIDERATION
FOR A FULL SCHOLAR IN A
SUBSEQUENT YEAR.
SO, I HOPE THAT'S HELPFUL.
>>IT'S EXCELLENT.
Dr. BEGG IT'S EXCITING THE
BIRCH IS GETTING SO MUCH
SUBPOENA OR THE AND I'M THRILLED
TO HEAR IT AND I'M JUST TRYING
TO MAKE SURE I CARRY OUT THE
RIGHT CONCEPT.
>>ONE OF THE REASONS IT'S ONLY
FOR ONE YEAR AND WE RECOGNIZE
THAT THESE PROGRAMS ARE
TIME-CONSUMING AND DIFFICULT AND
COMPLEX IMPLEMENT AND SO THE
ORIGINAL FUNDING AND THE
ORIGINAL DESIGN WAS ALWAYS FOR
THREE SCHOLARS AND SO THE FOURTH
WAS ADDED LAST YEAR AND NOW
WE'RE ADDING A FIFTH TRAINING AS
WE SUB THIS PERSON SO WE
RECOGNIZE IT'S INCREASED
ADMINISTRATIVE BURDEN AND
COMPLEXITY SO WE THOUGHT WE
WOULD MOVE THIS FORWARD AND
SECURE THE ADDED TRAINEES AND
THEN BE ABLE TO REDESIGN AND
TAKE INTO CONSIDERATION THE
EXTRA WORKLOAD AND ON THE P.I.
AND THE LEADERSHIP GROUP SO THIS
PERSON WOULD NOT BE A BIRCH
SCHOLAR?
>>WE DON'T THINK SO BECAUSE
IT -- NUMBER ONE THERE ISN'T
FUNDING FOR THAT AND ON THE
AVERAGE, AND THE P.I.s EX
THOSE ARE FAMILIAR WITH THE
PROGRAM AND ASSISTANT PROFESSORS
THESE ARE HIGHLY COMPETITIVE AND
THEY AVERAGE 190,000 A YEAR PER
SCHOLAR BECAUSE YOU NIH DOES
REQUIRE A MAXIMUM OF $100,000
FOR DIRECTION SALARY AND THAT
CAN BE AUGMENTED BY THE
INSTITUTION IN MANY TYPES IT IS
AND FRINGE BENEFITS AND WE
FIGURE THAT TO BE 33,000 AND ADD
50,000 FOR RESEARCH SUPPORT PER
YEAR AND THEN THE 8% GETS UP TO
190 TO 200,000 SO THESE ARE
VALUABLE TRAININGS BUT THEY'RE
EXPENSIVE, SO, OUR THOUGHT WAS
THAT AT LEAST GET THE PIPELINE
GOING HERE AND THEN BE ABLE TO
REGROUP IN FY24 AND BEYOND.
Dr. McGREGOR DO YOU WANT TO
ASK YOUR QUESTION.
FEEL FREE TO ASK YOUR QUESTION.
>>IT'S SPECIFIC TO THE BIRCH.
IS THERE SPECIFIC FUNDING TO
SUBPOENA OR THE ANY DELAYS DUE
TO THE PANDEMIC?
>>WELL, WHAT HAPPENED IS WE
WERE AND THIS WAS WHEN THE
PANDEMIC CAME OBVIOUSLY Dr.
COLLINS WAS OUR DIRECTOR AND DR.
TABAK HAS CONTINUED THAT
EVERYONE AT NIH WAS TOLD TO BE
AS FLEXIBLE AS YOU COULD WITH
THE RESTRICTIONS AND THE DELAYS
THAT WHY INHER ENTER BECAUSE OF
THE PANDEMIC AND WE DIDN'T HAVE
EXTRA FUNDING TO BE ABLE TO
PROVIDE MORE MONEY TO THE
PROGRAMS BUT OUR P.I.s WERE
REMARKABLE AND IN KEEPING
EVERYONE ON TARGET AND I HAVE TO
GET THEM A GREAT DEAL OF CREDIT
WE'VE HEARD COMMENTS ABOUT THE
IMPACT OF COVID ON WOMEN AND
RESEARCHERS AND SO, THE PROGRAM
STAYED TOGETHER AND THE RFA LAST
YEAR WAS HIGHLY COMPETITIVE AND
THE VAST MAJORITY OF THE ACTIVE
PROGRAMS WERE RENEWED AND SO I
THINK IT'S JUST A VERY STRONG
UNIT IN TERMS OF THE BIRCH
PROGRAM OVER ALL.
>>Samia Noursi: WE HAVE TIMES
FOR YOUR COMMENTS AND IF YOU
WANT TO SHARE ABOUT YOUR
EXPERIENCE AND YOU WOULD TALK
ABOUT IT.
WE HAVE TIME.
>>FELL FREE.
>>THERE WAS A LOT OF ACROSS
DESPERATION WITH OUR YOUNG
SCIENTISTS WHO WANTED TO DO
THEIR WORK AND COULD SUDDENLY
NOT DO IT IT AT ALL IN OUR
UNIVERSITY AND PEOPLE COULDN'T
DO RESEARCH FOR A PERIOD OF
SEVERAL MONTHS SO, NORMALLY OUR
SCHOLARS ARE BY AND LARGE
SCHOLARS FOR TWO YEARS AND OUR
BOARD, OUR INTERNAL ADVISORY
BOARD VOTED TO ALLOW A THIRD
YEAR ARE INFORM THE SCHOLARS
ACKNOWLEDGING THE PROGRESS WAS
SLOWED DOWN AND YOU KNOW, YOUNG
SCIENTISTS ARE VERY SERIOUS
ABOUT WANT TO GO DO THEIR WORK
AND BY GIVING THE THIRD YEAR NOW
WE'RE SEEING THEY'VE ALL STAYED
IN AND THEY'RE ALL DOING WELL
AND WE JUST HAD THE FIRST K COME
OUT OF THIS SCHOLAR FOR WHICH WE
ARE THRILLED AND THE BIRCH P.I.
AND SUPPORT OUR YOUNG SCHOLARS
AND I KNOW THAT OUR CITE IS NOT
THE ONLY ONE THAT FIGURED OUT A
WAY INCREASED FUNDING.
>>YES, AND YOU HAVE STRONG
INSTITUTIONAL SUPPORT AS WELL SO
I THINK THAT NODES TO BE
ACKNOWLEDGED THAT YOU'VE
NEGOTIATED QUITE WELL ON BEHALF
OF THE PROGRAM AND SO, WE
APPRECIATE THAT AND ORWH VERY
MUCH.
>>ALL RIGHT.
DO WE HAVE ANYMORE COMMENTS OR
QUESTIONS BEFORE WE MOVE ON TO
VOTING ON THE APPROVING THE
BIRCH POSTDOCTORAL CONCEPT
CLEARANCES?
I AM GOING TO MOVE ON AND ASK IF
ANYONE IS THERE A MOTION ON THE
TABLE TO APPROVE THE BIRCH?
POSTDOCTORAL OPPORTUNITIES COP
SEPTEMBER CLEARANCE.
IS THERE A MOTION?
Dr. SIMON DID YOU RAISE YOUR
HAND?
>>I MAKE A MOTION TO DO THAT.
>>Dr. SIMON MADE A MOTION.
DO I HEAR A SECOND.
>>IT'S A SECOND AND SECOND TIME
AND PAUL HAS BEEN OPEN FOR YOU
TO RESPOND IF YOU ARE IN FAVOR,
OPPOSED OR ABSTAINED PLEASANT
YOUR RESPONSES NOW AND YOU WILL
HAVE 30 SECONDS TO RESPOND.
>>DO WE HAVE THE VOTE.
>>YES, 14 IN FAVOR.
>>GREAT, THANK YOU EVERYONE.
THEY HAVE BEEN ACCEPTED WITH 14
IN FAVOR.
THANK YOU ALL FOR YOUR COMMENTS
WITH THAT I WOULD LIKE TO TURN
IT BACK TO THE CHAIR OF THIS
COMMITTEE Dr. CLAYTON.
>>Janine A. Clayton: THANK YOU
SO MUCH Dr. NOURSI AND THANK
YOU EVERYONE, SPECIAL THANKS TO
THE CAREER SECTION FOR TWO
AMAZING CONCEPT CLEARANCES AND
Dr. THE CAREER SECTION AND FOR
HELPING US GET TO THIS POINT AND
IT'S BEEN AN EXTREMELY BUSY YEAR
ACROSS THE BOARD AND THEY HAVE
BEEN WORKING HARD AS HAS TEAM
ORWH IN GENERAL SO I HOPE THAT I
WAS ABLE TO SHARE WITH YOU AND
MY PRESENTATION EARLIER A LOT OF
THE ACTIVITIES THAT WE HAVE
UNDERTAKEN WHICH HAVE CERTAINLY
INVOLVED THE ENTIRE STAFF OF
ORWH WHO I WANT TO ACKNOWLEDGE
NOW FOR THEIR INCREDIBLE EFFORTS
TO KEEP ALL OF THE MISSION AREAS
MOVING FORWARD WITH REALLY
ROBUST PROGRAMMINGEN OWE HAVE A
TIVE APPROACHES AND CREATIVE
STRATEGIES TO ADVANCE WOMEN'S
HEALTH AND WOMEN IN STEM.
WE HAVE TIME ON OUR AGENDA FOR
OPEN DISCUSSION AND WE'VE HAD
Q&A FOR SPECIFIC ISSUES DURING
THIS MEETING BUT I ALWAYS LIKE
TO MAKE SURE THAT WE HAVE A GOOD
SPOT ON THE AGENDA FOR MEMBERS
TO EXPRESSION THEIR THOUGHTS AND
REGARDING WOMEN'S HEALTH
RESEARCH HERE AT NIH AND
INTEGRATION ACROSS THE RESEARCH
CONTINUUM AND POLE SEIZE AND
WOMEN AND ALL OF THE AREAS
COVERED BY OUR MISSION SO LET ME
OPEN THE FLOOR FOR COMMENTS AND
SO THEY DON'T NEED TO BE
REQUESTED BUT THEY COULD BE
COMMENTS PERSPECTIVES AND YOUR
FEEDBACK ON THINGS THAT YOU
HEARD ABOUT THAT YOU APPRECIATE
THAT YOU WOULD LIKE FOR US TO
CONTINUE AND IT'S REALLY UP TO
YOU AND YOUR TIME ON THE AGENDA.
WITH THAT I'LL PAUSE.
Dr. ANDERSON.
YOUR LIGHT CAME ON.
>>O, YOU KNOW, YOUR
PRESENTATION MORNING ON MATERNAL
MORTALITY WAS COMPELLING AND
IT'S NOT ANY AREA AND THE THINGS
I WORK ON SEEM A LITTLE BIT
SMALL COMPARED TO THAT AND I
REALLY WOULD LIKE TO SEE A LOT
OF EMPHASIS ON ADDRESSING THAT
PROBLEM.
THERE ARE TWO OTHERS THAT I
WANTED TO MENTION AND THAT IS
ADDRESSING MENOPAUSE.
UNDERSTANDING BIOLOGICALLY WHAT
IS GOING ON AND HOW WE CAN
PROVIDE WOMEN AND PERRY
MENOPAUSE WITH REAL VERY SOLID
EVIDENCE BASED GUIDELINES ON HOW
TO AROUND THE SYMPTOMS OF
MENOPAUSE AND THERE'S A LOT OF
CONTROVERSY AND A LOT OF
INTEREST IN HOW WE HELP WOMEN
GOING TO THIS TRANSITION AND THE
OTHER ONE MENTIONED BEFORE AND
THAT IS CAREGIVING AND WOMEN
CERTAINLY A LOT OF THE BURDEN
CAREGIVING AND IT'S MID LIFE AND
THEN OLDER AGES TIP HE CANNILY
AND FOR ELDERS AND PARTNERS AND
THAT'S A HUGE BURDEN ON BOTH
MENTAL AND PHYSICAL HEALTH OF
WOMEN AND I THINK WE'RE NOT
DOING ENOUGH TO ADDRESS THAT.
>>THANK YOU SO MUCH FOR SHARING
BOTH OF THOSE SUGGESTED AREAS
AND THOSE ARE AREAS OF PROFOUND
INTEREST BUT WHAT I'M HEARING
FROM YOU IS ENCOURAGEMENT TO
ELEVATE THE ATTENTION TO
MENOPAUSE IN MID LIFE WOMEN AND
THE REMAINING RESEARCH QUESTIONS
OF COURSE YOU DO KNOW AND WE'LL
BE HOSTING THE SYMPOSIUM
FOCUSING ON THAT SO I HOPE YOU
CAN JOIN HIM THERE AND GIVE US
FOLLOW-UP AND FEEDBACK FROM THE
SYMPOSIUM AS WELL.
CAREGIVING AND ITS CONSEQUENCES
BOTH ON MOTEL PHYSICAL HEALTH
AND I DID MENTION THIS BUT ALSO
THERE ARE CAREGIVING
RESPONSIBILITY AND IT'S
INTERFACES WITH CAREER CHOICES
OF WOMEN AND STEM IS ALSO AN
IMPORTANT ISSUE AND YOU HAVE
HEARD A FEW THINGS ABOUT
STRATEGIES THAT ARE TAKEN TO TRY
IT TO ADDRESS THAT BUT, WITH THE
PANDEMIC, I THINK THIS SITUATION
HAS EVOLVED EVEN FURTHER AND SO
HOW CAN WE REMAIN CURRENT AND
CONTEMPORARY AND PROVIDE US MANY
OPTIONS FOR CAREER SIDE BUT ALSO
WAYS THAT WE'RE ADJUSTING AND
HEALTH RESEARCH PERSPECTIVES.
THANK YOU SO MUCH Dr.
ANDERSON.
I WILL GO WITH --
>>I SUPPORT THE COMMENTS ON THE
MENOPAUSE AND I'M GLAD THAT THEY
HAVE FOCUSED ON MENOPAUSE.
IT STRIKES ME SINCE ONCE HEALTH
INITIATIVE RESEARCH HORMONE
REPLACEMENT WAS SHUT DOWN AND AS
WAS NOTED IN THE "NEW YORK
TIMES," IT'S AMAZING HOW MUCH
SUFFERING PEOPLE WILL TOLERATE
FOR WOMAN SO I THINK THAT IS THE
ISSUE OF HORMONE REPLACEMENT
THERAPY IS REVISITED AND THERE'S
A LOT OF EVIDENCE SUGGESTING
THAT IT WASN'T ADDRESSED AND
GIVEN THE TIMES HE HAZARDED AS
BEST IT COULD BE THEM BUT
NEIGHBOR NOT DA FIN TO HAVE TEE
AND I WANT TO THANK YOU Dr.
CLAYTON.
IT'S AMAZING WHAT YOUR OFFICE
DOES AND WHAT YOU'VE DONE AND AS
I CONTINUE TO KEEP HOPING AND
WORKING ON MAKING WOMEN'S HEALTH
AND SEX DIFFERENCES RESEARCH
MORE OF A PRIORITY, YOU AND YOUR
OFFICE HAVE BROUGHT THIS TO BEAR
IN AN AMAZING WAY SO I WANT TO
THANK YOU.
>>THANK YOU, JUDY FOR THAT AND
IT'S A TRUE TEAM EFFORT AS YOU
KNOW AND INCREDIBLE COMMITTED
DEDICATED INDIVIDUALS HERE SO
WE'LL DEFINITELY SHARE THE CROSS
THE BOARD.
I AGREE WITH YOU THAT MENOPAUSE
RESEARCH AND UNDERSTAND HE'D AND
IT'S APP UNDER STUDIED TOPIC AND
MANY QUESTIONS THAT REMAIN
AROUND MENOPAUSE AND THAT AS WE
LEARN MORE, I MEAN, WE'VE
LEARNED SO MUCH SINCE THE W.H.I.
WAS OF COURSE, A LANDMARK,
AMAZING INCREDIBLE FOCUSED
INVESTMENTS AND FIRST EVER OF
ITS KIND JUST ON THE HEALTH OF
MID LIFE AND A LITTLE BIT OLDER
WOMEN THE FOCUS WAS A LITTLE BIT
DIFFERENT AT THAT TIME.
THE FORMULATIONS OF FORMAL
AVAILABLE FOR DIFFERENT AT THE
TIME AND WE ACTUALLY HAVE A LOT
MORE INFORMATION NOW BECAUSE OF
W.H.I. AND BECAUSE OF RESEARCH
AND SO NO AS WE LEARN MORE WE
CAN DEVELOP MORE QUESTIONS AND
COMPELLING QUESTIONS AND
SCENARIOS FOR WHICH WE NEED
EVIDENCE OF CLINICIANS HAVE
EVIDENCE IT MAKE THEIR TREATMENT
DECISIONS FOR MANY DIFFERENT
SITUATIONS AS POSSIBLE AND WE
HAVE VARIOUS BACKGROUNDS SO I
HEAR YOU ON THAT, JUDY.
>>TWO QUICK COMMENTS ABOUT THE
LIFE COURSE SLIDE AND ONE THING
I'VE BEEN THINKING ABOUT IS THE
FACT THAT WE UTILIZE THE WORD
CHILDREN A LOT AND THERE'S A LOT
OF SEX SPECIFIC DIFFERENCES THAT
ARE PRESENT FROM BIRTH AND SO WE
DON'T REALLY DISTINGUISH GIRLS
AND BOYS PRIOR TO ADD LESS
ENTERS AND I THINK PERHAPS WE
SHOULD AND IT'S LUMPING THEM ALL
TOGETHER.
THE OTHER THOUGHT IS I PUT THIS
IN THE CHAT ABOUT THE ADULTHOOD
CONCEPTS AND DEFINITELY HAVING
PERI-PRE POST MENOPAUSE BECAUSE
PART OF THAT I WAS TALKING ABOUT
A COLLEAGUE OF MINE AND MANY
MIGHT KNOW HER BUT SHE MADE A
GREAT POINT AND THAT WHETHER OR
NOT YOU HAVE CHILDREN EFFECTS
YOUR RISK OF IT PARTICULAR
DISEASES SO IF YOU HAVE CHILDREN
AND PRE-ECLAMPSIA AND RISK FOR
CARDIOVASCULAR DISEASE IF YOU
DON'T HAVE CHILDREN AND YOUR
RISK OF PRE PRODUCTIVE CANCER
DIFFERENCE AND SO IT MIGHT NOT
ALWAYS LOOK AT A LINEAR PROCESS
BUT THANK YOU AGAIN THIS WAS AN
AMAZING DAY.
>>THANK YOU FOR ADDING THOSE
ADDITIONAL CONTEXT.
THAT MULTI DIMENSIONAL FRAMEWORK
HAS SO MANY POTENTIAL WAYS IT
CAN BE NUANCES AND SO WE'RE
TRYING TO MAKE SURE WE HAVE THE
MOST SALIENT ELEMENT THE WITHOUT
HANGING THINGS ON IT AND HAVING
IT BE THE FOUNDATION ALLOWS US
TO EXPLORE ALL OF THOSE ISSUES
LIKE YOU MIND THAT ARE ALL VERY
IMPORTANT SO THANK YOU FOR THAT
AS WELL.
Dr. JONES IF.
>>THANK YOU FOR THE OPPORTUNITY
TO JUST SHARE TWO THOUGHTS THAT
HAVE COME TO ME TODAY AND I'M
LOOKING AT THE DIFFERENT THINGS
THAT WE HAVE.
AND A WONDERFUL PRESENTATIONS
THAT WITH GIVEN SO GOING BACK TO
THE MATERNAL MORTALITY PIECE AND
THE STRIKING DATA YOU PRESENTED
THIS MORNING AROUND SO MANY
OTHER COUNTRIES AND CULTURES ARE
DOING A BETTER JOB WITH THE TOTE
MORTALITY SO ASKING MORE
STRUCTURAL QUESTIONS AND WHAT
ARE THEY DOING RIGHT NOW AND
WHAT ARE THEY DOING AND THINKING
I KNOW MATERNAL DESERTS AND THAT
ARE HAPPENING IN OUR COUNTRY AND
THERE'S I THINK WE COULD ALSO
ASK QUESTIONS ABOUT THINGS LIKE
MIDWIVES AND FOLLOW-UP VISITS
AND OTHER COUNTRIES TEND TO SEE
AND VISITING THERE'S MUCH MORE
INTERACTIONS AND SUPPORT OF CARE
GIVEN.POSTPARTUM PERIOD SO JUST
MAKING SEE WE'RE LOOKING AT WHAT
OTHER CULTURES ARE DOING WELL
AND WHAT LESSONS COULD BE
LEARNED AND FIGHT WITHIN OUR
CULTURAL CONTEXT AND I THINK THE
SECOND THING SUCH AS THROUGHOUT
THE PAST YEARS SO, WE'VE SEEN A
LOT OF CHANGING AND REPRODUCTIVE
RIGHTS AND ACCESS TO ABORTION
AND THIS IS A IMPORTANT
OPPORTUNITY TO ASK QUESTIONS AND
TO BE ABLE TO FOLLOW AND MONITOR
AND PROVIDE SOME DATA IN TERMS
OF ALL DIFFERENT STATES ARE
DOING DIFFERENT THINGS AND WHAT
CAN WE LEARN FROM THAT.
SO THE SECOND PART FIRST AND I
JUST CONTINUED TO SUPPORT
RESEARCH ON REPRODUCTIVE HEALTH
AND EFFORTS THAT WOULD ALLOW US
TO CHARACTERIZE THE IMPACT OF
POLICY CHANGES ON THE HEALTH OF
WOMEN AND REPRODUCTIVE HEALTH
OPTIONS AND SO THAT IS AVAILABLE
AND I EXPECT TO SEE MORE DATA
THERE AND DATA ARE VERY
IMPORTANT TO FOREIGN POLICY AND
I AGREE THERE BUT THE FIRST ITEM
WAS ABOUT WHAT WE COULD LEARN
FROM OUR COLLEAGUES AROUND THE
WORLD AND THAT IS WHAT I THOUGHT
WHAT I SAW THE EASTERN EUROPEAN
DATA AND WHAT IS THE
INTERSECTION HERE AND FOR THE
COMMODITIES FUND DATA I CAN TELL
YOU THE UNITED STATES IS THE
LOWEST HIVE EXPECTANT SEE AND
THE SIGHEST COST OF HEALTHCARE
HAD THE LOWEST NUMBER OF
PHYSICIAN HEALTHCARE VISITS
BASICALLY INTERFACING WITH THE
HEALTH-CARE SYSTEM AND ONE OF
THE BIGGEST DIFFERENCES BETWEEN
THE U.S. AND THE OTHER COUNTRIES
WAS A LACK OF UNIVERSAL
HEALTHCARE PROVIDED.
AND THE PATHWAYS TO PRE FOCUSED
ON POSTPARTUM HEALTH MAY ADDRESS
SOME OF THE THINGS THAT YOU
MENTIONED SO I WOULD REALLY
ENCOURAGE YOU STRONGLY TO TAKE A
LOOK AT THAT DRAFT PANEL REPORT
AND WEIGH IN AND IT'S THE FULL
YEAR AND YOU MENTIONED MIDWIVES
AND DOULA AND ACTIONS THERE IN
TERMS OF HOW WE ARE PROVIDING
CARE AND WEIGH IN.
IMPROVE IS FUNDING RESEARCH IN
THAT SPACE AND THE MIDWIFE SPACE
SO, THAT HELPS TO GENERATE
ADDITIONAL DATA AND IT'S
CHALLENGING WHEN YOU HAVE A
COMPLICATED NATIONAL LANDSCAPE
AND REGARDING DELIVERY OF DOULA
CARE AND IT THE MORE COMPLICATED
FOR PREGNANT AND POSTPARTUM
PEOPLE SO WE'RE KEEPING AN EYE
ON ALL OF THE THINGS THAT AND I
APPRECIATE YOUR SUGGESTIONS ON
MAKING SURE THAT THESE ARE STILL
ON OUR RADAR AND HOW WE CAN
INCLUDE THEM IN OUR EVENTS GOING
FORWARD AND HOPE TO BE ABLE TO
SHARE MORE IN THE FUTURE AND THE
DOCTOR REMIND ME THAT WE ARE
SUPPORTING A NATIONAL ACADEMIES
STUDY ON THE EFFECTS OF
CAREGIVING ON PARENTS AND STEM
AND SO THAT IS ON GOING AND THE
COMMITTEE HAS SPENT SEVERAL
TIMES AND THERE ARE AT LEAST TWO
SESSION THAT'S HAVE BEEN OPEN TO
THE PUBLIC SO WE ARE SUPPORTING
THAT ALONG WITH OTHERS AND SO
HOPE TO BE ABLE TO BRING A
REPORT IN THE FUTURE AND THAT
WILL PROVIDE LARGE EVIDENCE
BASED RECOMMENDATIONS FOR THE
ECOSYSTEM AND AROUND CAREGIVING
IN STEM AND IT WAS PARTICULARLY
CONCERNED AND SHARED WITH YOU
ALL THE EFFECT OF PANDEMIC AND
WOMEN IN STEM EX CLINICAL
RESEARCH AND SOME FIELDS OF
RESEARCH AND IT WAS EASIER TO
KEEP THE RESEARCH GOING AND IT
WASN'T EASY FOR ANYONE BUT IT
WAS MORE DIFFICULT FOR SOME
PEOPLE AND DESPITE THE REPORTS
THAT WE SEE IN THIS THE
LITERATURE ABOUT PUBLISHING
RATES, WOMEN BEING FEWER, FIRST
FEW WOMEN BEING FIRST AUTHOR AND
SENIOR AUTHOR WHEN WE LOOK AT
THE APPLICATION RATES AND
RECOGNIZING THAT IS A VERY
SPECIFIC PART OF THE ECOSYSTEM.
FOR APPLICATIONS PUBLISHED BY
MIKE AND MAUREEN ON THE OPEN MIC
BLOG AND SO HOWEVER THE
ECOSYSTEM IS CHANGING AND I
THINK THAT IT'S IMPORTANT FOR US
TO UNDERSTAND ALL OF THESE FORCE
AND DO OUR BEST TO HAVE SUPPORT
INCLUSIVE EXCELLENCE BECAUSE WE
KNOTS TEST BEST FOR OUR SCIENCE.
THANK YOU FOR THOSE COMMENTS.
>>Samia Noursi: Dr. HIGGINS
HAS A COMMENT IN THE CHAT.
>>YES, I JUST WANTED TO CONQUER
TO CONCUR,IT'S BEEN A WONDERFUL.
IT'S BEEN MENTIONED BUT THE
IMPORTANCE OF THE ADVOCACY FOR
IMPLEMENTATION OF EVIDENCE BASED
INTERVENTIONS AND I KNOW IN MY
OWN FIELD, IT CAN BE STAGGERING
HOW OFTEN COMMUNITY CLINICS ARE
NOT USING EVIDENCE BASED
TREATMENTS, I DOUBT THAT IT'S
SPECIFIC TO ADDICTIONS AND IT
MAY BE MORE COMMON BUT THE OTHER
THING THAT COMES TO MIND IN THIS
AREA IS THAT I THINK THERE'S A
ROLE FOR NIH TO DO MORE ADVOCACY
THAN PERHAPS AS COMMON AND IT
ESPECIALLY FOR POPULATIONS OR
CONDITIONS THAT ARE OVER
REPRESENTED AND DISADVANTAGED
POPULATIONS AND BECAUSE THEY
DON'T HAVE THE LEVEL OF ADVOCACY
AND THE COMMUNITY THAT AFFLUENT
POPULATIONS DO OR PATIENTS.
AND IT COULD RELATE TO A LITTLE
BIT AT LEAST TO THE POINT THAT
Dr. JONES BROUGHT UP ABOUT US
DOING SOME POORLY WITH MATERNAL
MORTALITY AND I'LL GIVE YOU ONE
EXAMPLE, WE'VE BEEN WORKING ON
SMOKING CESSATION IN PREGNANCY
FOR 20 YEARS AND THERE'S A
PARTICULAR INTERCEPTIONS THAT
WORKS WELL THAT INVOLVES
FINANCIAL INCENTIVES WHICH CAN
BE A LITTLE CONTROVERSIAL BUT
THERE'S A COLLEAGUE IN FRANCE
WHO GOT ON TO THIS APPROACH JUST
SEVERAL YEARS AGO AND DID A
MULTI-SITE TRIAL AND I GOT AN
E-MAIL FROM HIM THAT FRANCE IS
GOING FORWARD WITH NATIONAL
IMPLEMENTATION.
HE WAS CHECKING IN WITH ME TO
SEE HOW WE'RE DOING IN THE U.S.
AND SADLY I HAD TO SAY, THERE'S
NOTHING THAT I KNOW OF THAT'S
EVEN CLOSE TO IMPLEMENTATION
EVEN IN THE HOME STATE.
I ONLY BRING IT UP TO YOU
BECAUSE I THINK THAT YOUR
ADVOCACY COULD BE IMPACTFUL.
SO, YEAH.
>>THANK YOU FOR YOUR FEEDBACK.
A COUPLE THINGS, SO REGARDING
UNDER REPRESENTED RACIAL AND
ETHNIC MINORITY POPULATIONS --
>>AND SO, IT IS A CONFLICT
ECOSYSTEM AND I APPRECIATE THE
ATTENTION BECAUSE THE GOAL OF
TRYING DISCOVERY INTO HEALTH IS
DEPEND AN ON THAT LAST STEP OF
CARE SO WE WANT TO CREATE NEW
KNOWLEDGE SO WE CAN BE APPLIED
AND WE CAN PREVENT RESULTS SO
THANK YOU SO MUCH FOR THAT.
OTHER QUESTIONS.
>>I JUST PUT THAT LINK TO THE
REPORT THAT Dr. CLAYTON
MENTIONED ABOUT MATERNAL
MORBIDITY THAT IS PART OF THE
WORKED ON WITH OUR OFFICE OF DIS
SEE PREVENTION AT THE NIH SO
THAT DATE FOR ACCEPTING COMMENTS
IS COMING UP ON APRIL 21 SO
FOLLOW THE LINK AND I'M SURE
THEY WILL BE VERY HAPPY TO I'M
NOT SURE IF SHE WANTS TO SAY IT
BUT FELL FREE TO PUT IT ON MUTE.
>>AND I HAVE ANY HERE AND I
PROMISE.
>>IT'S A JOKE.
IMPLEMENTATION SCIENCE AND YOU
SAID IT AND IT'S IMPORTANT WHEN
YOU SEE THIS AT THE U IS SPTF
AND NOW THE CDC COMMUNITY
PREVENTION SERVICES TASK FORCE,
AND ON THE GROUPED
IMPLEMENTATION LEVEL IS DUMPED
THAT WE DON'T KNOW HOW TO TAKE A
PACKAGE PROGRAM AND PUT IT IN
THE GROUND AND EVIDENCE BASED
GROUPED IS PUT IT INTO A
CLINICAL CARE WORKFLOW EASILY
AND AS MUCH AS IT SEEMS EASY TO
DO THAT'S WHY WE NEED TO REALLY
THINK ABOUT INNOVATING THE
SCIENCE OF IMPLEMENTATION
SCIENCE AND WHAT ARE DIFFERENT
IMPLEMENTATIONS STRATEGIES AND
HOW TO BEST DO THAT MAKES IT
WORK FOR DIFFERENT CLINICAL CARE
AND COMMUNITIES SETTINGS.
LIKE SOME OF THIS CIGARETTES
SMOKING CESSATION FOR PREGNANT
PERSONS COULD POTENTIALLY BE
EFFECTIVE IN THE LIBRARY SETTING
FOR EXAMPLE, DARE I SAY.
THERE ARE SO MANY OPPORTUNITIES
FOR PLACES AND SPACES TO ADVANCE
IMPLEMENTATION SCIENCE IN REALLY
IMPROVING HOW IMPLEMENT WORKS OF
IDIs THAT ARE LONG STANDING.
>>Samia Noursi: THAT'S ALSO I
WANT TO REMIND EVERYONE OF GOAL
FIVE OF THE NEW STRATEGIC PLAN
THAT FOCUSES ON.
SO I JUST WANT TO BRING THAT UP
AGAIN.
JONI RUTTER TALKED ABOUT SMOKING
CESSATION WITH A BREAST FEEDING
INTERCEPTIONS.
YOU SAW THAT Dr. HIGGINS?
>>YES I DID.
I MADE A NOTE OF THAT.
>>I WILL MAKE SURE WE FOLLOW-UP
WITH JANUA JONI ON THAT AND GIVA
FOLLOW-UP IN THE FUTURE.
I HOPE WE ALSO WOULD LOVE YOUR
FEEDBACK ON THE AGENDA THAT'S WE
CREATE FOR YOU IF THERE ARE
SPECIFIC TOPICS YOU WANT TO HEAR
MORE ABOUT OR A PARTICULAR
INSTITUTE DIRECTOR THAT YOU'D
LIKE TO HEAR FROM IN THE FUTURE
AND SINCE Dr. NOURSI HAS BEEN
EXECUTIVE SECRETARY WHICH WAS I
ASKED HER TO DO IT FOR A YEAR
AND IT'S BEEN MUCH MORE THAN A
YEAR, WE'VE DONE AT LEAST --
>>Samia Noursi: SIX MEETINGS, I
COUNTED.
>>Janine A. Clayton: AT LEAST
SEVEN IC DIRECTORS AND WE MIGHT
NOT HAVE GOT IT ON THE FIRST ONE
SO WE'RE GOING THROUGH ALL THE
THE IC DIRECTORS BUT THERE'S
SOMETHING THAT YOU WANT TO HEAR
ABOUT AND ISSUE, PLEASE LET US
KNOWS AND ANYTHING COME TO MIND
NOW?
PARTICULAR TOPIC OR INSTITUTE
THAT YOU WANT TO HEAR ABOUT IN
THE FUTURE PLEASE LET US KNOW.
>>Samia Noursi: IF YOU WOULD
LIKE ANY ADDITIONAL INFORMATION
THAT WE SENT YOU, YOU ALL
RECEIVED E-MAILS FROM US ON THE
BEGINNING OF EVERY MONTH AND
SOMETIMES ON THE SECOND IF IT'S
ON A SUNDAY WE TRY NOT TO
ACCEPTED US OIR NEWS LET ARE ONA
SUNDAY.
IF YOU NEED ANYTHING, ACCEPTED
US AN E-MAIL AND WE'LL BE HAPPY
TO DISCUSS IT WITH Dr. CLAYTON
>>Janine A. Clayton: ABSOLUTELY
.
AND I HOPE THOSE E-MAILS THAT
ARE HELPFUL TO KEEP YOU
UP-TO-DATE ON OUR ACTIVITIES ON
A MONTH TO MONTH BASIS SO WHEN
YOU COME TO MEET WITH US TWICE A
YEAR, YOU KNOW, I ALWAYS HAVE
MORE THAN I CAN TELL YOU IN MY
DIRECTOR'S REPORT THAN I HAVE
TIME TO CONVEY AND SOMETIMES
IT'S DIFFICULT TO LEAVE A PIECE
OF THAT INFORMATION OUT BUT IF
APPROXIMATE THERE'S INFORMATION
THAT YOU WANT TO HEAR ABOUT,
PLEASE DO LET US KNOW.
>>Samia Noursi: I THINK WE ARE
ALREADY, YOU CAN PLAN FOR THE
OTH MEETING TO BE VIRTUAL AGAIN.
>>Janine A. Clayton: YES,
THAT'S OUR PLAN.
>>Samia Noursi: THAT'S THE
PLAN.
UNLESS WE RECEIVE OTHER
GUIDANCE.
>>Janine A. Clayton: IF YOU
HAVE STRONG FEELINGS ABOUT THAT
LET US KNOW AS WELL.
Dr. NOURSI THERE'S NOTHING
WRONG WITH ENDING EARLY AND
GIVING OUR COLLEAGUES THE GIFT
OF TIME.
WE ALL APPRECIATE THAT.
IT'S BEEN A BUSY DAY.
THERE'S A LOT HAPPENING TODAY
BESIDES WHICH WE'RE DOING WHICH
WE THINK VERY IMPORTANT TOO.
I AM NOT SEEING -- THANK YOU FOR
FEEDBACK AND I PUT THE LINKS TO
THE DATA FROM MY SLIDE AND YOU
ARE GOING TO GET ALL THE SLIDES
AVAILABLE TO YOU SO YOU WILL
HAVE THAT INFORMATION AND THANK
YOU FOR THE FEEDBACK.
AND WITH THAT, SARAH AND SAMIA
ARE THERE ANY OTHER ITEMS WE
NEED TO COVER BEFORE WE ADJOURN?
>>Samia Noursi: BUT JUST A
COMMENT FROM Dr. TEMPLETON
IT'S HEAR FROM NIADS AND I
THOUGHT WE HAD Dr. --
>>Janine A. Clayton: WE DID,
YES.
YOU KNOW KIM YOU WERE IN THE
O.R. AT THE LAST MEETING AND YOU
COULD ONLY JOIN FOR A FEW
MINUTES AND Dr. CRISWELL
PRESENTED IF THE MORNING AND YOU
WERE IN THE O.R. IF I REMEMBER
CORRECTLY.
>>OKAY.
>>Samia Noursi: WE'LL BE HAPPY
TO DIRECT YOU TO THE REPORT IF
YOU CAN LISTEN TO OUR
PRESENTATION AND WE'LL BE HAPPY
TO FOLLOW-UP WITH YOU ON THAT.
>>Janine A. Clayton: ALL OF THE
MEETINGS ARE VIDEO CAST AND YOU
CAN LOOK AT THEM AND GET ACCESS
TO SLIDES AND CONTENT SO WE'LL
PROVIDE THAT FOR YOU, KIM, NO
PROBLEM.
WITH THAT I WANT TO DEFINITELY
ACKNOWLEDGE ALL OF THE AMAZING
WORK DONE THAT YOU HEARD ABOUT
TODAY.
THE COMMUNICATIONS SUPPORT,
LOGISTICAL SUPPORT PROJECT
MANAGEMENT SUPPORT, PROGRAM
SUPPORT, EXECUTIVE ASSISTANCE,
EVERYTHING, WE CAN'T DO ANYTHING
OF THIS WITHOUT OUR AMAZING
COLLEAGUES WHO HELP US DO IT AND
KEEP US ON TRACK.
THANK YOU VERY MUCH TO ALL OF
THEM INCLUDING OUR
COMMUNICATIONS SUPPORT AND OUR
PARTNERS ACROSS THE NIH
INSTITUTES AND CENTERS.
AS YOU VERY WELL KNOW, WOMEN'S
HEALTH RESEARCH IS BEING
CONDUCTED BY ALL OF THOSE
INSTITUTES AND CENTERS AND IT IS
IMPORTANT TO CONNECT THE DOTS
BETWEEN THOSE INSTITUTES AND
CENTERS AND THAT'S PART OF ROLE
THAT WE PLAY AS WELL AS
ELEVATING AND PRIORITIZING
SPECIFIC TOPICS WHICH ARE AGAIN
YOU PLAY A CRITICAL ROLE IN
HELPING UP IDENTIFY WHICH ARE
THOSE TOPICS WE NEED TO ELEVATE
AND MAKE ON THE RADAR SCREEN AND
I HAVE TO SAY, WE WERE VERY
EFFECTIVE IN GETTING ATTENTION
TO MORTALITY AT NIH AND A LOT
THAT HAVE CAME FROM INDIVIDUALS
ON OUR ADVISORY COMMITTEE AS
WELL AS IN ORWH AND NIH.
SO WE TRY TO WORK VERY
EFFECTIVELY WITH OUR INSTITUTE
AND CENTER PARTNERS AND I WANTED
TO ACKNOWLEDGE THEIR
CONTRIBUTION TO THE THINK TANKS
AS CO-CHAIRS AS PARTICIPANTS AND
AS THOUGHT PARTNERS AND TO OUR
COORDINATING COMMITTEE ON
RESEARCH ON WOMEN'S HEALTH WHERE
WE PRESENT A LOT OF IDEAS AND
HEAR SCIENTIFIC PRESENTATION AND
I WANT TO ACKNOWLEDGE OUR CWPT
AND WE HAVE SEVERAL WORKING
GROUP ON THAT BODY NOW TOO.
SOUND WITH THAT, I WOULD ALSO
THANK ALL OF THOSE WHO PRESENTED
TODAY.
FOR OUT STANDING PRESENTATIONS,
INTERESTING TOPICS, AND BEING
EXPANDED AND ENHANCES AND
IMPROVED HERE AT NIH AND WE HAVE
OF ORWH I WANT TO THANK ALL OF
YOU AND THANK YOU TO THOSE OF
YOU WHO HAVE ATTENDED VIRTUALLY
AND WE LOOK FORWARD TO SEEING
YOU AT THE 59th MEETING OF THE
ADVISORY COMMITTEE AND ON
OCTOBER 18th 2023 AND I WANT
TO END WITH SPECIAL THANKS TO
Dr. SAMMY AND Ms. SARAH HAIL
MAN AND Mr. ERIC BEHIND THE
SCENES AND EVERYONE ELSE HYPED
THE SCENES HELP US CREATE
TODAY'S MEETING FOR YOU AND STAY
SAFE AND HEALTHY AND TODAY'S
MEETING IS NOW ADJOURNED.
THANK YOU VERY MUCH.
>>Samia Noursi: BY, EVERYONE.